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Glycosaminoglycans (GAGs) are complex biopolymers that play important roles in 
inflammation, coagulation, angiogenesis, cell adhesion and viral invasion by interacting 
with several different proteins.
1,2
 Structurally, GAGs are built up of several different 
sulfated disaccharide units.
3
 Specific GAG sequences that uniquely recognize their cognate 
proteins exist. Such specificity typically arises from the binding of unique sulfation 
patterns on the linear GAG chain to highly electropositive protein domains. Thus, these 
highly charged, sulfated biopolymers potentially represent a new class of therapeutics. Yet, 
xvi 
2 
 
the major stumbling block to the development to these agents is their extremely 
complicated and tedious chemical synthesis. We hypothesized that replacing the saccharide 
skeleton with an equivalent non-saccharide and readily synthesized organic skeleton would 
usher in an era of new, GAG-based therapeutics. This challenge has been addressed on two 
fronts, computational design and chemical synthesis, by focusing on the heparin 
pentasaccharide-antithrombin system that represents an exhaustively studied model GAG-
protein system. With respect to chemical synthesis, a microwave-based synthetic procedure 
that can rapidly introduce multiple sulfate groups on a poly-hydroxyl substrate within 
minutes was developed.
4
 Using this method, the synthesis of a previously designed 
activator (IAS5), which otherwise proved to be problematic, was successfully completed. 
Biochemical screening of IAS5 and its analogs revealed that these molecules could activate 
antithrombin up to 30-fold in comparison to the 300-fold activation by the heparin 
pentasaccharide. In an effort to develop more potent antithrombin activators, a new method 
to predict high affinity GAG sequences for a given GAG-binding protein based on 
combinatorial virtual-library screening was developed.
5
 This combinatorial virtual-library 
screening method was applied to a library of 24,576 non-saccharide, sulfated molecules 
that were created using the structure of IAS5 as a template. Thirty seven‗hits‘ that had 
common structural features were identified from this study. Interestingly, all these ‗hits‘ 
bind to antithrombin similarly and orient the 4 negative charges identical to the 
corresponding groups in the heparin pentasaccharide. The synthesis of selected targets is 
currently in progress and several synthetic steps have already been optimized.
xvii 
  
1 
 
 
 
 
 
 
INTRODUCTION 
 
Heparin and heparan sulfate belong to a class of linear, sulfated polysaccharides 
known as glycosaminoglycans (GAGs). These complex and heterogeneous 
macromolecules play fundamental roles in a plethora of processes such as growth factor 
signaling, hemostasis, morphogenesis, inflammation, enzyme regulation and viral 
invasion.
2
 
First introduced in 1916,
6
 heparin is the prototype of a class of important 
anticoagulant drugs used in the clinic today.
7
 The prevention of postoperative thrombosis 
and the treatment of acute venous thrombosis are among heparin‘s established uses. While 
heparan sulfate (HS) is commonly thought to be similar to heparin, it is a distinct GAG 
with significant differences. HS is less sulfated, more heterogeneous and structurally 
diverse than heparin, and is tagged to core proteins on cell surfaces.
8
 Virtually every cell 
type in metazoan organisms contains HS. In contrast, heparin is found exclusively in mast 
cells and is not associated with proteins. Thus, HS is ideally poised to mediate cell-cell and 
cell-matrix interactions.  
Investigations into the biosynthesis of these GAGs in the recent past have 
significantly broadened our understanding of their physiological roles. The basic lesson is 
2 
 
that the biosynthesis results in incomplete structural modifications and consequently 
innumerable saccharide sequences that modulate the activity of several different proteins in 
our body. A partial list of heparin and HS-binding proteins may be found in Table 1. 
 
Table 1. Partial list of GAG-binding proteins (Adapted from Nugent, M.A. et al., 
Chemistry & Biology of Heparin and Heparan Sulfate, 2005, Eds: Garg, Linhardt, Hales, 
Ch 19, pg 537)  
 
Growth Factors ECM Components Inflammation/Angiogen
esis
FGFs Fibronectin Interferon
TGF 1&2 Laminins TNF 
VEGF Vitronectin L-selectin
PDGF Neutrophil elastase P-selectin
EGF
Amphiregulin
Heparin binding EGF
Betacellulin
Neuregulin
Cathepsin Endostatin
IGF-II Antithrombin Angiostatin
Activin Thrombin RANTES
TGF binding protein Tissue plasminogen activator Neutrophil activating factor
HGF Plasminogen activator inhibitor GM-CSF
 
A selection of heparin/HS-binding proteins. The abbreviations are: FGF, fribroblast growth 
factor; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; 
PDGF, platlet-derived growth factor; EGF, epidermal growth factor; IGF, insulin-like 
growth factor; TNF, tumor necrosis factor; GM-CSF, granulocyte-macrophage colony 
stimulating factor. 
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1.1. Physiological Roles of Heparin and Heparan Sulfate 
1.1.1. Inhibition of Coagulation and Thrombosis 
Coagulation is the first line of defense against trauma of the vascular system in 
humans.
9
 Yet, aberrant clotting is the most common cause of death in the industrialized 
world.
10
 The serine proteinase inhibitors (serpins), antithrombin (AT)
11
 and heparin 
cofactor II (HCII),
12
 are circulating anticoagulants that serve to prevent thrombosis under 
physiological conditions. The circulating concentrations of both these inhibitors is 
significant (1.2 and 2.3 M for HCII and AT, respectively).
13,14
 
AT is a major regulator of the clotting cascade in humans. In fact, AT is essential 
for survival as homozygous null mutant mice of AT die in utero.
15
 In addition, numerous 
cases of AT deficiency, both congenital and acquired, lead to enhanced risk of 
thrombosis.
16-19
 On the other hand, the physiological relevance of HCII remains unclear at 
the present time. Although HCII deficiency is not a significant risk factor for thrombosis, 
recent studies suggest that HCII plays an important role during extra-vascular injury and in 
preventing arterial thrombosis.
20-22
 While AT functions as an anticoagulant primarily by 
inhibiting the procoagulant proteases thrombin, factor Xa and factor IXa, HCII specifically 
inhibits thrombin. Additionally, HCII is able to inhibit clot-bound thrombin while AT 
cannot.
23
 
AT and HCII can inhibit their target proteases at physiologically relevant rates only 
in the presence of GAGs.
24,25
 The binding of GAG chains to these serpins induces a major 
conformational change resulting in enhanced recognition of target proteases. This process 
4 
 
is called ‗activation‘. In addition to conformational activation, GAG chains can bring about 
rate accelerations by serving as bridging templates for the inhibitor and protease. While 
only heparin and HS can accelerate the rate of AT inhibition of coagulation proteases, 
other GAGs such as dematan sulfate (DS) are also effective for HCII (Figure 1). 
The conformational activation of AT can be brought about by as little as a 5-
residue heparin/HS sequence that is commonly referred to as sequence-specific heparin  
 
 
pentasaccharide (H5, see Figure 7A for structure).
26,27
 The binding of H5 to AT causes 
some 300-600-fold acceleration in the inhibition of factors IXa and Xa (Figure 2).
28-30
 In 
contrast, thrombin inhibition by AT is dependent on GAG chains that contain at least 18 
monosaccharides.
31
 Although the bridging mechanism is the overriding factor in this case, 
physiologically relevant inhibition of thrombin by AT is achieved only with heparin chains 
that contain the H5 sequence. 
1
10
100
1000
10000
100000
1000000
10000000
100000000
1000000000
10000000000
HCII HCII AT
No GAG
With GAG
Only 
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HCII+Heparin
AT+Heparin
HCII+DS
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k
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H
(M
-1
m
in
-1
)
 
Figure 1. GAG activation of AT and HCII. kINH is the second order rate constant for 
the serpin-thrombin reaction 
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HCII binds heparin through an induced-fit mechanism similar to that of AT.
32
 Yet, 
HCII binds heparin chains 1000-fold more weakly (KD = 26 M)
32
 than does AT (KD = 20 
nM) to heparin chains containing the H5 sequence.
33
 This result is surprising because AT 
and HCII share significant structural similarities.
34
 Heparin chains containing as little as 10 
monosaccharides can activate HCII and produce approximately 1000-fold acceleration of 
thrombin inhibition.
32
 Thus, the major mechanism of HCII-rate acceleration appears to be 
conformational activation as is also suggested by mutagenesis studies of thrombin exosite 
 
 
thrombin
+ Ca2+, factor IXa 
AT
RCL
HBS
++++
RCL
AT : H complex
++++
- - - - - - - - -
Full-length Heparin
- - - - - - - - - - -
H5 sequence
factor Xa
+++
factor IXa  inhibition
++++
- - - - - - -
- -
+++
Gla domain
Ca2+
factor Xa inhibition
++++
- - - - - - - - - -
++++
+
thrombin inhibition
++++
- - - - - - - - - - -
+ + + 
 
 
Figure 2. Two major mechanisms of heparin activation of AT inhibition of factor Xa, 
factor IXa and thrombin - conformational activation and bridging mechanism. AT:H = 
antithrombin–heparin complex; H5 = high-affinity pentasaccharide sequence in heparin; 
RCL = reactive center loop; ‗+++‘ = exosite on enzyme; HBS = heparin-binding site 
(Adapted from Desai, U. R. Med. Res. Rev. 2004, 24, 151-181.) 
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mutants.
35
 While recent studies suggest that the heparin-HCII interaction follows a non-
specific binding model,
32
 it is important to point out that heparin may not be the 
physiological activator of HCII, but only serves as a binding model for HS that lines the 
vascular walls and extravascular spaces.  
The acceleration of serpin activity by GAGs is not just limited to AT and HCII but 
appears to be a general feature of coagulation-regulation by GAGs. Of the 35 serpins that 
have been identified in the human genome, five are known to bind heparin and HS. These 
include protease nexin-1
36
, protein C inhibitor (PCI)
37,38
 and plasminogen activator 
inhibitor-1
39
, in addition to AT and HCII. The bridging mechanism of GAGs appears to be 
the primary mechanism of rate acceleration in these cases. 
1.1.2. Cell Growth Control 
Since the original observation that heparin is a potent inhibitor of vascular smooth 
muscle cell growth in 1977,
40
 several studies have shown that heparin and HS interact with 
a variety of growth factors and cytokines to promote and inhibit cell proliferation during 
normal tissue development as well as in disease states.  
Growth factors are a class of 23 relatively small soluble proteins that produce a 
wide range of cellular responses such as proliferation, migration and differentiation 
through their action on specific cell surface receptors.
41
 During the development of 
methods for the isolation and purification of growth factors, many of them were found to 
bind to heparin-agarose columns.
42
 Since this original observation, it is now recognized 
7 
 
that heparin and HS play important roles in cell growth regulation by binding to growth 
factors.  
The prototypic HS-binding growth factor is fibroblast growth factor 2 (FGF 2).
43,44
 
HS participates in forming a ternary complex by interacting with both FGF II (KD = 39 
nM) and its receptor (KD = 3.2 M).
45,46
 Kinetic analyses have revealed that HS stabilizes 
this interaction primarily by lowering the dissociation rate without impacting the 
association rate. It has also been suggested that GAG chains assist in inducing FGF-2 
receptor dimerization and autophosphorylation although the physical orientation of the 
ligand (FGF-2), receptor and GAG remain controversial despite several high-resolution 
crystal structures.
47-54
 Similarly, HS appears to enhance the over-all affinity of vascular 
endothelial growth factor (VEGF)
55
 and epidermal growth factor (EGF)
56
 to their cognate 
receptors. It is interesting to note that endothelial cells treated with heparanases 
(heparin/HS degrading enzymes) show significant reduction in the binding to VEGF121 
even though this isoform does not contain a HS-binding domain. In this case mechanisms 
involving direct cell surface interactions between HS and the VEGF121receptor appear to 
be predominant.
57
 Thus, it is likely that a bridging mechanism is not the only mechanism 
utilized by HS in modulating growth factor-growth factor receptor interactions. 
The ability of HS to control growth factor- receptor interactions has also been 
shown to alter receptor signaling, although these two events do not correlate completely.
58-
63
 The effect of HS on growth factor receptor signaling is complicated by the fact that HS 
can directly modulate cell growth through mechanisms that are independent of growth 
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factor receptors. These mechanisms are not dependent on protein ligands and involve the 
direct interaction of heparin/HS with cell surface ―heparin‖ receptors.64,65 
Since heparin and HS are intimately involved with cell growth control, it is not 
surprising that these molecules are involved in cancer.
66
 Indeed, heparin and HS are 
implicated in nearly all stages of cancer such as tumorigenesis,
67,68
 angiogenesis,
69,70
 and 
tumor invasion
 
and metastasis.
71,72
 
1.1.3. Role of Heparin and HS in Inflammation 
There are several lines of evidence that point towards links between thrombosis and 
inflammation in vascular, cardio-vascular and inflammatory diseases.
73
 For example, pro-
inflammatory stimuli resulting from interleukins or exposure to E. coli endotoxin increase 
the levels of tissue necrosis factor-  (TNF- ) and other cytokines, which in turn leads to 
the activation of leukocytes. Activated leukocytes shed soluble L-selectin from their 
membranes, which leads to the generation of tissue factor (TF). TF initiates and amplifies a 
hypercoagulable state resulting in thrombin generation and platelet activation. Hence, 
molecules that regulate coagulation may also regulate inflammation.  
A large body of evidence supports the concept that heparin/HS has anti-
inflammatory actions.
74-76
 Apart from the modulation of the pathophysiological effects of 
endotoxin and TNF- ,
77,78
 heparin has been shown to suppress selected neutrophil 
functions such as superoxide generation and chemotaxis in vitro.
79,80
 The binding of 
heparin and HS to adhesion molecules expressed on the endothelial and/or leukocyte cell 
surfaces appears to be the mechanism of anti-inflammatory activity (see Table 1). Indeed, 
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several clinical studies have suggested that heparin and HS may be therapeutic in the 
management of ulcerative colitis and Crohn‘s disease.81,82 Interestingly, no hemorrhagic 
complications were observed during these studies. Since the anticoagulant effects of 
heparin are critically dependent on the H5 sequence, it is likely that heparin‘s anti-
inflammatory effects are distinct from its anticoagulant effects. 
Heparin-protein interactions also regulate the complement system. Comprised of 
about 25 proteins, the complement system is a major defense system that facilitates 
phagocytosis and bacterial cell lysis.
83
 Since the original report by Ecker and Gross in 
1929,
84
 several reports have shown that heparin/HS regulates multiple steps in the 
complement system by binding to complement proteins.
85-88
 Yet, most of these studies 
were qualitative and lacked kinetic and thermodynamic data. More recently, surface 
plasmon resonance (SPR) has been exploited to measure kinetic and thermodynamic 
constants for the interaction of heparin with several different complement proteins.
89
 These 
studies revealed that heparin binds most complement proteins with an affinity between 10 
and 400 nM. By factoring in the concentration of different complement proteins in the 
plasma, these studies may provide some insight into the design of therapeutic approaches 
to regulate complement activation. 
1.1.4. Heparin and HS mediate Viral Entry into Cells 
The ubiquitously expressed eukaryotic cell surface HS serves as binding sites to 
several different viruses, most notably Herpes Simplex Virus (HSV) 1 and 2,
90
 Hepatitis C 
Virus (HCV)
91
 and Human Immunodeficiency Virus 1 (HIV-1).
92,93
 These viruses contain 
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several glycoproteins integrated into a lipid bilayer-based envelope. Typically, viral entry 
takes place by the fusion of the viral envelope and the eukaryotic cell membrane. By 
recognizing viral glycoproteins, HS mediates the first step in the entry of viruses into cells. 
Although this step can be thought of as a non-specific anchoring event, recent evidence 
suggests that HS plays a role that goes well beyond a non-specific paradigm in certain 
cases. 
Several lines of evidence support the requirement of HS for the entry of HSV-1 
into cells. Cells treated with heparanases (HS cleaving enzymes) or that are genetically 
altered to prevent HS biosynthesis show reduced capacity to bind the virus.
94,95
 Soluble 
heparin or HS inhibit HSV-1 infection,
94,96
 while soluble forms of the viral glycoproteins 
gB and gC of HSV-1 bind HS.
97-99
 More interestingly, a third glycoprotein gD has been 
shown to bind to only a subset of HS sequences (KD = 2 M) suggesting specificity in 
recognition.
100,101
 Given that the binding of gD to cell surface receptors triggers the crucial 
step of fusion, this result can have therapeutic implications. It is important to point out that 
although HS is not absolutely required for viral invasion, it greatly increases the efficiency 
of infection. 
Although similar evidence exists in the case of HSV-2, it appears that HSV-2 
recognizes different structural features in HS,
102,103 
and differs in the relative importance of 
HS-binding glycoproteins for the initial step of binding.
 
Other viruses belonging to the 
herpes super family of viruses also require HS for the initial binding event. These include 
human cytomegalovirus (CMV), human herpes virus (HHV) and varicella zoster virus 
(VZV).
90
 Considering that the lysine-rich HS –binding domains of glycoproteins gB and 
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gC are conserved across these viruses, this result is not surprising. Similar conservation of 
positively charged residues in the N-terminus of hepatitis-C virus‘ envelope glycoprotein 
E2 implicates the involvement of HS.
91
 Indeed, heparin binds to E2 with an affinity of 5.2 
nM, while deletion of E2 hypervariable region-1 significantly reduced interaction with HS, 
suggesting that the collection of positively charged residues present in this region forms 
the HS-binding site.  
The situation for HIV-1 is particularly interesting because unlike the other viruses 
discussed above, HS binds gp120 of the HIV-1 virus at a late stage.
93
 Specifically, CD4, 
the primary receptor for HIV-1, induces a conformational change in gp120 that 
dramatically increases its affinity for HS. The domain formed by this conformational 
change (called the CD4-induced epitope) together with the V3 loop in gp120 form the HS 
binding sites. Importantly, this binding site is shared by other viral co-receptors suggesting 
potential therapeutic applications for HS mimetics. Other than gp120, HS has been shown 
to bind the Tat protein, a potent transcriptional activator of HIV-1, and mediate its 
internalization.
92
 Notably, essentially all Tat-mediated transcriptional activation is 
dependent on HS in a cell line that specifically expresses the HS proteoglycan perlecan.  
1.2. Chemical Structure of Heparin and HS 
Both heparin and HS are linear, unbranched polysaccharides composed of 
disaccharide units consisting of a hexuronic acid 1,4-linked to a D-glucosamine unit 
(Figure 3A).
2
 The hexuronic acid can be D-glucuronic acid (GlcAp) or its C5 epimer, L-
iduronic acid (IdoAp). While GlcAp units are largely unmodified, IdoAp units are 
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frequently modified by 2-O-sulfation. D-glucosamine residues (GlcNp) may be N-
acetylated or N-sulfated, while N-sulfated residues may be further modified by 3 and/or 6-
O-sulfation. These distinct possibilities and combinations have resulted in the 
identification of as many as 23 different disaccharide building blocks to date (Figure 4).
104
 
Thus, heparin and HS contain a staggering number of differentially sulfated saccharide 
sequences. 
Heparin has a molecular weight ranging from 5 to 40 kDa with an average of about 
15 kDa.
105
 The majority of heparin‘s uronic acid (> 70 %) residues are L-iduronic 
acid.
106,107
 A prototypical heparin disaccharide contains three sulfate groups rendering 
heparin the most acidic polymer in our body (Figure 3B). HS chains tend to be longer than 
A) B)
O
OX
OH
COO
O
NHY
OX
CH2OX
OO
_
O
OSO3
OH
COO
O
NHSO3
OH
CH2OSO3
OO
_
_ _
_
m n
NA domain NS domain
C) O
OH
OH
COO
O
O
NHAc
OH
CH2OH
O
OX
OH
COO
OO
O
NHSO3
OX
CH2OX
O
_
_
_
X = H/OSO3 , Y = H/Ac/SO3  
_ _
Hexuronic
Acid
D-Glucosamine
 
Figure 3. A) Variable disaccharide of heparin and HS. B) Preponderant disaccharide of 
heparin. C) Domain architecture of HS 
 
 
13 
 
heparin and vary from 5 to 50 kDa with an average molecular weight of 30 kDa. HS is 
considerably enriched in unsulfated N-acetyl GlcNp and GlcAp disaccharides. These 
disaccharides are present contiguously to form N-acetyl domains (NA domains, Figure 
3C).
108
 Relatively shorter segments of sulfated disaccharides containing IdoAp and N-
sulfated GlcNp derivatives (NS domains) are found between two NA domains. 
Interestingly, HS chains also contain some sections of mixed NA/NS domains with 
moderate degrees of sulfation. It is hypothesized that these mixed NA/NS domains 
constitute specific protein-binding motifs.
1
 It is important to note that the domain 
architecture of HS is absent in heparin, which may be considered as an extended NS 
domain of HS. 
1.2.1. Conformation of Heparin and HS 
Given the numerous biological roles of GAGs, several different research groups 
have attempted to understand the conformation of these molecules (full length polymers as 
well as oligosaccharides) through NMR studies.
109-114
 In addition, several GAG-protein 
crystal structures that have emerged in the past decade have helped corroborate 
conclusions that were derived from solution-based NMR studies.
50,52,53,115-122
 Some groups 
have studied the conformation of GAGs by X-ray diffraction of polysaccharide films.
123,124
 
Collectively, these studies have pointed out that, unlike proteins, GAGs do not fold into 
globular structures but remain linear in solution. Specifically, the GAG backbone retains a 
helical conformation wherein the exact helical parameters (n, the number of disaccharides  
14 
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per turn and h, the axial rise per disaccharide) depend on the nature of cationic counterions. 
For the sodium form of both heparin and HS, n=2 and h=8.4 Å. 
Given the helical symmetry, the precise topology of the GAG chain is determined 
by the glycosidic bond torsions and pyranose ring conformations. For heparin/HS, GlcNp 
and GlcAp residues adopt a relatively rigid 
4
C1 chair conformation, while IdoAp residues 
are more flexible and have the ability to populate multiple low-energy forms such as the 
1
C4 and 
4
C1 chair forms and the 
2
SO skew-boat form (Figure 5).
125
 While internal 
IdoAp 2S residues reside predominantly in the 
1
C4 chair (60 %) and 
2
SO skew-boat (40 %) 
forms, the equilibrium is displaced towards the 
2
SO form when an IdoAp2S residue is 
preceded by a 3-O-sulfated aminosugar.
114,125,126
 For terminal unsulfated IdoAp residues, 
the 
4
C1 chair form is also possible. 
 
 
1.3. Biosynthesis of GAGs 
HS chains are assembled while attached to a proteoglycan (PG) core protein. Three 
major families of core PG core proteins have been characterized: the syndecans,
127
 the 
glypicans,
128
 and the basement membrane PG perlecan.
129
 While the syndecans are 
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Figure 5. Major IdoAp conformations that exist in GAGs 
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membrane-spanning proteins, glypicans are anchored to the membrane via a phospholipid 
tether. Although these different core proteins are expressed in a cell-type specific manner,  
the structure of HS does not appear to correlate with the core proteins but rather on the cell 
type of origin.
130
 Heparin is also synthesized on a core protein called serglycin in 
mastoctyes. However, after biosynthesis, heparin is shed from the core protein and remains 
associated with mast cell granules. 
Heparin and HS are assembled via a similar pathway by over 30 different 
enzymes.
104
 Chain initiation occurs at the Golgi apparatus by the action of 4 different 
glycosyl transferases. The resulting tetrasaccharide attached to a specific serine residue on 
the core protein through an O-glycosidic bond, serves to prime chain elongation. 
Subsequently, N-acetyl-D-GlcNp residues and D-GlcAp residues are added in an 
alternating fashion to the non-reducing end of the nascent GAG chain. Two glycosyl 
transferases (EXT1 and EXT2) that form hetero-oligomeric complexes in the Golgi 
apparatus are responsible for the disaccharide addition. When these disaccharides remain 
unmodified, they constitute the NA domains of HS. As the polysaccharide chain forms, it 
is simultaneously modified by at least four different families of sulfotransferases and one 
epimerase. N-deacetylation and N-sulfation is the first of these modifications and is carried 
out by a multi-functional N-deacetylase/N-sulfotransferase. A C5 epimerase and different 
O-sulfotransferases perform subsequent modifications to generate different saccharide 
sequences. Interestingly for HS, these modifications remain localized forming short 
stretches of NS domains. 
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The sequence diversity of HS is governed by the controlled cell-type dependent 
expression of the biosynthetic enzymes and the presence of distinct enzyme isoforms with 
unique substrate specificities. Interestingly, the type of disaccharides and the relative 
content of NA, NS and NA/NS domains found in HS appear to be a stable characteristic of 
the cell type of origin.
131-136
 Not surprisingly, while the theoretical number of disaccharide 
units considering all combination of structural modifications is 48, only 23 have been 
identified (Figure 4).
104
 The sulfation states of HS are also dynamically regulated in 
embryonic cells during development and in adult normal and cancer cells that respond to 
growth factor signals.
137-140
 In addition, once HS chains have been synthesized, their 
sulfation states are subject to considerable degree of post-biosynthetic remodeling by 
sulfatase enzymes. Recently, a novel family of cell surface 6-O-endosulfatases has been 
discovered.
141
 These enzymes are distinguished in two respects: 1) they have a unique 
―endolytic‖ mode in contrast to the ―exolytic‖ mode of action of other HS sulfatases,142 
and 2) they play a key role in signaling pathways.
141
 Thus, HS sequence diversity is also 
governed by the controlled expression of sulfatases in cells. 
1.4. The Sulfation Code and Specificity in the Interaction of GAG with Proteins 
From the discussion above, it is apparent that GAGs can modulate protein activity 
in two fundamentally different ways. GAGs may serve as non-specific templates to 
proteins. Such templates may serve to a) reduce entropic costs of biological reactions, (see 
section 1.1.1) b) serve as a repository for extra-cellular proteins like growth factors,
143,144
 
and c) help maintain protein gradients across cells.
145
 Indeed, GAGs have been shown to 
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maintain morphogen gradients across cells and tissues that are essential for developmental 
processes.
145
 Maintaining such gradients would involve graded affinities between GAG 
sequences and protein. In such paradigms, it is the non-specificity in GAG-protein 
interactions that results in biologically significant functions. 
GAGs may also modulate protein function through specific high-affinity 
interactions. Such specific interactions are typically dependent on the presence of a unique 
set of modifications localized to a region of the GAG chain. In such a specific paradigm, it 
appears that the distribution of sulfate groups on a GAG chain dictates which protein it 
would bind. A limited number of specific GAG sequences have been elucidated to date.  
The most thoroughly researched specific GAG sequence is the antithrombin-
binding H5 sequence (Figure 3A). This sequence was discovered in the early 1980s by the 
Lindahl and Rosenberg groups and found to be essential for heparin‘s anticoagulant 
activity.
146,147
 The presence of the 3-O-sulfate in ring F and the D-glucuronic acid residue 
are striking features given that most of heparin consists of an IdoAp-based trisulfated 
disaccharide (Figure 3B). A second interesting specific sequence appears to be the HSV-1 
gD-binding sequence (Figure 6B). This sequence was reported in 2002 and contains a rare 
GlcNH33S residue.
148
 The precise configuration of the hexuronic acid rings and the 
minimal size required for binding remain unknown at the present time. It is worth 
mentioning that the 3-O-sulfotransferase isoform (3-OST3) that installs the 3-O-sulfate 
group in this sequence is different from the one that installs the 3-O-sulfate group in the 
H5 sequence (3-OST1).
90
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As little as a hexasaccharide is required to define the binding domain for FGF-2 (Figure 
6C).
149-151
 In addition to N-sulfation of the GlcNp units, the one IdoAp disaccharide is 
required for binding. It is known that HS serves to bridge FGF-2 and its receptor to form 
an active signaling complex in a 2:2:1 (FGF-2:FGF-2R:GAG) stoichiometry (see section 
1.1.2). Interestingly, while 6-O-sulfation is not required for binding to FGF-2, it is an 
essential requirement for HS binding to the FGF-2 receptor. Thus, 6-O-desulfated 
sequences serve as antagonists by binding to FGF-2 and preventing receptor signaling.
152
 
More recently, a specific chondroitin sulfate (a type of GAG) tetrasaccharide that 
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recognizes the neuronal protein midkine has been reported (Figure 6D).
153
 The authors 
have established through chemical synthesis of analogs that the distribution of sulfate 
groups on the tetrasaccharide is critical to activity. 
Over-all, GAGs are versatile molecules that modulate biological functions through 
either non-specific or specific interactions with proteins. Given the widespread roles of 
GAGs in biology, specific GAG sequences provide an opportunity for the development of 
GAG-based molecules to treat a wide range of disorders.  
1.5. Developing GAG-Based Therapeutics 
Several challenges in drug development need to be overcome in order to exploit the 
vast potential of complex GAGs and clarify important structure-activity relationships. 
First, methods to identify specific GAG sequences from a complex mixture of sequences 
need to be developed. Given the structural complexity of GAGs and difficulties of 
isolation of small amount of HS from cell surfaces, this represents a monumental task. 
Previous methods have circumvented the problem of HS isolation by relying on heparin, 
which may be readily extracted from porcine intestinal mucosa, as a substitute. Thus, 
affinity column chromatography of heparin oligosaccharides is the most common method 
for identifying specific GAG sequences. Although this method has successfully resulted in 
the identification of the antithrombin-binding H5 sequence, it is clearly limited to the 
sequences present in heparin, which largely consists of a single, repeating disaccharide. In 
order to exploit the structural diversity in GAGs, affinity chromatography of HS rather 
than heparin needs to be carried out. Yet, this method is not practical since it requires 
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significant quantities of isolated HS. Furthermore, unlike DNA, small amounts of isolated 
HS cannot be amplified because of the complex GAG biosynthetic machinery. Recently, 
Sasisekharan and co-workers reported a mass spectrometric-based method to sequence 
small amounts (pmol) of isolated HS.
154,155
 This method involved the immobilization of the 
target protein on a hydrophobic surface followed by the application of a HS mixture. Non-
specific sequences were removed by salt washes and any adherent specific sequences were 
structurally characterized using MALDI-MS. This work is novel and has the potential to 
expedite the identification of specific GAG sequences. It is important to point out that the 
main drawback of a HS isolation/sequencing approach is the impending risk that the 
isolated HS sample may not contain the sequences responsible for in vivo activity because 
of the variability of HS structure with tissue type of origin. 
Synthesis of a library of HS sequences followed by high-throughput screening 
represents a second approach to develop GAG-based therapeutics. Chemical synthesis of 
GAGs remains a formidable frontier and poses several challenges.
156
 While initial efforts 
aimed at targeting individual sequences, current efforts are modular and are geared towards 
the synthesis of different sequences from a common set of building blocks. The two 
primary obstacles in the development of an efficient modular synthetic approach are: 1) 
restricted access to the non-natural L-iduronic acid monosaccharides, which are often 
prone to epimerization along the synthetic pathway, and 2) stereoselective formation of the 
inter-glycosidic linkages.  
Automated, solid-supported synthesis of GAGs represents an attractive avenue to 
gain rapid access to HS libraries. While automated carbohydrate synthesis is a nascent 
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field, it is a rapidly burgeoning one too.
157
 Seeberger and co-workers have achieved the 
automated synthesis of a dodecasaccharide using a modified Applied Biosystems 443 
peptide synthesizer as the first prototype instrument.
157
 These workers have also assembled 
a hexasaccharide-based malarial antigen using a semi-automated approach. To date, no 
GAG sequences have been assembled using automated, solid-supported synthesis. Another 
innovative approach towards the synthesis of GAG libraries is the programmable one-pot 
strategy that Chi-Huey Wong and co-workers have developed.
158
 This approach relies on 
the sequential one-pot coupling of different monosaccharides that differ in their anomeric 
reactivity to yield a single sequence. Using this approach, a HS pentasaccharide was 
rapidly assembled. 
Chemo-enzymatic approaches to gain access to HS libraries have also been 
reported.
159-161
 These approaches involve chemical desulfation and/or deacetylation of 
heparin or heparosan polysaccharides followed by resulfation using O-sulfotransferase 
enzymes. By using different combinations of O-sulfotransferase enymes, libraries of 
polysaccharides may be generated. This approach can also be modified to generate 
oligosaccharides by cleaving heparin chains using heparanase before the resulfation step. 
While it is possible to generate milligram quantities of polysaccharides, chemo-enzymatic 
approaches provide limited information on structure-activity relationships because the 
enzymatic reactions do not proceed to completion and perform similar modifications 
across the entire polysaccharide chain. Nevertheless, chemo-enzymatic methods provide a 
powerful approach to further the development of GAG-based therapeutics and may serve 
to complement total synthesis efforts. 
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So far as high throughput screening of GAG libraries is concerned, several groups 
have reported carbohydrate microarrays to analyze carbohydrate-protein interactions and a 
few of these reports pertain to GAGs.
162-166
 The miniature array format permits detection of 
multiple binding events simultaneously and requires minimal amount of carbohydrate and 
protein. While these methods provide an opportunity for the rapid interrogation of GAG-
protein interactions, they are limited by the availability of GAG libraries. 
In conclusion, several different experimental approaches to develop GAG-based 
therapeutics are being pursued. It is worth mentioning that no theoretical approaches to 
identify specific GAG sequences have been developed. Significant hurdles need to be 
surmounted at the present time before an era of GAG-based therapeutics ensues. This is 
evident from the fact that only one GAG sequence (the H5 sequence) is currently in the 
clinic.
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DEVELOPING NON-SACCHARIDE MIMICS OF SPECIFIC 
GAG SEQUENCES 
 
Our research group questioned the fundamental assumption that the saccharide 
skeleton is essential for the activity of specific GAG sequences. We hypothesized that 
specific GAG sequences contain structural redundancies that complicate drug 
development. In addition, non-saccharide heparin/HS mimics may provide several 
advantages over the GAG skeleton: 1) ease of laboratory-scale chemical synthesis and 
amenability to industrial-scale production to meet growing market demands; 2) possibility 
of oral delivery due to enhanced hydrophobic character when compared to GAGs; 3) 
possibility of additional non-ionic binding energy and enhanced specificity to the target 
protein; and 4) ability to modulate responses in either an agonist or an antagonist manner. 
In the pursuit of a simplified yet effective approach to capitalize on the diversity of GAGs, 
non-saccharide mimics of the H5 sequence were designed and evaluated.
167
  
As described earlier, the H5 sequence binds to the serpin antithrombin (AT) in the 
pentasaccharide-binding site and induces a major conformational change that dramatically 
enhances its rate of factor-Xa inhibition (section 1.1.1). Desai and co-workers have shown 
through structure-activity relationship studies that while residues D, E, F, G, and H of the  
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H5 sequences are required for high-affinity binding (50 nM) and complete activation (300-
fold) of antithrombin, residues D, E and F can bring about full activation at 1000- fold 
higher concentrations (Figure 7A).
168
 Thus, the H2S group is important for high affinity 
interaction but does not contribute to AT activation.  Using the trisaccharide DEF as a 
template, Desai et al. designed small, non-saccharide molecules called sulfated flavans 
using hydropathic interaction (HINT)
169
 analysis (Figure 7B). These molecules were 18 
and 80 M and weakly activate the inhibitor (~10-fold). Competitive binding experiments 
                                                 
 The importance of the H2S group has been determined by the synthesis of an analog that is devoid of this 
group (van Boeckel, C. A. A; Petitou, M. Angew. Chem. Intl. Ed. Engl., 1993, 32, 1671-1818) 
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Figure 7. Structures of the H5 sequences (A), and non-saccharide DEF mimics (B). 
Critical sulfate groups of the H5 sequence are encircled. While the H2S group 
contributes to affinity only, the D2S, F2S and F3S groups are required for both high 
affinity and activation. 
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readily synthesized in one step from commercially available flavonoids and biochemically 
evaluated.
170
 The results indicated that sulfated flavans bind to AT with an affinity 
betweensuggested that the non-saccharide designs by-pass the targeted pentasaccharide-
binding site in AT and bind in the adjoining extended heparin-binding site.
171
 This result 
explains the weak activation of AT. In order to determine structure-activity relationships 
several analogs of sulfated flavans including sulfated flavones were synthesized (Figure 
7B). However, initial synthetic efforts towards sulfated flavones were unproductive 
because these non-saccharide designs possess significantly greater charge density than 
GAGs.
172
 Hence an alternate synthetic route to sulfated flavones that involved reductive 
cleavage of 2,2,2-trichloroethyloxysulfonyl-protected flavonoids was developed (Figure 
8).
173
 Using this method, six sulfated flavones bearing different sulfate group distributions 
were synthesized and evaluated. The results indicated that the activity of these molecules 
were comparable to sulfated flavans and not critically dependent on the location of sulfate 
groups.
173
 Thus, sulfated flavans and flavones bind non-specifically to the smaller 
extended-heparin binding site in AT and result in weak activation. 
To improve upon the activation potential of non-saccharide mimics, it was 
hypothesized that increasing the length of these molecules by the addition of a linker 
between the bicyclic and unicyclic flavonoid rings may favor binding to the larger 
pentasaccharide-binding site. Taking synthetic feasibility into consideration, HINT 
analysis was used to arrive at the tetrahydroisoquinoline-based design IAS5 (Figure 9). 
When compared to sulfated flavonoids, this molecule contains a modified bicylcic ring, a 
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Figure 9. Structure of IAS5 
 
 
one-carbon linker between bicyclic and unicyclic rings and an extra negative charge in the 
form of a carobxylate group. Molecular modeling was used to confirm that there was a 
close correspondence between the sulfate and carboxylate groups of a low energy 
conformation of IAS5 and that of the 
trisaccharide DEF. Despite exhaustive attempts 
to synthesize IAS5 from commercially available 
precursors, IAS5 remained intractable to 
chemical synthesis because of problems with sulfation and introduction of a free 
carboxylate group. In this regard, both traditional sulfation and TCE protection-
deprotection failed.  
2.1. Specific Aims of the Research Project 
Taking into account the problems encountered with the chemical synthesis of small 
sulfated non-saccharide molecules and the lack of computational approaches to identify 
specific GAG sequences (section 1.5), a set of specific aims were devised as follows – 
O
O
OH
HO
R
O
O
OTCE
TCEO
R
TCE = 2,2,2-trichloroethyloxysulfonyl (CCl3CH2OSO2-)
O
O
OSO3
O3SO
R
_
_
 
Figure 8. TCE-protection-deprotection strategy for the synthesis of sulfated flavones 
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Aim 1) Develop a rapid and efficient synthetic method for highly sulfated small 
molecules 
Aim 2) Synthesize and biochemically characterize the potential non-saccharide AT 
activator, IAS5, and its analogs 
Aim 3) Develop a computational method to identify specific GAG sequences that 
may bind to any given GAG-binding protein  
Aim 4) Use the method developed in aim 3 to design non-saccharide molecules that 
may target the pentasaccharide-binding site in antithrombin 
Aim 5) Synthesize and biochemically characterize the non-saccharide designs from 
aim 4 
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MICROWAVE-BASED SYNTHESIS OF HIGHLY SULFATED 
SMALL MOLECULES 
 
3.1. Introduction 
Recent work in our laboratory shows that designed highly sulfated, aromatic, small 
organic molecules possess interesting physico-chemical and biological 
properties.
167,170,171,173 
Biochemically, these molecules form multiple ionic as well as non-
ionic interactions, which form the backbone of most protein-recognition elements. 
Structurally, these represent mimics of glycosaminoglycans (GAGs), which are 
increasingly being recognized as modulators of key physiological functions,
2,3
 while 
toxicologically, the sulfated structure represents a highly water-soluble, already-
metabolized form that is expected to possess minimal toxicity. Despite these novel 
features, highly sulfated organic molecules remain largely unexplored. 
A major limitation in exploring these novel structures is their challenging synthesis. 
Nearly all small organic sulfates reported in the literature are mono- or di-sulfated 
molecules,
174-178
 typically prepared using sulfur trioxide complexes with amines in a highly 
polar solvent (DMF or DMA). Sulfation of such organic scaffolds may require as many as 
13 hrs and temperatures as high as 95 C in the presence of a large excess of the sulfating 
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complexes,
174-178
 while sugars, which contain multiple –OH groups, require reaction times 
in the range of 12 hrs to several days.
153,179-182
 
Theoretically, this method could be extended for synthesis of highly sulfated drug-
like molecules, yet practically it is a synthetic nightmare because these molecules possess 
significantly higher negative charge density.
172
 The major challenge is driving the reaction 
to completion in order to sulfate all available hydroxyl groups (alcoholic or phenolic) on 
the substrate. As the number of –OH groups increase on a small scaffold, sulfation 
becomes progressively more difficult because of anion crowding, resulting in numerous 
partially sulfated side-products. 
A further challenge is the isolation of the chemically pure per-sulfated product, 
which requires aqueous isolation techniques. Yields in the range of 11 and 100% have 
been reported, yet the presence of inorganic salts arising from the use of buffers and salts 
leads to significant inconsistencies and inaccuracies. Additionally, instability of highly 
anionic products introduces limitations on reaction times and temperature.
153
 This is likely 
to be especially true for highly sulfated, aromatic, small organic molecules, which are 
expected to be less stable than the saccharide scaffolds. 
To avoid these problems with one-step sulfation, we recently synthesized some 
small aromatic per-sulfated structures using a two-step approach involving the 2,2,2-
trichloroethyl protecting group.
173
 The two-step protection-deprotection protocol resolved 
some of the problems of the direct sulfation approach, yet required careful real-time 
monitoring of the reaction by RP-HPLC to prevent product degradation and was not 
particularly applicable to substrates that were acid and/or metal sensitive. These limitations 
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led us to seek an alternative sulfation approach, which can be rapid, efficient, and widely 
applicable to a number of poly-hydroxy scaffolds. We hypothesized that significant rate 
enhancements are likely to be achieved using microwaves, especially because the ionic 
sulfated product may couple to microwaves through ionic conduction, e.g., in CH3CN.
183
 
CH3CN was chosen as the solvent over the commonly used DMF because a) it can be 
evaporated at lower temperature (thus aiding isolation) and b) it was likely to solubilize the 
per-sulfated product with an amine counter-ion. We also hypothesized that introducing free 
base in the reaction mixture should promote the difficult per-sulfation reaction. 
3.2. Results 
We began our studies on microwave-aided sulfation using the polyhydroxyl 
precursor 1 (see Table 2).  This structure was chosen for its resemblance to the targeted 
molecule IAS5, which was designed to mimic the trisaccharide DEF of the antithrombin-
activating H5 sequence (see Figure 9).  
Sulfation of 1 with SO3●Me3N complex (6 equivalents per –OH group) at 100 C 
in the absence of free base gave only 4.7 % of per-sulfated product 1s in 20 minutes (Table 
2, entry 1).  Inclusion of 1 equivalent of free Et3N per –OH group resulted in 13.5 % 
conversion (entry 2), while 79.8 % of 1s was formed with 5 equivalents of Et3N (entry 3).  
                                                 
 Compound 1 was synthesized in two steps from commercially available materials. See Chapter 4 for details.  
 
 RP-HPLC profile showed peaks from 4.3-6.0 min, in addition to one at 9.0 min. The peak at 4.3 was 
subsequently isolated after optimization of conditions and determined to be per-sulfated (1s). The peak at 9.0 
min was identified as 1 by comparison with synthetically pure sample. Conversions (%) were determined by 
area normalization. 
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Table 2. Optimization of microwave-assisted sulfation of tetrahydroisoquinoline 
derivative 1 
 
 
 
 
Time 
(min) 
Temp 
( C) 
Additional Conditions 
HPLC 
Yield 
(%) 
1 20 100 No base 4.7
 
2 20 100 1 equiv. Et3N per OH grp. 13.5
 
3 20 100 5 equiv. Et3N per OH grp. 79.8
 
4 20 100 a 80.0 
5 10 100 
1 equiv. SO3 Me3N per 
OH grp. 
14.5 
6 10 100 
3 equiv. SO3 Me3N per 
OH grp. 
46.1 
7 10 100 a 47.4 
8 10 100 
9 equiv. SO3 Me3N per 
OH grp. 
79.5 
9 10 100 
12 equiv. SO3 Me3N per 
OH grp. 
80.7
 
10 10 100 DMF as solvent 17.2
 
11 10 100 CH3NO2 as solvent 23.2
 
12 10 100 
With 6 equiv SO3 py/OH 
grp and 10 equiv py/OH 
grp as base. 
82.3
 
13 10 40 a 0 
14 10 70 a 18.2 
15 10 120 a 90.8 
16 30 100 a 91.2 
 
a 
Reaction conditions here are as listed above with no other modifications 
 
 
 
 
 
 
N
O
OH
OH
OH
OH
N
O
OS
OS
SO
SO
MW; CH3CN
40 – 100 C, 5–30 min
6 Equiv Me3N SO3 per OH grp
10 Equiv Et3N per OH grp
1                                                               1s (S=SO3Na)
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Further increase to 10 equivalents Et3N per –OH group had a negligible increase in the 
yield of 1s (entry 4). Increasing the proportion of SO3●Me3N per –OH group from 1 to 9 
molar equivalents (Table 2, entries 5-8) gradually increased the yield of the per-sulfated 
product from 14.5 to 79.5 %, while further increase to 12 equivalent was found to be not 
particularly advantageous (entry 9). Thus, 6 and 10 molar equivalents of the sulfating 
complex and base, respectively, were chosen for further studies. 
To assess the effect of solvent, we chose to evaluate nitromethane and DMF, both 
of which are solvents with high dielectric constant and known to be microwave-friendly. 
While only 23.2 and 17.2 % of per-sulfated product 1s was formed from 1 in 10 minutes at 
100 C in CH3NO2 and DMF, respectively, 47.4% of the product was formed in CH3CN 
(Table 2, entries 10 and 11). Thus, our initial choice of CH3CN proved to be optimal. To 
assess the effect of temperature and reaction time, sulfation was performed for 10–30 
minutes at 40 to 120 C. While 30 minutes were required to yield 91.2 % of 1s at 100 C, 
only 10 minutes were needed for 90.8 % conversion at 120 C. In striking contrast, no 
product was detected at 40 C within 10 minutes. Finally, SO3●py/py complex was found 
to give nearly twice as much per-sulfated product as SO3●Me3N/Et3N complex (entries 7 
and 12) in 10 minutes at 100 C. Since pyridine is ~ 10,000-fold weaker base in 
comparison to Et3N, this result suggests general base catalysis as the predominant 
mechanism of sulfation rather than a process involving deprotonation of the substrate 
followed by nucleophilic attack. 
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Table 3. Microwave-assisted sulfation of poly-hydroxyl substrates 
 Microwaves, 100 C, 20-30 min
Et3N (10 equiv/OH), SO3 Me3N 
(6 equiv/OH), CH3CN
Substrate Product
 
 
Entry Substrate Product 
a
 
Isolated 
Yield (%) 
1 
 
N
O
OH
OH
OH
OH
 
1  
N
O
OS
OS
SO
SO
 
1s 
85 
2 
 
N
O
OH
OH
OH
OH
 
2  
N
O
OS
SO
SO
OS
 
2s 
87 
3 
 
N
O
OH
OH
OH
OH
OH
 
3  
N
O
OS
SO
SO
OS
OS
 
3s 
54
b
 
4 
 
N
O
OH
OH
OH
OH
COOEt
 
4  
N
O
OS
SO
SO
OS
COOEt
 
4s 
74 
5 
 
O
CH
2
OH
O
OH
OH
OH
CH
2
OH
 
5  
O
CH
2
OS
O
OS
OS
OS
CH
2
OS
 
5s 
84
c
 
6 
 
CH
3
OH
OH  
6 
CH
3
OS
SO  
6s 
94
c
 
7 
 
O H
H
OH
O
OH
OH
HOH
2
C
OH
OH
 
7 
O H
H
SO
O
SO
SO
SOH
2
C
OS
SO
 
7s 
72
d
 
8 
 
OH
CHO
 SO
CHO
 
97
c,e
 
 
a
S: SO3Na. 
b
With 9 equiv of SO3 Me3N/OH group. 
c
With SO3 py (6–9 equiv/OH group) and pyridine as 
base. 
d
Reaction conditions: 120 , 10 min, SO3 py (12 equiv/OH group) and pyridine as base. 
e
S = 
SO3 pyH
+
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Appropriate control reactions in the absence of microwaves using two different substrates 
– 1 and 3 (entries 2 and 3 in Table 3) – at 60 C in DMF with no free base showed poor 
product yields. For example, it took 24 hrs in the absence of microwaves to yield 1s in 
60% yield, while 3s was not detected even after 24 hrs (entry 3, Table 3). These results 
highlight the importance of microwaves in achieving rapid per-sulfation. 
Having optimized the reaction conditions, we assessed whether the method works 
for a variety of different substrates. Per-sulfation of 2 proceeded smoothly in a manner 
identical to 1 (Table 3).
24
 More importantly, per-sulfation of 3, containing the crowded 
3,4,5-trihydroxy moiety, was achieved under microwave conditions in an isolated yield of 
54 %, while the conventional procedure completely failed to give 3s. Finally, microwave-
assisted per-sulfation also works extremely well for substrates 5 through 8 containing one 
to six –OH groups. Interestingly, 5 and 6 gave a mixture of products with SO3●Me3N, but 
yielded the per-sulfated products with SO3●py. 
3.3. Discussion 
Several points make the microwave-assisted synthetic protocol particularly 
attractive. A) The method appears to tolerate a range of functional groups including amide 
(Table 3, entries 1 through 4), ester (entry 4), aldehyde (entry 8) and double bond (entry 7). 
The relatively isolated yields (~70–95%) in each case make the reaction especially suitable 
for library construction. B) The method works equally well for substrates containing one –
OH group and those that contain six –OH groups. This is important because the small size 
of these molecules introduces considerable anion–anion repulsion as the number of sulfate 
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groups increase. C) The method applies equally well to alcoholic and phenolic –OH 
groups, especially with SO3●py complex. D) The method provides high purity per-sulfated 
product that is readily isolated using an aqueous G10 filtration column. Typically, the 
purity of these highly water soluble, per-sulfated, small, organic molecules was found to be 
more than 95% using reverse polarity capillary electrophoresis. E) The method is 
particularly suitable for quantitative isolation of small amounts (<10 mg) of the per-
sulfated products, but could be linearly scaled up at least 20-fold without affecting the 
yields to a significant extent. 
It appears that the rate-accelerations achieved in our experiments is related to the 
phenomenon of microwave-induced dielectric heating
184
 and the ability of acetonitrile to 
efficiently absorb microwave energy and convert it into heat. When the reaction mixture is 
irradiated with microwaves at a frequency of 2.45 GHz, the acetonitrile dipoles align in the 
applied electric field. As the applied field oscillates, the dipoles tend to realign with 
oscillating electric field and, in the process, lose energy in the form of heat (dielectric loss). 
If the solvent dipoles realign too quickly or do not have enough time to realign, no heating 
will occur. It appears that at 2.45 GHz, the frequency of most commercially available 
microwave system, the molecular dipole realignment time is optimal. Microwave 
irradiation of the sulfation reaction mixture therefore produces internal heating resulting in 
highly efficient heat transfer and consequently rapid reaction rates. 
In summary, we have developed a rapid and high yielding microwave-based 
synthesis of variably functionalized, per-sulfated organic molecules. The protocol is 
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expected to greatly facilitate the construction of a library of per-sulfated, small organic 
molecules for screening as glycosaminoglycan mimetics. 
3.4. Experimental Section 
3.4.1. General Methods 
All reactions sensitive to air or moisture were carried out under nitrogen 
atmosphere in oven-dried glassware. All reagent solutions unless otherwise noted were 
handled under an inert nitrogen atmosphere using syringe techniques. Anhydrous 
dichloromethane and acetonitrile were purchased from Sigma-Aldrich and Acros Organics, 
respectively, and were used without further drying. Trimethylamine-sulfur trioxide and 
pyridine-sulfur trioxide complexes were purchased from Alfa-Aesar and Fluka, 
respectively. All other reagents/chemicals were purchased from Sigma-Aldrich and were 
used as supplied. Analytical thin-layer chromatography (TLC) was performed using 
UNIPLATE
TM
 silica gel GHLF 250 m pre-coated plates (ANALTECH, Newark, DE) that 
were analyzed by fluorescence (254 nm). Column chromatography was performed using 
silica gel (40-60 m, 60 Å, Silicycle, Quebec, Canada) and the indicated technical grade 
solvents. After chromatography, solvents were evaporated using a Büchi rotary evaporator, 
followed by further treatment under high vacuum. 
Microwave-based sulfation reactions were performed using a CEM-Discover 
(Matthews, NC) synthesizer in sealed reaction vessels (7 mL). The stirring parameter in the 
microwave synthesizer was set to ―Hi-speed‖. The reaction mixture was ramped to 100 or 
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120 ºC using the following power-temperature steps: 1) 50 W, r.t. – 80 ºC, and 2) 10 W, 
80-100/120 ºC. The reaction vessel was simultaneously cooled using nitrogen (45 psi) to 
maintain the set temperature. 
Sephadex G10 chromatography (de-salting) and SP Sephadex-Na chromatography 
(cation exchange) were performed using Flex columns (KIMBLE/KONTES, Vineland, NJ) 
of dimensions 170 × 1.5 cm and 75 × 1.5 cm, respectively. Cation exchange was 
performed with 30-fold excess of sodium ion equivalents. Samples were chromatographed 
at a controlled flow rate of 0.5 mL/min with water as eluent. Five mL fractions were 
collected and analyzed by RP-HPLC or capillary electrophoresis (see below). 
1
H-NMR and 
13
C-NMR were recorded on Varian Mercury-300 MHz or Varian 
Inova-400 MHz spectrometers in CDCl3, DMSO-d6, CD3OD or CD3COCD3. All signals 
are reported in ppm with the internal chloroform, DMSO, CD3OD and CD3COCD3 signals 
at 7.26, 2.50, 3.31 and 2.05 ppm, respectively, as standards. The data is being reported as: 
chemical shifts (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quadruplet, m = 
multiplet or unresolved, br = broad signal), coupling constant(s) (Hz), and integration 
ESI mass spectra were recorded using a Micromass ZMD 4000 single quadrupole 
spectrometer. Samples were dissolved in methanol or methanol-acetonitrile (1:1) and 
infused at a rate 10 L/min. Mass scans were obtained in the range 100-1300 amu at a scan 
rate of 400 amu/s. Ionization conditions were optimized for each compound to maximize 
ionization of the parent ion. The capillary voltage was varied between 3.0 and 4.5 V, while 
the cone voltage usually ranged from 20 to 80 V. For all experiments, the extractor voltage 
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was set to 4.0, the Rf lens voltage to 0.1 V, the source block temperature to 100 ºC and the 
desolvation temperature to 120 ºC. 
Capillary electrophoresis using a Beckmann PACE/ MDQ unit was performed to 
test completion of sulfation reaction and assess isolated product purity. An uncoated fused 
silica capillary of 50 m internal diameter and 32.5 cm effective length to the detector 
window was used. Samples were typically injected under a pressure of 0.5-1 psi for 5 s and 
detected spectrophotometrically using a 254 nm filter. Electrophoresis was performed 
under reverse polarity conditions at 25 °C and a constant voltage of 10 kV using 20 mM 
sodium phosphate, pH 2.7 or 4.3. 
HPLC analysis was carried out on a Shimadzu chromatography system using 
Waters Atlantis dC18 column (5 , 4.6 × 250 mm). The mobile phase consisted of a 100 
mM sodium chloride-acetonitrile mixture(7:3 v/v) run at a constant flow rate of 0.5 
mL/min. Analysis was carried out using a uv-vis detector at 254 nm. 
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3.4.2. Experimental procedures and spectral data 
Synthesis of amides 11a -c:  To a stirred suspension of amine 9 (2g, 8.7 mmol) and 
triethylamine (6.1 mL, 43.5 mmol) in dichloromethane (40 mL) at 0 ºC, was added acid 
chloride 10a-c (9.14 mmol, 1.05 equiv.). The reaction mixture was allowed to warm to 
room temperature and refluxed. After 4 hrs, the reaction mixture was diluted with 
dichloromethane (50 mL), washed with 0.5 N HCl (3 × 50 mL) and potassium carbonate (3 
× 50 mL), dried over anhydrous Na2SO4, and concentrated in vacuo to obtain a colorless 
oil (82 - 87 %). 11a: 
1
H-NMR (300 MHz, CD3COCD3): δ 6.59 – 6.90 (m, 5H), 4.71 (br s, 
2H), 3.64 – 3.84 (m, 14 H), 2.87 (br, 2H); ESI (+ve) m/z calcd for C20H23NO5 [(M+H)
+
] 
358.17, found 358.3; 11b: 
1
H NMR (300 MHz, CD3COCD3) δ 6.87 – 6.92 (m, 3H), 6.60 
Et3N, CH2Cl2
reflux 
(82 – 87%)
9 10a: R1, R3 = OMe, R2 = H
10b: R1, R2 = OMe, R3 = H
10c: R1, R2, R3 = OMe
BBr3, CH2Cl2
-78 ºC – rt
(52 – 70%)
SO3.Me3N, Et3N, MeCN
Microwaves, 100 ºC
(54 – 87 %)
+NH.HCl
MeO
MeO
R1
R2
Cl
O
R3
1: R1, R3 = OH, R2 = H
2: R1, R2 = OH, R3 = H
3: R1, R2, R3 = OH
N
HO
HO
O
R1
R2
R3
N
NaO3SO
NaO3SO
O
R1
R2
R3
1s: R1, R3 = OSO3Na, R2 = H
2s: R1, R2 = OSO3Na, R3 = H
3s: R1, R2, R3 = OSO3Na
N
MeO
MeO
O
R1
R2
R3
11a: R1, R3 = OMe, R2 = H
11b: R1, R2 = OMe, R3 = H
11c: R1, R2, R3 = OMe
 
Figure 10. Synthesis of poly-sulfated tetrahydrosioquinoline derivatives 1s-3s 
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(s, 2H), 4.5 (s, 2H, CH2), 3.63 – 3.72 (m, 14 H), 2.67 (t, J = 5.7 Hz, 2H); ESI (+ve) m/z 
calcd for C20H23NO5 [(M+H)
+
] 358.17, found 358.1; 11c: 
1
H-NMR (300 MHz, 
CD3COCD3): δ 6.77 – 6.79 (m, 4H), 4.68 (s, 2H), 3.77 – 3.88 (m, 17 H), 2. 84 (t, J = 5.7 
Hz, 2H); ESI (+ve) m/z calcd for C21H25NO6 [(M+H)
+
] 388.18, found 388.1 
Polyphenols 1-3: To a stirred solution of the amide (7.0 – 7.5 mmol) in 
dichloromethane (80 mL) at -78 ºC, was added BBr3 (36 – 42 mL of 1M solution in 
CH2Cl2, 1.2 equiv per OMe group) under N2 over 15 minutes. After stirring for 12 hrs at rt, 
the reaction was quenched at 0 C with MeOH (10 mL) and water (10 mL). The reaction 
mixture was partitioned between EtOAc (220 mL) and 2N HCl (50 mL). The aqueous 
layer was diluted with brine (50 mL) and washed with EtOAc (6 х 50 mL). The combined 
organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified 
by silica gel chromatography (Hexanes/EtOAc = 1:1, 1:4, 1:4.5, 0:1) to give a yellow solid 
(52 - 70%). 1: 
1
H NMR (300 MHz, CD3OD) δ: 6.30 – 6.61 (m, 5H, isomers I & II), 4.66 
(s, 2H, isomer I), 4.44 (s, 2H, isomer II), 3.88 (t, J = 6.0 Hz, 2H, isomer II), 3.62 (t, J = 6.0 
Hz, 2H, isomer I), 2.80 (t, J = 6.0 Hz, 2H, isomer II), 2.73 (t, J = 6.0 Hz, 2H, isomer I); 
ESI (+ve) m/z calcd for C16H15NO5 [(M+H)
+
] 302.10, found 302.2, ESI (-ve) calcd for 
C16H15NO5 [(M-H)
-
] 300.09, found 300.07; 2: 1H NMR (300 MHz, CD3OD): δ 6.40 - 6.91 
(m, 5H), 4.63 (br s, 2H), 3.68 – 3.86 (m, 2H), 2.77 (s, 2H); ESI (+ve) calcd m/z for 
C16H15NO5 [(M+H)
+
] 302.10, found 302.16, ESI (-ve) calcd for C16H15NO5 [(M-H)
-
] 
300.09, found 300.1; 3: 
1
H NMR (400 MHz, CD3OD): δ 6.54 (s, 2H), 6.44 (s, 2H), 4.48 – 
4.56 (m, 2H), 3.62 – 3.78 (m, 2H), 2.72 (s, 2H); ESI (+ve) m/z calcd for C16H15NO6 
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[(M+H)
+
] 318.10, found 318.0, ESI (-ve) calcd for C16H15NO6 [(M-H)
-
] 316.08, found 
316.0 
Per-sulfates 1s and 2s: To a stirred solution of the poly-alcohol (20 mg, 0.066 
mmol) in MeCN (1 mL) at rt, Et3N (0.4 mL, 2.9 mmol) and Me3N.SO3 (220 mg, 1.6 
mmol) was added. The reaction vessel was sealed and micro-waved for 20 minutes at 100 
ºC. The reaction was repeated for 4 times and the reaction mixture was pooled together. 
The MeCN layer was decanted and pooled, while the residue from each tube was washed 
with MeCN (5 mL) and centrifuged. The combined MeCN layers were concentrated in 
vacuo. Water (5 mL) was added to the residue and stirred for 10 min. The water layer was 
concentrated to approximately 2 mL, loaded onto a Sephadex G10 column (~ 160 cm) and 
chromatographed using water as eluent. Fractions were combined based on RP-HPLC 
profiles, concentrated and re-loaded onto a SP Sephadex C25 column for sodium 
exchange. Appropriate fractions were pooled, concentrated in vacuo and lyophilized to 
obtain a white powder (84 - 87 %). 1s: 
1
H NMR (DMSO, 400 MHz) δ: 7.29 – 7.30 (m, 
2H), 6.94 – 6.97 (m, 3H), 4.58 (s, 2H, isomer I), 4.48 (s, 2H, isomer II), 3.58 (s, 2H, 
isomer II), 3.50 (s, 2H, isomer I), 2.66 (br, 2H, isomer I & II); ESI (-ve) m/z calcd for 
C16H11NNa4O17S4 [(M-Na)
-
] 685.86, found 686.1; 2s: 
1
H NMR (DMSO, 400 MHz) δ: 7.65 
(d, J = 2.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.29 (s, 2H), 6.99 (dd, J = 8.4, 1.6 Hz, 1H), 
4.54 (s, 2H), 3.70 (br, 2H), 2.69 (t, J = 4.8 Hz, 2H); ESI (-ve) m/z calcd for 
C16H11NNa4O17S4 [(M-Na)
-
] 685.86, found 686.0 
Per-sulfate 3s: To a stirred solution of the poly-alcohol (20 mg, 0.063 mmol) in 
MeCN (1.3 mL) at rt, Et3N (0.5 mL, 3.6 mmol) and Me3N.SO3 (390 mg, 2.8 mmol) was 
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added. The reaction vessel was sealed and microwaved for 30 minutes at 100 ºC. The 
reaction was repeated for 4 times for scale up. The product 3s (121 mg, 54 %) was isolated 
according to the above procedure for 1s and 2s. 3s: 
1
H NMR (DMSO, 400 MHz) δ: 7.37 
(s, 2H), 7.29 (s, 2H), 4.54 (s, 2H), 3.53 (s, 2H), 2.68 (s, 2H); ESI (-ve) m/z calcd for 
C16H10NNa5O21S5 [(M-Na)
-
] 803.79, found 804.1 
 
 
Ester 13 — To a stirred solution of amino acid 12 (2 g, 7.32 mmol) in EtOH (50 
mL) at rt, HCl (g) was passed for 2 minutes and the reaction was refluxed. After 24 hrs, the 
reaction was brought to rt and the solvent was evaporated off. Ethyl acetate (50 mL) was 
added to the residue and extracted with 5 % K2CO3 solution (3 х 25 mL) and water (2 х 20 
mL). The organic layer was dried (Na2SO4) and evaporated to obtain a colorless oil (1.4 g, 
72 %). 
1
H NMR (CDCl3, 400 MHz) δ: 6.59 (s, 1H), 6.51 (s, 1H), 4.22 (q, J = 7.2 Hz, 2H), 
12: R = COOH
10b, Et3N, CH2Cl2
14: R = OMe
4: R = OH
4s: R = OSO3Na
13: R = COOEt
EtOH, HCl (g)
(74 %)
reflux 
(72 %)
BBr3, CH2Cl2
-78 ºC – rt
(73 %)
SO3.Et3N, Et3N, MeCN
Microwaves, 100 ºC
(74 %)
NH.HCl
MeO
MeO
R
N
R
R
COOEt
O
R
R
 
Figure 11. Synthesis of poly-sulfate 4s (IES4) 
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4.03 (s, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 3.68 (dd, J = 10.4, 4.4 Hz, 1H), 2.98 (dd, J = 16, 
4.4 Hz, 1H), 2.86 (dd, J = 15.6, 10 Hz, 1H), 1.29 (t, J = 7.2 Hz, 3H) 
Amide 14: The procedure for the synthesis of amides 11a-c was used to prepare 14 
(72%) 
1H NMR (DMSO, 400 MHz) δ: 6.69 – 7.03 (m, 5H), 4.81 – 5.14 (m, 1H, isomers I - 
III), 4.27 – 4.57 (m, 2H, isomers I – III), 3.98 – 4.04 (m, 2H, isomers I – III), 3.62 – 3.78 
(m, 12H, isomers I – III), 3.09 – 3.32 (m, 2H, isomers I – III), 1.00 – 1.11 (m, 3H, isomers 
I – III); ESI (+ve) m/z calcd for C23H27NO7 [(M+H)
+
] 430.18, found 430.4 
Poly-phenol 4: The procedure for the synthesis of polyphenols 1-3 was to prepare 4 from 
amide 14 (73%). 
1
H NMR (DMSO, 400 MHz) δ: 8.78 – 9.35 (m), 6.35 – 6.81 (m, 5H), 
4.69 – 4.99 (m, 1H, isomers I - III), 4.17 – 4.43 (m, 2H, isomers I – III), 3.50 – 3.57 (m, 
2H, isomers I – III), 2.89 – 3.02 (m, 2H, isomers I – III), 1.00 – 1.11 (m, 3H, isomers I – 
III) 
Per-sulfate 4s (IES4): The procedure for the synthesis of poly-sulfates 1s and 2s 
was used to prepare 4s from polyphenol 4 (74%). 
1
H NMR (DMSO, 400 MHz): δ 6.96 – 
7.70 (m, 5H), 4.83 – 5.16 (m, 1H isomers I - III), 4.18 – 4.44 (m, 2H, isomers I – III), 3.55 
– 3.61 (m, 2H, isomers I – III), 2.99 – 3.13 (m, 2H, isomers I – III), 1.08 – 1.16 (m, 3H, 
isomers I – III); ESI (-ve) m/z calcd for C19H15NNa4O19S4 [(M-Na)
-
] 757.88, found 757.5 
Salicin per-sulfate 5s (Figure 12): To a stirred suspension of salicin (5, 20 mg, 0.07 
mmol) in MeCN (1 mL) at rt, pyridine (0.3 mL, 3.8 mmol) was added to form a clear 
solution. C5H5N.SO3 (500 mg, 3.14 mmol) was added and the reaction vessel was sealed 
and micro-waved for 30 minutes at 100 ºC. The reaction was repeated for 4 times. The 
reaction  
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mixture was quenched with methanol (2 mL), pooled and concentrated in vacuo. The 
residue was taken up in water (1 mL) and chromatographed following the protocol 
established for 1s to obtain 5s (236.8 mg, 84 %). 
1
H NMR (DMSO, 400 MHz) δ: 7.33 – 
7.35 (m, 1H), 7.16 – 7.20 (m, 1H), 6.93 – 6.97 (m, 1H), 6.88 – 6.90 (m, 1H), 5.24 (d, J = 
5.2 Hz, 1H) (s, 2H), 3.53 (s, 2H), 2.68 (s, 2H); ESI (-ve) m/z calcd for C16H10NNa5O21S5 
[(M-Na)
-
] 772.81, found 
772.7  
Estradiol-3,17 -disulfate (6s): The procedure for the synthesis of salicin per-sulfate 
5s was used to prepare 6s from estradiol (94%). 
1
H NMR (DMSO, 400 MHz) δ: 7.1 (d, J = 
8.4 Hz, 1H), 6.81 – 6.83 (m, 2H), 4.02 (t, J = 8.0 Hz, 1H), 2.71 – 2.74 (m, 2H), 2.21 – 2.25 
HOH2C
O
O OH
OHHO
HO
NaO3SOH2C
O
O OSO3Na
OSO3NaNaO3SO
NaO3SO
5 5s
 
Figure 12. Synthesis of poly-sulfate 5s 
HO
OH
H
H
H
NaO3SO
OSO3Na
H
H
H
6 6s
 
Figure 13. Synthesis of estradiol-3,17 -disulfate (6s) 
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(m, 1H), 2.08 – 2.12 (m, 1H), 1.87 – 2.00 (m, 2H), 1.75 – 1.78 (m, 1H), 1.48 – 1.60 (m, 
2H), 1.09 – 1.34 (6H), 0.66 (s, 3H); ESI (-ve) m/z calcd for C18H22Na2O8S2 [(M-Na)
-
] 
453.07, found 453.1 
 
7s: The procedure for the synthesis of salicin per-sulfate 5s was essentially used to 
prepare 7s from stilbene 7, except that 12 equiv. SO3.py complex per –OH group was used 
and the reaction vessel was irradiated for 10 min at 120 ºC (72%). 
1
H NMR (DMSO, 400 
MHz) δ: 7.56 (s, 1H), 7.54 (s, 1H), 6.99 – 7.10 (m, 7H), 6.61 (s, 1H), 5.36 (s, 1H), 4.63 (s, 
1H), 4.59 (s, 1H), 4.39 (s, 1H), 4.14-4.18 (m, 1H), 4.08 (d, J = 8.8 Hz, 1H) 3.81 (t, J = 10 
Hz, 1H); ESI (-ve) m/z calcd for C20H16Na6O26S6 [(M-Na)
-
] 978.77, found 979.0 
p-Hydroxy benzaldehyde O-sulfate (8s) (Figure 15): The procedure for the 
synthesis of salicin per-sulfate 8 was essentially used to prepare 8s from aldehyde 8, except 
that the reaction vessel was irradiated for 10 min at 120 ºC following which the product 
with pyridinium cation was directly isolated by lyophilization after G10 chromatography 
(97%,). 
1
H NMR (DMSO, 400 MHz) δ: 9.76 (s, 1H), 8.94 – 8.96 (m, 2H), 8.62 – 8.68 (m, 
HOH2C
O
O
OHHO
HO
HO
HO
7 7s
NaO3SOH2C
O
O
OSO3NaNaO3SO
NaO3SO
NaO3SO
NaO3SO
 
Figure 14. Synthesis of poly-sulfate 7s 
47 
 
1H), 8.09 – 8.14 (m, 2H), 7.72 – 7.75 (m, 2H), 6.92 – 6.95 (m, 2H); ESI (-ve) m/z calcd for 
C12H11NO5S [(M-pyH
+
)
-
] 200.99, found 200.8 
 
CHO
OH
8 8s
CHO
OSO3pyH
_
+
 
Figure 15. Synthesis if poly-sulfate 8s 
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3.4.3. Capillary electropherograms of sulfated compounds 1s – 8s 
The following electropherograms were recorded to assess the purity of synthesized 
poly-sulfated compounds 1s-8s (see Table 3). Experimental conditions may be found in 
section 3.4.1). 
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SYNTHESIS AND BIOLOGICAL EVALUATION OF DESIGNED 
ANTITHROMBIN ACTIVATOR IAS5 AND ANALOGS 
 
4.1. Introduction 
Antithrombin (AT)-based anticoagulants, first introduced in 1916,
6
 include heparin, 
low molecular weight heparin (LMWH) and the recently (2001) introduced fondaparinux 
(FX),
185
 and are all administered parenterally. Structurally, these agents belong to the 
glycosaminoglycan superfamily and are highly anionic molecules.  Their anticoagulant 
effect arises from binding to and activating the circulating coagulation inhibitor, AT . 
The prototype of this group, heparin, suffers from several limitations: e.g., potential 
to cause bleeding, heparin-induced thrombocytopenia (HIT), osteoporosis, platelet function 
inhibition, and unpredictable dose-response effects.
7
 While LMWH is gradually replacing 
heparin and is more therapeutically cost-effective, it still suffers from similar drawbacks.
186
 
The heterogeneity and polydispersity of both heparin and LMWH are the causes of the 
above mentioned side-effects. These side-effects are reduced by using the homogeneous 
heparin preparation  fondaparinux, which is a synthetic five-residue sequence based on  
                                                 
 Detailed information on the structure and conformation of heparin may be found in section 1.2 
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the naturally occurring H5 sequence (Figure 7). Compared to heparin or LMWH, result s 
from clinical trials with fondaparinux are more promising with a low probability of causing 
HIT but its long term efficacy and safety is yet to be ascertained.
187
 In addition, 
fondaparinux does not interact with protamine sulfate, the heparin antidote, making it 
difficult to manage drug-induced bleeding. Nevertheless, the initial success of 
fondaparinux has validated factor Xa as a target for new AT-based anticoagulants. 
The heparin-binding site in antithrombin (AT) is an engineering marvel. The 
binding site is located some 20 Å away from the reactive center loop (RCL) which is 
required for recognition and covalent inhibition of  target proteases like thrombin and 
factor Xa. The heparin-binding site is formed by the positively charged residues of helices 
A and D of AT, and the polypeptide N-terminus.
118
 Binding of the H5 sequence causes a 
conformational change that is relayed to the RCL resulting in enhanced exposure (Figure 
16).
188
 Specifically, H5 binding causes elongation of helix D (1-2 turns) which results in 
positive pressure on sheet A. This results in expulsion of the partially inserted RCL and 
enhanced recognition of target proteases. Importantly, the conformational change also 
results in the creation of an exosite in -strand 3C that plays an important role in specific 
recognition of factor Xa.
189
 Thus, conformational activation by H5 specifically enhances 
the rate of the AT-factor Xa reaction.  
The H5-binding domain, called the pentasaccharide-binding site (PBS), is primarily 
formed by a positively charged triad comprised of Lys114, Lys125 and Arg129 (Figure 
17). Biochemical site-directed mutagenesis studies suggest that these three residues 
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Figure 16. Structures of the native (left) and activated (right) conformations of antithrombin. Structural differences are 
highlighted as follows – red: reactive center loop (RCL), green: helix D of the heparin-binding site, orange: elongation of 
helix D on heparin binding, yellow: formation of a new helix P 
5
1
 
 
  
52 
 
helix D
helix P
RCL
helix A
A)                                                            B)
Lys136
Arg133
Lys132
Arg129
Lys125
Arg47
Arg46
Lys114
D
E
F
G
H
EHBS
PBS
 
Figure 17. Stucture of heparin-complexed antithrombin. Part A shows the heparin-binding site and its position relative to the 
reactive center loop (RCL). Part B shows a zoomed-in version of the heparin-binding site along with critically interacting 
aminoacids. This figure is adapted from reference 167. 
5
2
  
  
53 
 
contribute ~50%, 25-33% and 28-35% of the total binding energy, respectively.
190-192
 
Other residues that play a minor role include Lys11, Arg13, Arg24, Arg46, Arg47 and 
Trp49.
193-195
 Each of these residues contribute some 5-20 % of the total binding energy. In 
addition to interacting with the PBS, full-length heparin chains also interacts with residues 
Arg132, Lys133 and Lys136 located at the C-terminal end of helix.
196
 The domain formed 
by these residues is called the extended heparin-binding site (EHBS). This interaction is 
supported by the fact that mutation of Arg132 and Lys133 selectively impairs the binding 
of heparin but not H5. 
Although heparins and fondaparinux are effective at treating thrombotic disorders, 
their adverse side effect profiles make them less desirable anticoagulant medications. We 
reasoned that an alternative approach with nonsaccharide activators of antithrombin, 
molecules that are completely devoid of the heparin‘s saccharide scaffold, would be 
desirable. In our first attempt, we designed non-saccharide sulfated flavonoids (Figure 7) 
as mimics of trisaccharide DEF based on hydropathic interaction (HINT) analyses.
170,171
 
These sulfated flavonoids possess a structure dramatically different from heparin and were 
found to bind antithrombin with an affinity comparable to DEF and accelerated factor Xa 
inhibition approximately 10-fold. Competitive binding experiments suggested that the 
sulfated flavonoids by-pass the targeted PBS in AT and bind in the adjoining EHBS.
171
 We 
hypothesized that an incremental increase in the size of the flavonoid skeleton may favor 
binding to the PBS. Based on this premise, a tetrahydroisoquinoline derivative, IAS5, was 
designed and evaluated along with a few analogs. 
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4.2. Rationale for the design of tetrahydroisoquinline derivative, IAS5 
To improve on the antithrombin activation potential of these organic activators, a 
tetrahydroisoquinoline-based bicyclic-unicyclic sulfated activator IAS5 was designed. 
Figure 18 shows the pharmacophore-based rational design of tetrahydroisoquinoline 
activators. Structure-activity studies show that three sulfate groups, i.e., the 6-O-sulfate on 
residue D and 3-O-sulfate and 2-N-sulfate on residue F, and the 6-carboxylate group of 
residue E are critical for conformational activation of antithrombin, while the trisaccharide 
scaffold only serves to position these groups for optimal interaction.
26
 Thus, the 
pharmacophore was extracted and the four critical groups were connected in three-
dimensional space using a linear carbon linker to arrive at a first ‗blueprint‘ of an activator. 
The blueprint was transformed into a potential organic activator by introducing rigidity and 
simplifying the structure for rapid synthesis. In this process, several scaffolds were 
modeled and their similarity with the pharmacophore assessed. IAS5, the 
tetrahydroisoquinoline-based activator containing an acid functionality and five sulfate 
groups, was selected because it retained the three-dimensional configuration of the four 
critical groups (Figure 19). In addition, the 2-N-sulfate of residue D was also effectively 
mimicked by a sulfate group of the isoquinoline ring. Calculation of the root mean square 
deviation between the five corresponding groups gave a value of 2.0 Å (range 1.1 to 2.7 
Å), which reduced to 1.6 Å when only the groups of the pharmacophore were considered. 
In this design, it is suggested that the bicyclic ring mimics the D and E rings, the unicyclic 
ring mimics ring F, and the carboxylate groups match each other. To assess the importance 
of selected groups, we decided to study ester analogs, IES5 and IES4, as well as an acid 
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derivative with one less sulfate group, IAS4 (Figure 20). 
4.3. Results 
4.3.1. Synthesis of IAS5 and its analogs 
Nearly all small organic sulfates reported in the literature are mono- or di-sulfated 
molecules, typically prepared using sulfur trioxide complexes with amines in a highly 
polar solvent (see section 3.1 for a discussion). Yet, as the number of –OH groups increase  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Rationale used in the design of tetrahydroisoquinoline-based organic activator 
IAS5. Four critical anionic groups (highlighted as filled ovals) of trisaccharide DEF 
formed the pharmacophore. Connecting the groups using a carbon framework followed 
by engineering of rigidity that matches their orientation gave rise to a ‗blueprint‘, which 
was transformed into a synthetically plausible target, IAS5 
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on a small scaffold, sulfation becomes progressively more difficult because of anion 
crowding. We recently developed a rapid and high-yielding microwave-based synthesis of 
polysulfated organic molecules using trimethylamine– or pyridine– sulfur trioxide 
complexes in the presence of excess amine in anhydrous acetonitrile at 100 – 120 OC.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Overlay of DEF and IAS5 showing superposition of five anionic groups. The 
three critical sulfate groups – 6-OSO3
-
 on residue D and 3-OSO3
-
 and 2-OSO3
-
 on residue 
F – as well as the 6-COO- group of residue E overlay well on three sulfate and one 
carboxylate groups of IAS5 in three dimensional space. In addition, the 2-OSO3
-
 group of 
residue D matches one of the remaining two sulfates on IAS5. The overall RMSD for the 
five anions was 2.0 Å. See text for details. 
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Thus, ester analogs IES4 (4s) and IES5 were prepared in four steps from commercially 
available starting materials (see Appendix A for details on the synthesis). However, the 
microwave-assisted sulfation failed to yield any sulfated products when the substrate was 
the polyphenolic molecule containing an acid group (Figure 21A). It is possible that the 
presence of naked carboxylic acid functionality under microwave conditions induces 
degradation of organic sulfates resulting in multiple products. To circumvent this problem, 
the carboxylic acid ester in IES4 and IES5 was hydrolyzed in excellent yields by simply 
stirring with KBuO-t / H2O (2:1) in anhydrous DMSO at RT (Figure 21B).
197
 It is 
worthwhile to mention that this hydrolysis fails miserably when standard saponification 
X Y
IAS5 SO3 COO
IAS4 H COO
IES5 SO3 COOEt
IES4 H COOEt
N
O3SO
O3SO
O
Y
X
OSO3
OSO3
_
_
_ _
_
_
 
Figure 20. Structures of IAS5 and its analogs that vary in number of sulfate groups 
and/or presence/absence of free carboxylate group 
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conditions (NaOH/water) are used. 
4.3.2. Equilibrium Dissociation Constant of Antithrombin Interaction with 
Sulfated Isoquinoline-based Activators 
Previously we have used fluorescence spectroscopy for measuring the affinity of 
ligands for antithrombin. For saccharide ligands, e.g., DEFGH and DEF, the ~30% 
increase in intrinsic tryptophan fluorescence affords a convenient signal for the 
determination of the KD of the interaction,
27,168
 while for our first generation sulfated 
favonoids, we used an external probe, TNS, to determine binding affinity.
170,171
 In this 
study, we found that interaction of our designed organic ligands with antithrombin resulted 
KBuO-t, H2O (2:1), 
DMSO
N
NaO3SO
NaO3SO
O
R1
R2
R3
COONa
N
NaO3SO
NaO3SO
O
R1
R2
R3
COOEt
IES4/4s: R1 = R2 = OSO3Na,   R3 =H
IES5: R1 =R2 = R3 = OSO3Na
IAS4: R1 = R2 = OSO3Na,   R3 =H
IAS5: R1 =R2 = R3 = OSO3Na
N
NaO3SO
NaO3SO
O
OSO3Na
OSO3Na
R
COOH
N
HO
HO
O
OH
OH
R
COOH
R = H/OH R = H/OSO3Na
A)
B)
 
Figure 21. Synthesis of acid derivatives IAS4 and IAS5 by selective cleavage of 
corresponding ethyl esters (B). Direct sulfation of the precursor carboxylic acid results in 
an intractable mixture of products (A). 
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in a decrease in intrinsic tryptophan fluorescence that reached a plateau at high ligand 
concentrations (Figure 22). An equivalent limiting decrease of ~100% was obtained for 
IAS5, IES4 and IES5, which could be fitted with the standard quadratic binding equation I 
(see section 4.5) to obtain the KD of interaction at pH 7.4, I 0.15, 25 
O
C. KD values of 320, 
330 and 805 M were measured for IAS5, IES4 and IES5, respectively, corresponding to a 
similar free energy of binding between 4.2 and 4.8 kcal/mol (Table 4). For IAS4, the 
fluorescence titration could not be made to reach an endpoint and, hence, a significantly 
weaker affinity (KD > 1mM) is estimated. The affinity of reference trisaccharide DEF for 
antithrombin under similar conditions (pH 7.4, I 0.15, 25 
O
C) has not been reported, 
however a KD value of 66  4 M has been measured in the absence of any added salt (pH 
7.4, I 0.05, 25 
O
C).
168 
In comparison, the affinities of IAS5, IES4 and IES5 under these 
conditions were found to be 37, 50, and 130 M (data not shown), respectively, suggesting 
that the designed activators compare favorably with trisaccharide DEF in antithrombin 
affinity. Likewise, the affinities of the first generation, flavonoid-based scaffolds under pH 
7.4, I 0.15, 25 
O
C conditions were found to be approximately 130 ± 20 M corresponding 
to a ∆GO of 5.3 kcal/mol,171 approximately 0.5 to 1 kcal/mol better than the 2nd generation 
agents. 
4.3.3. Competitive Binding of Pentasaccharide DEFGH to Antithrombin in 
the Presence of IAS5 
To test whether the 2
nd
 generation organic activators bind in the PBS, we studied 
the affinity of pentasaccharide DEFGH for antithrombin in the presence of varying  
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Figure 22. Fluorescence-based measurement of the equilibrium dissociation constant of 
organic activator – antithrombin complex at pH 7.4, I 0.15, 25 OC. Interaction of organic 
activators with antithrombin resulted in a saturable decrease in intrinsic tryptophans 
fluorescence at 340 nm ( EX = 290 nm), which was fitted to the quadratic binding equation 
I (section 4.5)to calculate the observed KD. Solid lines represent the non-linear 
regressional fit. 
Table 4. Thermodynamic and kinetic parameters for the interaction of the organic 
activators with plasma antithrombin at pH 7.4, I 0.15, 25 
O
C. 
 KD,OBS 
( M)
a 
FMAX  
(%)
 
G
O
 
(kcal/mol) 
kACT 
(M
-1
s
-1
)
 Acceleration
 
IAS5 320 10
c 
-1.3 0.2 4.8 0.2 69,780 580 30 
IES5 805 70 -1.2 0.2 4.2 0.4 6160 240 2.7 
IES4 330 20 -1.4 0.2 4.8 0.3 10860 480 4.7 
IAS4 >1000
 
na na 5,370
 
2.3
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concentrations of a representative activator, IAS5. The competitive binding experiment is 
made particularly easy because the two ligands induce opposite changes in intrinsic 
antithrombin fluorescence. While DEFGH induces ~30 – 35 % increase in intrinsic protein 
fluorescence at 340 nm,
27,168
 IAS5 induces ~100% decrease (above). Thus, if IAS5 and 
DEFGH compete for the same binding site, it would be reasonable to expect that the 
affinity of DEFGH for antithrombin decreases in a manner predicted by the Dixon-Webb 
relationship.
 
Figure 23 shows the observed affinity (KD) and maximal fluorescence change 
(∆FMAX) in antithrombin – DEFGH titrations in the presence of increasing concentrations 
of IAS5. The KD value remained steady between 50 5 nM (0 M IAS5) and 31 7 nM (264 
M IAS5) suggesting that the presence of the organic activator does not affect the 
interaction of DEFGH with antithrombin. Likewise, the ∆FMAX value remained essentially 
constant between 37 (17 M IAS5) and 31 % (67 M IAS5), further supporting the 
independence of the two ligands in interacting with antithrombin. These results suggest 
that IAS5 does not bind in the PBS. Alternatively, the results suggest that the 2
nd
 generation 
activators may bind in the EHBS in a manner similar to the first generation agents.
171
 
4.4. Discussion 
Overall, the results show that non-saccharide IAS5, designed on the basis of 
mimicking the trisaccharide pharmacophore activates antithrombin nearly 30-fold for the  
                                                 
 Dixon-Webb relationship states that for competing ligands L1 and L2, the affinity of L2 in the presence of 
L1 (KL2,L1≠0) would be related to that in its absence (KL2,L1=0) through the relationship KL2,L1≠0 = 
KL2,L1=0 [1+[L1]O/KD,L1]. 
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accelerated inhibition of factor Xa. This represents a 2-3-fold improvement in acceleration 
in comparison to that achieved with the first generation flavonoid-based activators. Despite 
the advance, IAS5 is approximately 10-fold weaker than trisaccharide DEF (or 
pentasaccharide DEFGH) suggesting that major structural improvements in the organic 
scaffold are necessary. 
The key reason for the difference in the antithrombin activation potential between 
IAS5 and DEF (or DEFGH) is the difference in their site of binding. Whereas IAS5 does 
 
 
 
 
 
 
 
 
 
Figure 23. Competitive binding of pentasaccharide H5 to antithrombin in the presence 
of organic activator IAS5. Equilibrium dissociation constants (KD, shaded bars) and 
maximal change in fluorescence (∆FMAX, open bars) of fluorescence titrations of 
DEFGH binding to antithrombin at pH 7.4, I 0.15, 25 
O
C in the presence of varying 
concentrations of IAS5 (0 to 264 M) are shown. Error bars represent 1 S. E 
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not engage the pentasaccharide-binding site (PBS), DEF (and DEFGH) is known to bind in 
the PBS. This implies that IAS5 does engage the three members of the electropositive triad, 
Lys114, Lys125 and Arg129, which is known to play a crucial functional role in the 
mechanism of heparin binding and conformational activation of antithrombin.
167,198
 Thus, 
IAS5 is similar to sulfated flavonoids with respect to site of binding. 
Despite these results, it is interesting that IAS5 is able to significantly enhance the 
inhibition of factor Xa. A plausible explanation is that IAS5 binds to the activated form of 
antithrombin that exists in pre-equilibrium with the native form, thereby altering the 
equilibrium more in favor of the activated state. This mechanism of antithrombin 
activation has been noted earlier with smaller oligosaccharides that possess relatively weak 
affinity for the serpin.
168
 
4.5. Experimental section 
Synthesis and Characterization of Organic Activators    IES4 and IES5 were 
synthesized from corresponding methoxy-protected intermediates in two steps, namely 
demethylation and sulfation (see Appendix A). The carboxylate derivatives IAS4 and IAS5 
were synthesized from IES4 and IES5, respectively. Briefly, each ester (0.03 – 0.08 mmol) 
was stirred with potassium t-butoxide and H2O (2:1 molar equivalent, 3 equiv. KBuO-t) in 
DMSO (0.1 M) under nitrogen at room temperature until the starting material was 
consumed (HPLC analysis, 1 – 3 h),16 after which sodium dibasic phosphate (10 equiv) in 
H2O (2 mL) was added to the reaction mixture. Following 15 min of stirring, the reaction 
                                                 
 Detailed synthetic procedures, schemes and capillary electropherograms may be found in Appendix A 
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mixture was loaded onto a Sephadex G10 column (160 cm) and chromatographed using 
water as an eluent. Fractions were combined, concentrated under vacuum and lyophilized 
to obtain the sodium salt of the carboxylate as a white solid. Capillary electrophoresis of 
both products using a fused silica capillary in 20 mM sodium phosphate buffer, pH 2.3, at 
10 kV showed a single peak with greater than 95% purity (see Appendix A). IAS4: 
1
H-
NMR (400 MHz, 
2
H2O): δ 6.99-7.51 (m, 5H), 4.72 – 4.85 (m, 2H), 4.42 – 4.52 (m, 1H), 
3.01-3.16 (m, 2H); ESI (-ve) m/z calcd for C17H10NNa5O19S4 [(M-Na)¯] 751.83, found 
751.91; IAS5: 
1
H NMR (400 MHz, 
2
H2O) δ 7.05 – 7.46 (m, 5H), 4.75-4.99 (m, 2H), 4.47-
4.53 (m, 1H), 3.03–3.11 (m, 2 H); ESI (-ve) m/z calcd for C17H9NNa6O23S5 [(M+H)
+
] 
869.77, found 869.83. 
Proteins and Chemicals  Antithrombin and factor Xa (human forms) was 
purchased from Haematologic Technologies (Essex Junction, VT) and used as received. 
Molar concentrations of antithrombin were calculated from absorbance measurements at 
280 nm using a MAX of 37,700 M
-1
cm
-1
. Antithrombin was stored in 20 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM NaCl, 0.1 mM EDTA and 0.1% (w/v) 
PEG8000 at -78 
O
C, while factor Xa was stored in 5 mM MES buffer, pH 6.0, containing 
25 mM NaCl at -78 
O
C until use. Factor Xa substrate Spectrozyme FXa was obtained from 
American Diagnostics, Greenwich, CT. Trimethylamine-sulfur trioxide complex was 
purchased from Alfa-Aesar (Ward Hill, MA). All other reagents/chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO). 
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Experimental Conditions  Antithrombin interaction and activation studies were 
performed at 25 
O
C and in 20 mM sodium phosphate buffer, containing 100 mM NaCl, 0.1 
mM EDTA and 0.1% (w/v) PEG 8000, adjusted to 7.4. The ionic strength of this buffer is 
0.135 and the buffer is labeled as pH 7.4, I 0.15, 25 
O
C buffer. 
Fluorescence Spectroscopy and Equilibrium Binding Studies  Fluorescence 
experiments were performed using a QM4 fluorometer (Photon Technology International, 
Birmingham, NJ) in pH 7.4, I 0.15, 25 
O
C buffer. Equilibrium dissociation constants (KD) 
for the interaction of organic activators with plasma antithrombin were determined by 
titrating the activator into a solution of plasma antithrombin and monitoring the decrease in 
the fluorescence at 340 nm ( EX = 290 nm). The slit widths on the excitation and emission 
side were 1 mm and 2 mm, respectively. The decrease in fluorescence signal was fit to the 
quadratic equilibrium binding equation I to obtain the KD of interaction, wherein F 
represents the change in fluorescence following each addition of the activator ([ACT]O) 
from the initial fluorescence FO and FMAX represents the maximal change in fluorescence 
observed on saturation of antithrombin ([AT]O). 
O
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Competition between DEFGH and IAS5 binding to antithrombin was studied in pH 
7.4, I 0.15 buffer at 25 
O
C by monitoring the increase in fluorescence at 340 nm ( EX = 280 
nm) as a function of the concentration of DEFGH. Several titrations were performed at 
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different concentrations of activator IAS5 (0 to 264 M) and the KD and FMAX values 
were calculated using equation 1. 
Factor Xa Inhibition Studies  The kinetics of inhibition of factor Xa by 
antithrombin in the presence of organic activators under pseudo-first order conditions was 
measured spectrophotometrically in a manner similar to our earlier work.
10,12
 A fixed 10 
nM concentration of factor Xa was incubated with fixed concentrations of plasma 
antithrombin (0.1 to 0.5 M) and the sulfated activator (0 to 100 M) in pH 7.4, I 0.15 
buffer at 25 
O
C. At regular time intervals, an aliquot of the inhibition reaction (100 L) 
was quenched with 900 L of 100 M Spectrozyme FXa in pH 7.4, I 0.15 buffer and the 
initial rate of substrate hydrolysis was measured from the increase in absorbance at 405 
nm. The exponential decrease in the initial rate of substrate hydrolysis as a function of time 
was used to determine the observed pseudo-first order rate constant of factor Xa inhibition 
(kOBS). A plot of kOBS values measured as a function of different concentrations of an 
organic activator could be described by equation II, in which kUNCAT is the second-order 
rate constant of factor Xa inhibition by antithrombin alone, i.e., 2300 M
-1
s
-1
 at pH 7.4, I 
0.15, 25 
O
C,
10
 and kACT is the second-order rate constant of factor Xa inhibition by 
antithrombin – organic activator complex. 
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COMBINATORIAL VIRTUAL SCREENING OF HEPARIN & 
HEPARAN SULFATE 
 
5.1. Introduction 
Glycosaminoglycans heparin and heparan sulfate play diverse roles in a number of 
physiological and pathological processes including coagulation,
 
angiogenesis, immune 
response and viral infection.  These functions originate from their interaction with 
numerous proteins, which include serpins, antithrombin and heparin cofactor II, 
coagulation proteinases, fibroblast growth factors and their receptors, cytokines and viral 
cell envelope glycoproteins. It is commonly assumed that these roles arise from an optimal 
combination of specificity and affinity, yet, except in a few cases, the specificity of heparin 
and heparan sulfate (HS) interactions remain ill-defined and poorly understood.  
A major reason for the ill-defined structure-activity relationships in these 
heparin/HS interactions is the phenomenal structural diversity of heparin/HS 
glycosaminoglycans (GAGs), and its concomitant difficulties, especially synthesis, 
                                                 
 See section 1.1 for a discussion of the physiological roles of GAGs 
 For a discussion of specific GAG sequences, see section 1.4 
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purification, and structure identification.
 
Both heparin and heparan sulfate are complex, 
highly anionic polysaccharides composed of alternating 14-linked glucosamine and 
uronic acid residues, which are variously modified through sulfation, acetylation and 
epimerization.
199
 These modifications can produce 48 different building blocks, or 
disaccharides, of which 23 have been found to date. Further, the iduronic acid residue 
(IdoAp) can exist in multiple conformations, especially 
1
C4 and 
2
SO for internal locations, 
that can inter-convert relatively easily.
111,125
 Thus, combination of structural and 
conformational variability generates millions of sequences, of which few are expected to 
recognize a target protein. This expectation is further borne out by the growing evidence 
that the heparan sulfate biosynthetic apparatus has considerable specificity and 
organization.  
On the protein front, considerable effort has been made in trying to deduce 
consensus binding sequences that recognize heparin structures. Whereas Cardin and 
Weintraub suggested linear consensus sequences with specific repeat pattern to be 
important for heparin binding, others have suggested a spatial distance relationship.
200-202 
Although it is clear that arginine and lysine residues lining protein surfaces dominate 
heparin-binding sites, their optimal 3D orientation that generates high specificity and 
affinity remains unclear. The situation is further compounded because not all arginine and 
lysine interactions with sulfate and carboxylate groups of heparin/HS are identical. While 
heparin interaction with antithrombin and basic fibroblast growth factor involves ~40 and 
                                                 
 See section 1.5 for an extensive discussion of the problems associated with defining GAG SAR 
 Section 1.3 discusses the biosynthesis of heparin and HS 
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30% ionic binding energy,
168,203
 respectively, that with thrombin involves ~80%.
204
 Thus, 
identifying the precise heparin-binding site on proteins, although expected to be 
straightforward, has not been an easy task. 
In the past decade fifteen heparin-protein co-crystal or NMR structures have 
become available. These include complexes with thrombin,
115
 growth factor and growth 
factor receptors,
50,52,53
 annexin V,
116
 heparan sulfate 3-O-sulfotransferase,
117
 RANTES
121
 
 
and antithrombin. Of these, antithrombin is the most studied protein with five co-crystal 
structures detailing the interaction of a five-residue sequence with the inhibitor in either a 
binary or a ternary complex.
118-120,122
 Yet, these represent a small fraction of the vast 
number of physiologically active complexes. Further, except for antithrombin, the 
‗heparin‘ structure reported in these complexes is the fully sulfated saccharide (see Figure 
3B), the most common structure found in heparin, which may not be the optimal sequence. 
In view of the limited structural knowledge on GAG–protein interactions and the 
phenomenal structural diversity of HS, computational docking approaches represent a 
powerful means of assessing binding affinity and specificity. In fact, the computational 
literature is replete with numerous GAG studies, yet no approach has been devised that 
predicts high specificity sequences. Modeling GAGs is challenging because of their high 
negative charge density, which induces recognition of practically any collection of 
positively charged residues, and their surface–exposed, shallow binding sites on 
proteins.
50,52,53,115-117,121
 With respect to antithrombin in particular, two computational 
attempts have been made to understand heparin binding with mixed results.
205
 Both 
Grootenhuis and van Boeckel
206
 and Bitomsky and Wade
205
 attempted to derive the 
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heparin pentasaccharide binding site on antithrombin using molecular dynamics and 
docking, but their modeled geometry turned up to be significantly different from the co-
crystal structure. Similar challenging results were noted with our small, sulfated molecules, 
which were rationally designed to recognize the pentasaccharide-binding site in 
antithrombin but were found to preferentially interact with the extended-heparin binding 
site.
170,171,173
 Thus, we reasoned that a robust docking protocol for GAGs in general, and 
heparin/HS in particular, would be very useful for understanding specificity of their 
interactions. 
This chapter describes our novel approach of predicting high specificity GAG 
sequences with the well-studied antithrombin–heparin interaction as a test case. Our 
approach is based on a two-filter strategy, with the first step involving an affinity filter 
followed by a geometry convergence filter using a genetic algorithm-based docking tool, 
GOLD
TM
.
207
 The two-filter strategy rapidly sorted a combinatorial virtual library of nearly 
7,000 heparin hexasaccharides into specific and non-specific sequences,  thus suggesting 
its potential use for identifying ‗needle(s) in a haystack‘. 
5.2. Results and Discussion 
5.2.1. GOLDTM predicts the binding geometry of synthetic pentasaccharide 
H5CRYS to within 0.6 Å 
                                                 
 In this chapter and chapter 6, ‗specificity‘ refers to the existence of a few, structurally unique HS sequences 
from a combinatorial library of all possible sequences that can recognize the protein binding site in a single, 
well-defined binding mode. Therefore, specific HS sequences were determined by performing multiple 
molecular docking experiments to assess the reproducibility of computed binding modes. 
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The ability to predict conformation of GAG in the receptor-bound state was 
performed using a rigid body docking procedure in GOLD
TM
. The rigid body docking 
procedure reduces the search space significantly and allows an assessment of GOLD‘s 
fitness function, which is comprised of four energy terms – external and internal hydrogen 
bonding and van der Waals energy. Docking was evolved for 100,000 iterations in each 
run to ensure sampling of most of the conformational space available in the pre-defined 
binding site on antithrombin. Further, to ensure greater confidence in docked geometries, 
the process was repeated three times. 
Successful docking is typically evaluated by RMS difference between the docked 
solution(s) and the X-ray geometry, if available. While a RMSD value of less than 1.0 Å 
would indicate near identity of the two geometries, values between 1. 0 and 3.0 Å have 
been utilized by many researchers for correctly docked geometries of drug-like small 
molecules (MW <500).
208-210
 Considering that our penta- and hexasaccharides are 
significantly bigger (MW ~2,000) and the resolution of antithrombin–heparin–thrombin 
crystal structure was only 2.5 Å,
119
 we employed a 2.5 Å RMSD criterion. When the 
synthetic pentasaccharide H5CRYS was docked onto antithrombin (Figure 24), the GA 
search pre-terminated in all three independent runs, each with a high GOLD score of 
greater than 100. All 6 solutions were identical with an inter-solution RMSD of less than 
0.6 Å suggesting a strong preference for this geometry in the binding site (not shown). 
Comparison of these solutions with the H5CRYS structure present in the crystal suggests 
identical orientation and binding site. The maximal RMSD between the docked solutions 
and the crystal structure was also 0.6 Å. In addition, interaction at the atomic level for the  
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docked and co-crystal complexes were found to be essentially identical, suggesting that the 
rigid-body docking procedure can reliably identify the binding geometry and the binding 
site of the most active pentasaccharide sequence. 
5.2.2. Prediction of binding geometry of natural pentasaccharide sequence 
DEFGH with an ―average GAG backbone‖ conformation to within 2.0 Å 
X-ray fiber diffraction studies indicate that GAGs adopt a helical structure,
123
 
which has now been confirmed through several crystal structures.
50,52,53,115-119,121
 For 
heparan sulfate-like GAGs (HL-GAGs), the helix has a 21 symmetry with inter-glycosidic 
torsion angles ( H [HUA-CUA-O-CGlcNp] and H [CUA-O-CGlcNp-HGlcNp]) constrained to 
generate the helix. These conclusions are borne out in a number of NMR and molecular 
dynamics studies on heparin
111-113
 and heparin oligosaccharides,
109,110,114
 which show that 
the H/ H angles vary within a relatively narrow range in solution. Thus, heparin appears 
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Figure 24. Structure of a H5 derivative, H5CRYS, extracted from the crystal 
structure study of Li et al
119
 and used in docking studies. Note that all N-
sulfate and free hydroxyl groups of H5 are modified to O-sulfate and OMe 
groups, respectively.  
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to maintain a 2-fold helix irrespective of its sequence and substitution patterns. 
Additionally, crystal structures of pentasaccharide-antithrombin
118-120,122
 and 
hexasaccharide-FGF
53
 complexes demonstrate that only small changes in H/ H angles 
occur on protein binding, a result also observed with NMR studies of pentasaccharides 
bound to AT.
109,114
 Compiling these results indicates that H and H values vary from 35
O
 
to 61
O
 and 6
O
 to 25
O
, respectively, for the UAp(14)GlcNp inter-glycosidic linkage, 
while H varies between –68
O
 and –9O and H varies between –60
O
 and –1O for 
GlcNp(14)UAp linkage. These variations represent a maximal change of only 19 to 59O, 
or less than ±30
O
, a relatively small deviation considering the large number of possibilities 
for a structurally diverse molecule. Thus, we reasoned that HL-GAGs, irrespective of their 
sequence and substitution pattern, could be simulated by an ―average‖ structure, wherein 
the H/ H inter-glycosidic bond angles are held constant at the mean of known solution 
values. This implies that docking of any heparin/HS sequence with an ―average backbone‖ 
model should reliably simulate the physiological GAG binding structure. To test our 
hypothesis, the natural sequence-specific pentasaccharide H5 (Figure 7) was modeled in 
which inter-glycosidic torsions were held at the ‗average backbone‘ values, rather than set 
to those obtained from the crystal structure of H5CRYS. Docking was performed in which 
the inter-glycosidic torsions and intra-ring conformations were held constant, while 
substituents present at the 2-, 3-, and 6- positions were allowed conformational flexibility. 
All three docking experiments terminated rapidly, indicating a strong preference for one  
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Figure 25. Comparison of GOLD
TM
 predicted binding geometry of natural 
pentasaccharide H5 having ‗average backbone‘ with that of H5CRYS determined in the 
crystal structure. An overlay of 6 solutions from three independent docking runs shows 
high consistency in the predicted binding geometry, which matches the crystal structure 
geometry with an RMSD less than 2.5 Å. Structure in green is the crystal structure 
geometry, while those in atom-type color (red, yellow, grey and blue) are 6 docking 
solutions. Note the identical orientation of key groups, 2- and 3-OSO3
-
 of residue F (2SF 
and 3SF), 6-COO
-
 of residue E (6AE)  and 6-OSO3
-
 of residue D (6SD). Helices A, D 
and P of antithrombin (in ribbon diagram) are indicated as hA, hD and hP, while D, E, 
F, G, and H labels correspond to residues of the pentasaccharide. K114, K125 and R129 
are shown in ball and stick representation. 
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type of binding geometry. Figure 25 shows a comparison of the 6 GOLD solutions with the 
geometry present in the crystal structure. All 6 solutions predict an essentially identical 
binding geometry, an observation typically not found in such statistical docking studies. 
Small differences are found for the orientation of the terminal –OSO3
-
 and –OCH3 groups, 
especially in the G and H residues. All 6 solutions were within 2.5 Å RMSD (Figure 25) of 
each other and comparison of these structures with H5CRYS present in the crystal structure 
indicates nearly identical orientation, conformational state and interactions (Figure 
25).Analysis of the GOLD solutions at the atomic level facilitates identification of groups 
important for specificity of interaction. For example, the average RMSDs for the sulfate 
groups at positions 2 and 3 of residue F were found to be 0.2 0.1 and 0.3 0.2 Å indicating 
a virtually invariant conformation in all solutions. Likewise, the average RMSDs for 
sulfates at 6 and 2 positions of residues D and H, respectively, were found to be 1.1 0.5 
and 1.0 0.8 Å suggesting reduced tendency for alternative rotational states. In contrast, the 
average RMSDs of sulfates at the 6-, 2- and 6-positions of residues F, D and H were 
2.4 1.2, 2.1 1.2 and 1.6 0.9 Å, respectively, indicating greater conformational variability. 
Our docking results suggest that four sulfate groups, at positions 6-, 2- and 3-, and 2- of 
residues D, F and H, respectively, have minimal conformational variability in the binding 
site. Thus, these sulfate groups organized in a specific three-dimensional orientation afford 
the specificity of interaction, a conclusion proposed earlier on the basis of a large number 
of structure-activity studies (see Figure 7).
146,167,168,211,212
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5.2.3. Prediction of binding geometry with a flexible H5 fails to give 
reasonable solutions 
The above docking procedure utilized constrained intra- and inter-glycosidic 
conformations to maintain solution-state structure in the protein-bound state. To test 
whether full conformational flexibility during docking would result in better predictability, 
docking of H5 was performed under conditions wherein the HL-GAG backbone and 
saccharide conformations were unrestrained. Striking differences were noted in these 
docking studies. None of the three docking experiments converged suggesting a lack of 
preference for a defined binding geometry (not shown). In addition, the final six solutions 
display completely random profiles. Further, the pyranose rings in the docked solutions 
were found to exhibit conformations not found in solution. To test whether partial 
flexibility is tolerated, H5 was docked with unrestrained inter-glycosidic torsions, but 
constrained intra-ring torsions matching geometries in their bound state. The RMSD 
matrix showed an inconsistent set of 6 solutions corresponding to several different binding 
geometries (not shown). Only 1 of these geometries was within 2.5 Å RMSD of H5CRYS. 
These experiments suggest that determining binding geometries with a fully flexible 
ligand, though highly desirable, is difficult. These results demonstrate that the imposition 
of an average backbone constraint significantly increases the chances of arriving at the 
experimentally-derived binding geometry by reducing the conformational search space. 
 
 
 
77 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Structures of H5 and its truncated variants studied for docking . D, E, F, G, and 
H refer to residue labels. Variations in structure (V, W, X, Y, Z, and Z‘) to give variants 
with either one more sulfate group (H5+3SH, H5+3SE and H5+3SG) or one less sulfate 
group (H5-6SD, H5-3SF, H5-2SH) are highlighted as filled ovals. Truncated 
pentasaccharides H5-H, H5-GH, H5-D, and H5-DE refer to one or two residue deletion 
variants from either end. 
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5.2.4. The docking protocol sorts pentasaccharides based on specificity of 
interaction with antithrombin. 
The natural pentasaccharide sequence H5 is a rare sequence in heparin in which the 
EF unit (Figure 7) with the presence of the 3-O-sulfate group is both unique and 
interesting. Studies with a large number of H5 derivatives have led to the understanding 
that other sulfate groups present in the pentasaccharide sequence, e.g., the N-sulfate of D 
and 6-O-sulfate of F, are not important.
26
 Interestingly, certain analogs with sulfation level 
higher than H5, e.g., H5+3SE and H5+3SG (Figure 26), were less active than H5 in sharp 
contrast to the expectation that greater sulfation level, especially 3-O-sulfation, would 
induce higher antithrombin-affinity.
26
 At the same time, studies by Desai et. al. suggested 
that 3-O-sulfation of residue H was not detrimental to biological activity.
168,213
 
An obvious explanation for the changes in antithrombin affinity is the loss or gain 
of favorable or unfavorable interactions. Yet, this explanation suggests that individual 
interactions affect the changes independently. To gain a more fundamental understanding, 
we studied the docking of several H5 variants including H5 3SF, H5 6SD, and H5 2SH 
(Figure 26), each lacking a sulfate at position 3 in F, position 6 in D, and position 2 in H, 
respectively, onto antithrombin. In addition, H5+3SE and H5+3SG, described above, and a 
heparin hexasaccharide with common repeat sequence GH (IdoAp2S GlcNp2S6S) were 
also studied. Finally, a H5 sequence with IdoAp residue locked in the unfavorable 
1
C4 
conformation (H5/G*) was studied to understand the importance of conformational 
flexibility in this residue. 
 
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Specificity of GAG sequence for antithrombin. Variation in the RMSD among 
six solutions (1, 1‘, 2, 2‘, 3, and 3‘) obtained from three independent docking experiments 
of heparin pentasaccharide H5 variants, containing either one additional sulfate group at 3-
position of residue E or lacking a sulfate at the 3-position of residue F, binding to 
antithrombin.
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These H5 analogs were prepared in silico, minimized at the average GAG H / H values, 
and docked using the protocol described above for H5. Figure 5 shows the RMSD among 
the solutions obtained in three docking experiments for each of H5 variant. Whereas for 
H5, all 6 solutions are essentially identical with RMSD less than 2.5 Å (Figure 27A), none 
of the variants display this behavior. For example, H5 3SF, lacking the critical 3-O-sulfate 
group, displays only two RMSDs within 2.5 Å (Figure 27B), while H5+3SE, possessing an 
additional 3-O-sulfate in residue E, displays only one (Figure 27C). Likewise, the number 
of docked solutions that are within 2.5 Å RMSD of each other is 8, 7, and 4 for H5 2SH, 
H5 6SD, and (GH)3, respectively, out of the possible 15, while that for H5+3SG and H5/G* 
are 6 and 1, respectively (not shown). Thus, whereas 100% of solutions are found within 
2.5 Å of each other for H5, only 53%, 47%, and 13% are found for H5 2SH, H5 6SD, and 
H5 3SF, respectively. For H5+3SE and H5+3SG, variants with additional 3-O-sulfation, 
this percentage is 13 and 40%, while for 
1
C4 conformationally locked H5 (H5/G*) it is 
only 6.7%. 
The above results indicate that self-consistency of docking geometries is sensitive 
to sulfate group distribution and pentasaccharide topology. Alternatively, the loss or gain 
of sulfate groups or 
1
C4 iduronate conformation gives rise to alternate binding modes 
significantly differing from each other and from that of the natural high-affinity sequence 
H5. A closer inspection of the binding geometries suggests that many of these variant 
sequences favor a completely different pattern of interactions. These altered preferences, 
especially a multitude of them, are likely to be non-productive generating significant non- 
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Figure 28. Correlation of GOLD score with antithrombin binding affinity. 
Modified GOLD score (See experimental section) determined following 
100,000 iterations and multiple docking runs linearly increases with the 
observed antithrombin binding affinity under physiological conditions. Only 
those antithrombin complexes for which binding affinities were measured 
under essentially equivalent conditions are used for analysis. 
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specific binding, thus resulting in loss of binding affinity. Thus, these docking experiments 
indicate that the ‗self-consistency‘ of the RMSD matrix of top-ranked solutions is a 
sensitive measure of GAG specificity. 
5.2.5. GOLD scores correlate with antithrombin affinity 
Implicit in our docking protocol is the assumption that GOLD scores correlate with 
protein binding affinity. To establish that this is indeed true, we studied the docking of 
pentasaccharide variants with antithrombin for which the binding affinity had been 
measured under standardized conditions.
168,190-192,213
 These include H5, H5+3SH, H5 GH, 
H5 H, H5 D, and H5 DE binding to wild-type antithrombin
2,26,57
 and H5 binding to 
R129H, K125M and K114Q antithrombin mutants.
58-60
 These 9 complexes represent a 
range of ~12 kcal/mol in free energy of binding, a wide range spanning very strong to very 
weak interactions. Docking was performed in a manner identical to that for native 
pentasaccharide H5 and the top solution analyzed for binding energy correlation.  
Figure 28 shows a profile of modified GOLD score versus the observed free energy 
of binding under physiological conditions. For the 9 complexes studied, the modified 
GOLD score increased linearly from ~95 to ~150 giving a slope of 4.2 GOLD score per 
kcal/mol and an intercept of 78.9. The reasonable linear correlation between modified 
GOLD score and ∆GOOBS validates the docking protocol. Yet, the slope of 4.2 GOLD score 
per kcal/mol reflects a less-than-optimal sensitivity to structural change, especially 
considering that multiple docking geometries were not considered in the analysis. In 
general, predicting protein-binding affinities of GAGs has been difficult because of the 
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exposed nature of the binding site and the unquantified interaction parameters of sulfate 
groups. In addition, knowledge-based or empirical scoring functions do not take into 
account entropic contributions to ∆GO, which arise from the release of Na+ and H2O 
species from antithrombin and GAG surfaces following saccharide binding and are the 
dominant factors in the stabilization of the complex. Finally, the scoring function cannot 
compute the energy required for conformational flips of iduronate residues as well as the 
energy consumed to induce an allosteric, two-step binding interaction necessary for 
antithrombin.
168,213
 In light of these unknowns, the correlation observed in Figure 28 is 
reasonably good, especially considering that the affinity varies from the high M to the 
low nM. 
5.2.6. Identification of high-affinity, high specificity sequences through a 
combinatorial virtual screening approach 
Although a large number of proteins interact with HL-GAGs in our body, little 
information is available on sequences that recognize these proteins. This is also the status 
for other GAGs, such as dermatan sulfate, chondroitin sulfate and keratan sulfate. In 
addition, knowledge regarding the specificity of these interactions is completely lacking. 
We reasoned that our protocol, which combines two functions – affinity in the form of 
GOLD score and specificity in the form of consistency of docking – represents a powerful 
tool to deduce high-affinity GAG sequences that bind proteins with high specificity. 
To test this hypothesis, we generated a combinatorial library of heparin 
hexasaccharides for docking onto antithrombin. The library was generated from a set of 19  
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disaccharides (Figure 4), which included all monosaccharides found in nature, except for 
the rare free glucosamines.
104
 The library considered the conformational flexibility of 
IdoAp residues in an explicit manner through inclusion of both 
1
C4 and 
2
SO conformations. 
Thus, the combinatorial library consisted of 6,859 unique heparin hexasaccharides built 
with the ‗average backbone‘ geometry in an automated manner. 
A biphasic docking protocol was used for screening this library. The first phase 
evaluated the binding of each hexasaccharide onto antithrombin using 10,000 iterations, 
instead of 100,000, followed by GOLD score screening. The histogram of GOLD score 
frequency obtained from this analysis suggests an approximately Gaussian distribution of 
sequences centered between 40 and 55 GOLD score with the highest at 115 (Figure 29). A 
majority of hexasaccharides, 6,352 sequences or 92% of the total, have a GOLD score of 
75 or less suggesting that these sequences minimally or do not bind antithrombin. Nearly 
6.4% or 439 sequences have a GOLD score between 75 and 100. This score corresponds to 
M to mM antithrombin affinity, most probably arising from non-specific, non-productive 
interactions. 
The top 1% of the sequences or 28 sequences, each with a GOLD score greater than 
100 were identified as ‗hits‘ or high-affinity sequences. Of these 28 sequences, 23 were 
strikingly similar in possessing three sulfate groups, 6SD, 3SF, and 2SF. In addition, these 
23 sequences had glucuronic acid residue in the ‗E‘ position. This similarity is particularly 
significant considering that 513 sequences of the 6,859 hexasaccharides, i.e., ~7%, contain 
these structural features. In other words, the ‗DEF‘ motif has been enriched from ~7% to 
~82% through the affinity filter. 
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The 28 ‗hits‘ identified in the affinity screen were then subjected to specificity 
analysis through a ‗consistency test‘ with 100,000 iterations over triplicate docking runs. 
This step involved greater evolution of docking geometries, whereby significantly more 
conformational space around the binding site is searched multiple times. Of the 28 high-
affinity sequences, 10 docked to consistently give a single geometry with an RMSD of less 
than 2.5 Å among its final solutions (Figure 30). The other 18 sequences did not dock 
consistently 100% of the time. The self-consistent binding geometry for each of the 10  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Histogram of number of HS hexasaccharide sequences for every 5 unit 
change in GOLD score. Modified GOLD score was calculated for all 6,859 
hexasaccharides docked onto antithrombin following the first phase of combinatorial 
library screening. Inset shows an expanded portion of the histogram in the range 95–
120 GOLD score. 
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Figure 30. A) An overlay of final 10 hexasaccharide sequences obtained after second 
phase of combinatorial library screening. Structure in green is the H5CRYS, while those in 
atom-type color are 9 sequences with nearly identical binding orientation and geometry. 
Sequence in purple color was found to bind antithrombin reproducibly with high 
specificity and affinity but dramatically different orientation. Labels 2SF, 3SF, 6AE and 6SD 
represent sulfate or carboxylate groups at the 2- and 3-position of residue F, 6-position of 
residue E and 6-positon of residue D. B) Symbolic representation of the high-affinity, 
high-specificity hexasaccharide structures shown above. The hexasaccharide library 
sequence runs {UAp(14)GlcNp(14)}3, where UA is either IdoAp (shaded hexagon) or 
GlcAp (shaded square). Sulfated substitution at 2-, 3- or 6-positions of either UAp or 
GlcNp is indicated with a line ( ), while acetate substitution at the 2-positon of GlcNp is 
indicated with a line-dot ( ). Iduronic acid residues in 
2
SO conformation are shown as 
fully shaded hexagons, while those in 
1
C4 conformation are shown as half-filled hexagons. 
 
 
3SF
2SF
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87 
 
sequences indicates a high specificity interaction. Of the 10 sequences, 9 bind antithrombin 
in manner identical to the natural pentasaccharide H5, while one hexasaccharide interacts 
with a significantly different geometry and orientation (Figure 30). 
A closer look at these 9 sequences shows that 8 contain the 4) GlcNp6S (14) GlcAp 
(14) GlcNp2S3S (1 structure that matches key structural features within DEF 
necessary for high-affinity interaction with antithrombin (Figure 7).
167,168,213
 The last 
sequence in this category also has this structure, except for the absence of 6SD. Structural 
differences within DEF in these eight sequences include the presence of either an acetyl or 
a sulfate group at the 2 position of residue D and the presence or absence of a sulfate at 6-
position of residue F. Our virtual screening shows that an IdoAp residue, either with or 
without a sulfate in 2-position, is consistently present at the G location in these 9 
sequences (Figure 30). Alternatively, GlcAp residue is forbidden in this position. Further, 
the IdoAp residue overwhelmingly prefers 
2
SO conformation over 
1
C4 (~89%) suggesting 
that the self-consistency filter is greatly sensitive to the local topology of the GAG helix. 
Finally, location H with GlcNp residue tolerates considerable variations, e.g., sulfation and 
acetylation in the 6- and 2-positions assuming that the high-affinity DEF sequence is 
present. 
The GOLD scores for the 9 hexasaccharide sequences ranged from 109.5 to 127.5 
suggesting each of these sequences to be potent antithrombin ligands. Yet, despite having 
all the key structural features these are not as potent as sequence-specific pentasaccharide 
H5, which shows a GOLD score of 140. Comparison of the docking geometry of H5 with 
that of the hexasaccharide sequences reveals a lateral displacement of 0.3–0.5 Å in all 
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solutions irrespective of substitution pattern. This effect is most noted on G and H residues 
resulting in weaker interactions at the reducing end of the sequence. Although the small 
difference in binding geometry between pentasaccharide H5 and hexasaccharides remains 
unconfirmed, previous biochemical experiments have suggested a lateral movement as 
chain length increases.
212
 
5.2.7. Identification of an unusual high-affinity, high-specificity sequence 
Our combinatorial virtual screening approach results in one hexasaccharide 
sequence that binds antithrombin in an unusual, unexpected manner. This sequence, 
IdoAp2S (14) GlcNp2Ac (14) IdoAp2S (14) GlcNp2Ac (14) IdoAp (14) 
GlcNp2S6S (Fig. 8), does not have the critical DEF scaffold, is much less sulfated than 
H5, and has all three IdoAp residues in 
1
C4 conformation. The sequence binds 
antithrombin reproducibly in triplicate docking experiments with a GOLD score of 109.0 
indicating a high-affinity, high specificity interaction. The binding geometry is unique but 
distinct from H5 and other sequences identified above (Figure 30), specifically the 
sequence occupies part of both the pentasaccharide-binding site and the extended-heparin 
binding site in antithrombin. Significant binding energy originates from hydrogen bonding 
with amino acids Arg13, Arg46, Arg47, Lys125 and Arg129, in which the sulfate groups at 
the 2-position of the GlcNp and IdoAp residues make multi-valent interactions. At the 
same time, greater than 50% of its binding energy originates from van der Waals 
interactions. Thus, despite a lower than normal sulfation level, a fortuitous combination of 
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sequence and conformational features introduces high antithrombin affinity in this 
sequence. 
It is difficult to predict whether this sequence will be physiologically active. The 
observation that less sulfated GAG sequence can demonstrate high antithrombin specificity 
in silico is exciting. Assuming that specific interactions of H5 are responsible for the 
allosteric conformational change in antithrombin, the dramatically different binding 
geometry suggests reduced likelihood of an agonist activity in this unusual sequence. At 
the same time, the high affinity of the sequence suggests an antagonistic activity may be 
expected. 
5.3. Conclusion and Significance 
Despite being the anticoagulant of choice for the past 8 decades, heparin-based 
therapy is still beset with several adverse effects, principal being an enhanced risk toward 
bleeding. A large body of structure-activity studies spanning more than two decades 
resulted in several potent pentasaccharides, of which fondaparinux was introduced in the 
clinic in late 2001.
26,146,211
 Yet, these pentasaccharides, and also several low-molecular-
weight heparins introduced in mid-1990s, are essentially ‗heparin‘ and structurally 
represent a small advance. 
Non-heparin anticoagulants with high specificity for antithrombin may afford a 
solution to current adverse effects of heparin therapy. Yet, designing non-heparin, organic 
activator(s) of antithrombin is challenging, especially due to the non-availability of 
computational techniques that address induced-fit mechanisms and specificity of binding 
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in highly-charged, solvent exposed systems.
171
 Previous two simulations of heparin 
pentasaccharide binding to antithrombin were successful in identifying only few of the 
critical interactions.
205,214
 A major reason for this is the difficult simulation of GAG 
interactions originating from the primary sequence complexity of GAG polymers, the 
inadequate parameterization of sulfate groups, and the shallow, exposed and highly 
flexible nature of GAG binding pockets. 
Most docking approaches to date focus primarily on the affinity of interaction, and 
minimally on the specificity of interaction.
215
 Predicting affinity of protein–ligand 
complexes accurately is in its infancy, especially due to poorly defined contribution of 
water molecules in the process. Further, affinity alone is not a powerful tool in predicting 
potent GAG sequences because of poor sensitivity to structural change, as current study 
(see Fig. 6) and work elsewhere demonstrate.
170
 Instead of affinity, our genetic algorithm-
based approach places emphasis on specificity of interaction. This approach affords 
screening of a large amount of conformational space that ensures elimination of a number 
of false positives. Thus, specificity is perhaps a more critical filter that offers significantly 
high reliability. 
Our work represents the first approach of combinatorial library screening for 
heparin/HS GAGs. The phenomenal structural diversity of these GAGs is a challenge to 
medicinal chemists and represents a frontier extremely difficult to traverse through 
traditional structure-activity studies.
26
 This work demonstrates that library screening is 
feasible for heparin/HS oligosaccharides, especially if a high-resolution crystal structure of 
the protein is available. Further, the approach is geared toward predicting high specificity 
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sequences. Thus, it is expected to be especially useful for heparin binding proteins, e.g., 
heparin co-factor II, protein C inhibitor and growth factors, for which specificity features 
remain poorly defined. In addition, for many other proteins, including glycoprotein D of 
herpes simplex virus–1 and protease nexin 1, information regarding heparin-binding site 
may also become feasible. 
Our dual filter strategy – affinity and specificity – utilized fairly stringent criteria 
for selection. While the affinity filter selected the upper 20% of sequences, the specificity 
filter was set to select only those sequences that satisfy self-consistency 100% of the time. 
In combination, a high overall enrichment was realized (~660-fold). If one considers only 
those hexasaccharide sequences that possess IdoAp (14) GlcNp (14) GlcAp (14) 
GlcNp (14) IdoAp (14) GlcNp structure, which is the base sequence present in the 
final 9 hexasaccharides, even then the enrichment remains substantial (~77-fold). It was 
possible to use high filtering stringency because antithrombin–heparin interaction is 
biochemically a well-studied system. However, the stringent criteria may eliminate 
potentially useful information, especially for not as well-understood systems. 
Our combinatorial screening approach relies on a fundamental hypothesis. The 
combinatorial library was generated based on the ‗average backbone‘ hypothesis in which 
uniformity of inter-glycosidic torsion angles, irrespective of sequence and intra-ring 
conformational variability, is assumed.
109,110,113,114
 For heparin/HS, this hypothesis appears 
to hold true for all known cases, although only a fraction of possible homogeneous 
sequences have been studied in solution. For GAGs other than HS, such as dermatan 
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sulfate and chondroitin sulfate that involve mixed inter-glycosidic linkages, the approach 
needs rigorous testing. 
Although this approach is designed to identify individual GAG sequences with high 
specificity, it facilitates the extraction of a ‗pharmacophore‘, key interactions that drive 
binding specificity. A map of RMSD of individual atoms, backbone as well as functional 
groups, can be readily created from the combinatorial library screening experiments to 
identify those locations with minimal variation, e.g., 3SF, 2SF, and 6SD in DEF, which 
define the pharmacophore. In contrast, domains with higher RMSD, and therefore 
possessing significant movement, define locations in which structural modification can be 
introduced to design new ligands. Thus, this approach is also likely to be useful for 
designing therapeutically useful molecules. 
In conclusion, the work describes identification of high-affinity high specificity 
heparin/HS sequences that bind antithrombin utilizing a combinatorial virtual library 
screening approach. The approach relies on a dual filter strategy involving affinity and 
specificity filters and is based on average heparin/HS backbone hypothesis. The approach 
uses genetic algorithm based docking and scoring protocol. The dual filter strategy, if 
found useful for other heparin/HS systems, is likely to be extremely useful in the design of 
pharmaceutically useful agents. 
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5.4. Methods 
5.4.1. Software/Hardware 
SYBYL 6.9.2 (Tripos Associates, St. Louis, MO) was used for molecular 
visualization, minimization and for adding hydrogens to protein structures from the Protein 
DataBank. All modeling was performed on MIPS R16K or R14K IRIX 6.5-based SGI 
Tezro and Fuel graphical workstations. GOLD
TM
 (version 2.2, Cambridge Crystallographic 
Data Center) was used for docking experiments.
207
 Combinatorial GAG structures were 
built in an automated manner using in-house SPL (SYBYL Programming Language) 
scripts. 
5.4.2. Energy Minimizations 
Energy minimization of modeled structures was performed to optimize the 
geometric conformation of GAG and AT. Except where stated, energy minimization was 
performed using the Tripos forcefield with Gasteiger-Hückel charges, a fixed dielectric 
constant of 80 and a non-bonded cutoff radius of 8 Å. Minimization was carried out for a 
maximum of 5,000 iterations subject to a termination gradient of 0.05 kcal/(mol·Å). 
5.4.3. Protein Co-ordinates 
The coordinates for the activated form of AT were extracted from the crystal 
structure of the ternary AT-pentasaccharide-thrombin complex (PDB entry 1TB6).
119
 
Hydrogen atoms were added in SYBYL 6.9.2 and the structure minimized with fixed 
heavy-atom co-ordinates using the Tripos forcefield for 1,000 iterations subject to a 
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termination gradient of 0.05 kcal/(mol·Å). Single-point mutants of AT, including K114Q, 
K125M and R129H, were generated using the residue mutation protocol in SYBYL. The 
side-chains of the mutated residues were optimized through energy minimization in which 
the all other side chains were held rigid. 
5.4.4. Co-ordinates for synthetic pentasaccharide H5CRYS 
The 1TB6 antithrombin–heparin–thrombin ternary crystal structure119 has a heparin 
chain containing a synthetic pentasaccharide sequence, H5CRYS, which is a variant of the 
natural pentasaccharide DEFGH (Figure 24). This synthetic pentasaccharide H5CRYS has 
six O-sulfate groups in residues D (position 6), F (positions 2,3 and 6) and H (positions 2 
and 6), has glucose residues, instead of glucosamines, and has all available –OH groups in 
residues D (positions 2 and 3), E (positions 2 and 3), G (positions 2 and 3) and H 
(positions 1 and 3) protected in the form of –OCH3 groups. The atom type of sulfur and 
oxygen atoms in –SO3 groups was modified to S.o2 and O.co2, respectively, and the bond 
type between these atoms was modified to aromatic bond. Hydrogen atoms, absent in the 
PDB structure, were added in SYBYL and the resultant structure minimized to optimize 
geometry of hydrogen atoms only (no change in non-H atoms). 
5.4.5. Natural Pentasaccharide DEFGH co-ordinates 
The sequence-specific pentasaccharide H5, or sequence DEFGH (Figure 7A), was 
modeled by introducing the necessary changes to the 1TB6 pentasaccharide. The 
methylated anomeric reducing end was retained to simulate the environment of the +1 
residue. Several research groups have reported H/ H inter-glycosidic torsion angles for 
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HL-GAGs in the free and bound conformations.
109-111,113,114,118
 These torsion angles fall 
within a relatively narrow range and suggest that they remain fairly constant irrespective of 
a change in substitution pattern around the inter-glycosidic bond. Thus, we utilized an 
average value of bond torsion for each inter-glycosidic linkage, which was the mean of the 
two extremes reported in literature. The natural sequence H5 was minimized at the average 
H/ H values, subject to a restraining force constant of 0.01 kcal·mol
-1
·deg
-2
. The final 
H/ H values, following minimization, deviated by not more than 7  from the initial 
values. The minimized structure retained the initial 
2
SO IdoAp conformation and was used 
for docking studies. 
5.4.6. Co-ordinates for Variant Pentasaccharides 
The ‗average-backbone‘ natural pentasaccharide DEFGH structure was used as a 
template for the generation of H5 variants. These variants include truncated forms, 
tetrasaccharides H5-H and H5-D, trisaccharides H5-GH and H5-DE, and functional group 
variants H5+3SH, H5+3SE, H5+3SG, H5-6SD, H5-3SF and H5-2SH (Figure 26). For each of 
these structural variants, following appropriate structural modifications in the natural 
pentasaccharide sequence, minimization was performed with constraints that retain the 
average H/ H values. In addition to these structural variants of the natural sequence, a 
DEFGH sequence was also prepared in which the iduronic acid residue G was in the 
1
C4 
conformation, labeled as H5/G*, rather than the 
2
SO form. The 
1
C4 IdoAp ring co-ordinates 
were taken from the crystal structure of FGF2-GAG (PDB entry 1BFC)
53
 and the structure 
minimized as described above. 
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5.4.7. Co-ordinates for HL-GAG Virtual Library 
The co-ordinates for the HL-GAG sequences of the virtual HS hexasaccharide 
library were generated with a series of SPL scripts and a set of nineteen HS disaccharide 
building blocks (Figure 31, below). Although the number of possible HL-GAG 
UAp(14)GlcNp disaccharides is 48 (Figure 4), only 23 have been experimentally 
observed. Based on sequence-specific natural pentasaccharide sequence, we restricted our 
library to include GlcAp sequences that have GlcNp3S and IdoAp sequences that do not 
contain GlcNp3S. Because IdoAp residues in heparin can exist either in the 
2
SO or 
1
C4 
conformations, each IdoAp residue was modeled explicitly in these two different states. 
Thus, our virtual library consisted of 16 IdoAp- and 3 GlcAp-containing disaccharides 
generating a total of 19 building blocks. 
GlcAp- and 
2
SO-IdoAp-containing disaccharides were generated using the EF and 
GH residues from the 1TB6 co-crystal structure as template, while the template for the 
1
C4-
IdoAp disaccharides was obtained from the 1BFC structure.
53
 Appropriate side-chain 
modifications were made to generate the 19 building blocks. Each disaccharide was 
minimized at the average H/ H value subject to a restraining force constant of 0.01 
kcal·mol
-1
·deg
-2
. The 19 disaccharides were then used to build a combinatorial HS 
hexasaccharide library using an SPL script, following which each sequence was minimized 
as described above in an automated manner. Thus, the HS combinatorial library contained 
19×19×19 = 6,859 hexasaccharide sequences. 
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5.4.8. Docking of HL-GAG Sequences 
Docking of saccharide ligands onto the activated form of antithrombin was 
performed with GOLD
TM
 v.2.2. The binding site in antithrombin was comprised of all 
atoms within 16 Å from the C  atom of Phe121 in the D helix. This dimension of the 
binding site covers all important known heparin-binding residues including Lys11, Arg13, 
Arg46, Arg47, Trp49, Lys114, Phe121, Lys125, Arg129, and Arg132.
25,118,167
 GOLD
TM
 is 
a "soft docking" method that implicitly handles local protein flexibility by allowing a small 
degree of interpenetration, or van der Waals overlap, of ligand and protein atoms. GOLD 
also optimizes the positions of hydrogen-bond donating atoms on Ser, Thr, Tyr and, most 
importantly, Lys residues as the part of the docking process. Whereas all saccharide bonds 
were constrained for the rigid body docking experiment, only the inter-glycosidic bonds 
were constrained when docking structures with the average torsion angles. 
For the native H5 sequence, and its truncated and variant forms (Figure 26), 
docking was performed using a genetic algorithmic search with 100,000 iterations for each 
of 10 runs.
207
 In this search, GOLD
TM
 starts with a population of 100 arbitrarily docked 
ligand orientations, evaluates them using a scoring function (the GA ―fitness‖ function) 
and improves their average ―fitness‖ by an iterative optimization procedure that is biased 
towards high scores. As the initial population is selected at random, several such GA runs 
are required to more reliably predict correct bound conformations. In this study 10 GA 
runs were performed with the GOLD score as the ―fitness‖ function. Collectively, these 10 
GA runs will be referred to as one docking experiment. In addition, to enhance speed, the 
GA was set to pre-terminate if the top two ranked solutions were within 2.5 Å RMSD. 
98 
 
Docking experiments were performed in triplicate to ensure reproducibility and to reduce 
false positives. The top two solutions of each docking experiment were considered for 
further analysis. Thus, a typical triplicate docking experiment would yield a minimum of 6 
solutions. 
In contrast, when docking the HS combinatorial library made from 19 
disaccharides (Figure 31, below), a two-step docking protocol was utilized. The first step 
consisted of screening all possible sequences using 10,000 GA iterations and GOLD score 
evaluation of only the top-ranked solution. This step identified the most promising 
sequences (~ top 1%) that have a relative high GOLD score. The second step consisted of 
docking these most interesting sequences according to the protocol described above for the 
natural pentasaccharide DEFGH and its variants. 
Docking was driven by the GOLD scoring function. Although this scoring function 
correlates with the observed free energy of binding, a modified form of the scoring 
function has been found to be more reliable.
50
 This modified GOLD score, which utilizes 
hydrogen-bonding and van der Waals interactions (Equation III), was used to rank the final 
docked solutions. 
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. 
EXTEXT VDWHBScoreGOLD 375.1  [III] 
where HBEXT and VDWEXT are the ―external‖ (nonbonded interactions taking place where 
HBEXT and VDWEXT are the ―external‖ (nonbonded interactions taking place between the 
ligand and receptor) hydrogen bonding and van der Waals terms, respectively 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Disaccharide sequences used to build virtual library of 6,859 
hexasaccharides. 
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THE INTERACTION OF HEPARIN / HEPARAN SULFATE WITH 
HEPARIN CO-FACTOR II  A HYPOTHESIS 
 
6.1. Introduction 
Heparin cofactor II (HCII) and antithrombin (AT) are serine proteinase inhibitors 
(serpins) present in human plasma at significant levels (1.2 and 2.3 M, respectively).
216
 
AT and HCII bind heparin (H) and heparan sulfate (HS), two important members of the 
glycosaminoglycan (GAG) superfamily. Whereas the interaction of AT with H/HS has 
been the basis for several pharmaceutical agents, e.g., full-length heparin, low molecular 
weight heparins and fondaparinux, the interaction of HCII with H/HS has not been 
exploited for drug design to date. 
AT binds to a five-residue sequence in H/HS – the so-called heparin 
pentasaccharide sequence, H5 (Figure 7) – with high affinity in the region formed by 
helices A and D.
118
 This high affinity interaction is known to be highly specific. Of the 11 
positively charged amino acid residues in this heparin-binding site (HBS) in AT, Lys114, 
Lys125 and Arg129 have been found to be critical for recognition, affinity and specificity 
of the H5 sequence.
167,190-192
 Recently solved crystal structures
34
 of HCII in its native and 
thrombin-complexed states show a striking similarity with AT in the organization and 
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orientation of several positively charged amino acid residues in the putative HBS, e.g., 
Arg103, Lys173, Lys185, Arg189, Arg192, and Arg193. Yet, the heparin pentasaccharide 
sequence does not bind HCII with high affinity and specificity.
217
 In fact, the interaction of 
heparin cofactor II with heparin and heparan sulfate is believed to be non-specific.
32
 
In addition to the structural similarities between the two serpins, mechanistic similarities 
also exist. Both serpins undergo a two-step, induced-fit, allosteric activation mechanism to 
inhibit the target enzyme.
27,32,168
 In this mechanism, an initial loose recognition complex is 
first formed, which undergoes a rapid conformational change in the second step to form a 
tight, high-affinity heparin-serpin complex. This conformational change is the basis for the 
~300-fold activation of AT in its inhibition of factor Xa
27,168
 and the ~1000-fold activation 
of HCII in its inhibition of thrombin.
32
 Yet, whereas the pentasaccharide sequence (Figure 
7) in H/HS specifically performs this activation for antithrombin, the sequence(s) that 
activate HCII remain(s) unknown. 
The identification of H/HS sequences that bind HCII with high affinity and high 
specificity could have major advantages. In contrast to AT, which inhibits several 
proteinases of the coagulation cascade, e.g., thrombin, factor Xa and factor IXa,
11,218
 HCII 
inhibits thrombin only.
12
 This intrinsic specificity may be a unique advantage because 
HCII deficiency does not appear to enhance risk for thrombosis,
21
 while studies suggest 
that the serpin may play a role in preventing arterial thrombosis.
20,21,219,220
 Further, HCII is 
able to inhibit clot-bound thrombin, in striking contrast to antithrombin.
221
 Thus, an HCII-
based anticoagulant may serve as a much needed potent, yet safe, regulator of clotting. 
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To understand H/HS – HCII interaction, we utilized our dual-filter genetic 
algorithm-based combinatorial virtual screening approach, which we developed to deduce 
H/HS sequences that recognize AT.
5
 Using this dual-filter strategy, we have identified five 
H/HS sequences from a combinatorial library of 46,656 H/HS hexasaccharides that are 
predicted to bind HCII with ‗high affinity and high specificity‘. Contrary to the common 
thinking, our results suggest that discrete sequences in H/HS may exist for specific 
interaction with HCII. Our computational work highlights a critical need for detailed 
solution molecular interaction studies using chemically synthesized, homogeneous H/HS 
sequences, which may pave the way for new, specific HCII-based anticoagulants. 
6.2. Results and Discussion 
6.2.1. Structure of the Activated Form of Heparin Cofactor II 
Two experimentally determined structures of HCII are available, native and S195A 
thrombin-complexed.
34
 The overall structure of native HCII is similar to that of native AT. 
Superposition of the structure of native HCII on that of native AT (PDB file: 2ANT)
188
 
gives a RMSD of 1.8 Ǻ for 352 equivalent C  atoms (not shown). Likewise, superposition 
of C  atoms of the residues that define the HBS in AT, i.e., Arg46, Arg47, Lys114, 
Lys125, Arg129, Arg132 and Lys133, with corresponding residues in HCII results in a 
RMSD of 1.5 Ǻ indicating a high degree of similarity between the two native serpins. 
The structure of GAG-activated HCII is not available as yet. However, the structure 
of the serpin in complex with S195A thrombin displays extensive similarities with that of 
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the heparin pentasaccharide-activated AT (Figure 32). The S195A thrombin-complexed 
HCII shows an expelled reactive center loop (RCL), as found in pentasaccharide-activated 
AT.
118,119
 The reason for the expulsion of the RCL appears to be the extensive exosite 
interactions that the RCL makes with S195A thrombin. Likewise, exosite interactions also 
stabilize the heparin-induced, conformationally activated AT, as borne out in experiments 
with factor Xa and factor IXa.
222,223
 Thus, the overall structure of HCII in the S195A 
thrombin-complexed state is similar to that of the pentasaccharide-activated AT. 
Further evidence that these forms are nearly identical comes from the superposition 
of the corresponding C  atoms of the activated serpins. Figure 32 shows the superimposed 
activated forms of the two serpins. The RMSD in C  atoms of the core amino acid residues 
was found to be 2.4 Ǻ suggesting significant similarity in the orientation of most structural 
domains including -sheets and helices. More importantly, the RMSD for corresponding 
basic residues in helices A and D was found to be 1.5 Ǻ indicating a high degree of 
similarity between the two activated forms in this region. These structural similarities 
indicate that the S195A thrombin-complexed HCII is likely to be the H/HS-activated form 
of the serpin. 
Despite the structural similarity, fine differences exist between the two activated 
serpins in the relative orientation of helices A and D, and in the extension of RCL. 
Whereas A helices superpose nearly completely, the D helices display a significant ~30
O
 
angle between the two serpins (Figure 32). Likewise, the RCL in the activated forms show 
a significantly greater extension of the loop in the S195A thrombin-complexed HCII than 
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Figure 32. Comparison of the structure of S195A thrombin-complexed heparin cofactor II with heparin pentasaccharide 
activated antithrombin. Core polypeptide sequences, devoid of residues of the N-terminus and the RCL, were aligned using 
Sybyl 7.2 homology fit algorithm. Note the small rotational difference in helix D axis and at the N-terminal end of helix A 
between the two proteins, while the expulsion of RCL in HCII is much greater than that in AT. Antithrombin ribbon is shown 
in green and red (hD, hA and RCL), while HCII is shown in gray and yellow (hD, hA and RCL). 
RCL
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hF
1
0
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in the pentasaccharide-activated AT. In addition, helix D of HCII contains an additional 
electropositive residue, Arg184, which has no counterpart in AT. Despite these differences, 
the S195A thrombin complexed HCII structure is very similar to the pentasaccharide-
activated AT structure and is a good model for investigation of H/HS interactions, 
especially considering that the structure of GAG-activated HCII is unknown. 
6.2.2. Rapid filtering of sub-optimal HS sequences from a library of 46,656 
sequences 
Recently, we designed a genetic algorithm-based virtual screening approach that 
utilized a dual-filter process to identify hexasaccharide sequences in heparin that recognize 
AT with high specificity.
5
 This sequential dual-filter algorithm utilizes GOLD score, a 
measure of ‗affinity‘, as the first filter, followed by convergence of binding geometries, a 
measure of ‗specificity‘, as the second (Figure 33). The dual-filter algorithm predicted ten 
‗high-affinity and high-specificity‘ AT-binding hexasaccharide sequences from a 
combinatorial library of ~7,000 sequences. Nine of the 10 sequences contained structural 
features matching the high-affinity heparin pentasaccharide sequence shown in Fig. 1A. 
Additionally, the computationally predicted binding geometry matched the crystal 
structure geometry to within 2.5 Ǻ.5 
In the present study with HCII, we used a comprehensive library of H/HS 
hexasaccharide sequences built from all of the 23 disaccharide building blocks reported to 
date (Figure 4). To address the conformational variability possible in IdoAp residues, two 
major ground state conformers 
1
C4 and 
2
SO, were explicitly modeled, increasing the  
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Figure 33. Dual-filter algorithm used to screen a combinatorial library of 46,656 H/HS 
hexasaccharide sequences. The combinatorial library was built from 36 naturally occurring 
disaccharide building blocks and screened using a dual filter protocol. 
START
Automated Generation of Virtual Library of 
46,656 H/HS Hexasaccharide Sequences
Minimize Sequences 
(Glycosidic Bond Torsion Constraints)
GOLD Score (‘Affinity’) Test 
(10,000 GA iterations, one run per GAG)
Score in top 0.1%?
Geometry Convergence (‘Specifici ty’) Test
(100,000 GA iterations; three runs per GAG)
RMSD 2.5 Å?
‘High-Affinity, High Specificity’ Sequence(s)
END
DISCARD
YES
YES
NO
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number of building blocks to 36 to give a library of 36
3
 = 46,656 hexasaccharide 
sequences. The H/HS binding site in activated HCII was defined to include the domain 
formed by helices A and D
34
 considering the similarity with the H – AT system. Figure 33 
displays the histogram of GOLD scores following the first step of the dual filter protocol. 
The profile is Gaussian and shows that a majority of H/HS sequences (83.5%) bind HCII 
with an average GOLD score in the region of 30 – 80 units. Nearly 15.7 % of sequences 
bind poorly (GOLD score below 30 units), while 0.8 % hexasaccharides recognize the 
serpin with high GOLD scores between 80 – 106 units. This included 2 sequences with 
GOLD score higher than 100 and 45 sequences with score between 90 and 100 units. In 
comparison to the H – AT system,5 these overall GOLD scores are approximately 20–30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Histogram of number of H/HS hexasaccharide sequences for every 10 unit 
change in GOLD score. shows an expanded portion of the histogram in the range 90–110 
GOLD score units. 
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units lower suggesting that the affinity of H/HS hexasaccharides for HCII may be slightly 
lower than that for the high-affinity pentasaccharide binding to AT. 
6.2.3. Structural features of the ‗high-affinity‘ H/HS hexasaccharides 
Structural analysis of the sequences identified through the ‗GOLD score‘ filter 
reveals interesting insight into recognition of HCII. Of the 47 hexasaccharides, only 4 
carry the maximal possible sulfation load of 9 groups, while the library contains a total of 
1728 sequences with the maximum load. This suggests that the majority of the high-
affinity sequences that bind HCII are not highly sulfated. Alternatively, it suggests that the 
GOLD fitness function does not arbitrarily select for higher sulfation level, although the 
binding site in HCII is electropositive. Eight topologies corresponding to the common 
heparin hexasaccharide sequence, [IdoAp2S-GlcNp2S6S]3, which carry maximal sulfation 
load, have GOLD scores in the range of –2.7 to 66.4 units, suggesting that these sequences 
recognize HCII with poor affinity. These results are consistent with solution experiments 
with heterogeneous, polydisperse heparin sample that show poor HCII affinity in the range 
of 45 – 140 M.32,224,225 
The ratio of IdoAp- and GlcAp-containing disaccharides in our combinatorial 
library was 2.6:1, while it was found to be 1.2:1 in the 47 hexasaccharides. This implies a 
significant enrichment of GlcAp-residues. Additionally, the top 0.1 % identified ‗hits‘ (47 
topologies) do not contain any sequence related to the high-affinity pentasaccharide 
sequence (IdoAp2S {
2
SO / 
1
C4}-GlcNp2S6S-GlcAp-GlcNp2S3S6S-IdoAp2S {
2
SO / 
1
C4}-
GlcNp2S6S) that binds AT. This result is also consistent with Maimone and Tollefsen, 
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who have shown that heparin molecules with or without the high-affinity antithrombin-
binding pentasaccharide sequence equally activate HCII.
217
 
6.2.4. Finding Needle(s) in the Haystack: Only five H/HS hexasaccharides are 
predicted to recognize that activated form of HCII with ‗high-specificity‘ 
The geometry convergence filter used in our dual-filter algorithm is a robust 
strategy to identify sequences that possess exceptional complementarity to the receptor. 
This filter utilizes 3 experiments of 10 GA runs each, in which each GA run is allowed to 
evolve over 100,000 iterations, resulting in 6 final binding geometries. Binding is deemed 
to be ‗specific‘ if the RMSD among these 6 geometries is  2.5 Ǻ. Of the 47 sequences that 
were subjected to this stringent criterion, only 5 sequences were found to recognize 
activated HCII with ‗high specificity‘ (Figure 35). 
Several points about the structure of these five hexasaccharide sequences are 
striking. None of the GlcNp residues have an acetyl group at the 2-position. This is striking 
because natural heparan sulfate consists of nearly 50–60 % GlcNp2Ac residues.226,227 The 
total number of sulfate groups in these sequences ranges between 6 (sequence I) to 8 
(sequence V). This averages to about 2.0 to 2.6 sulfate groups per disaccharide sequence. 
In contrast, the degree of sulfation of human liver HS and porcine liver HS is 1.2 and 1.0, 
respectively, while that of porcine intestinal heparin is 2.6.
226-228
 Thus, these sequences are 
significantly more sulfated than natural HS, but either equal to or slightly less sulfated than 
natural heparin. Yet, these sequences are unlike natural H because the IdoAp composition 
(20%) is dramatically lower than that expected of natural heparin (>80%).
1
 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Structures of five H/HS hexasaccharides, sequences I through V, which are 
predicted to recognize HCII with ‗high affinity and high specificity‘. Each sequence 
contains more than one residue that is rarely found in naturally occurring HS. 
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An IdoAp residue is present at the non-reducing terminus in sequences I and II, and at an 
internal position – residue E – in sequence III. Each of these IdoAp residues has the 2SO 
conformation. At the remaining twelve locations for uronic acid residue, a GlcAp residue 
is present. In addition to these differences, variations in the presence or absence of sulfate 
group(s) are found in ring B, C, D, or ring F (Figure 35). Despite these differences, closer 
inspection reveals striking similarity. The fundamental structure that is common to all five 
sequences is UAp–GlcNp2S–GlcAp–GlcNp2S–UAp2S–GlcNp2S. Further, the 2- and 3-
positions of rings C and D bear a sulfate group in 4 out of 5 sequences highlighting their 
importance in HCII recognition. 
6.2.5. Molecular Interaction Profile of the Five Predicted ‗High-Affinity, 
High-Specificity‘ Sequences 
When modeled in complex with activated HCII, all five sequences bind in an 
essentially identical orientation with the non-reducing end recognizing helix A, while the 
reducing end is oriented toward the C-terminus of helix D (Figure 36). This suggests 
exquisite specificity in the recognition of activated HCII. In fact, a RMSD of 0.76 Ǻ is 
found for backbone atoms of the central tetrasaccharide BCDE among the top scoring 
solutions for each of the five sequences, which increases to 1.6 Ǻ, if one considers the 
backbone atoms of all six residues. The H/HS hexasaccharides orient at a ~60º angle 
relative to the axis of helix D. This alignment is significantly different from heparin 
pentasaccharide binding to AT, which orients almost parallel to the axis of helix 
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Figure 36. Combinatorial virtual screening predicted interaction of H/HS with HCII. Ribbon diagram of HCII, from S195A 
thrombin-complexed HCII, interacting with five H/HS sequences I through V of Figure 35. The top scoring solutions from 
the first docking run are shown. H/HS hexasaccharides (shown in capped sticks) bind in the domain formed by helix D 
(shown in yellow) and N-terminal residues of helix A (magenta). Prominent basic residues are shown as ball and stick. Note 
that the four central residues – BCDE – superimpose with almost no deviation. Reactive center loop (RCL) is shown in blue. 
hF = helix F; sA = -sheet A. 
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D.
118,119
Three residues, Arg184, Arg192, and Arg464, form strong hydrogen bonds with all 
five sequences (Figure 37), while Arg193 and Arg189 formadditional hydrogen bonds with 
two and one of five hexasaccharides, respectively (not shown). No hydrogen bonds are 
predicted to form with Lys101, Arg103, Lys173 and Lys185, other basic residues present 
in the binding site. Correlations can be found between HCII site-directed mutagenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. A close-up view of the HS hexasaccharide sequence I, with highest GOLD 
score, binding to activated HCII. 
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results and our computational results. For example, affinity chromatography studies 
suggest that Arg184, Arg192 and Arg193 of HCII interact with heparin, while Arg103 
does not.
229,230
 Our computational study supports these observations. In contrast, studies 
with Lys173 mutant show that this residue may bind H/HS,
231
 while none of our final 
H/HS hexasaccharides appear to interact with Lys173. It is possible that chains longer than 
hexasaccharides may be needed because Lys173 is present ~2.0 Å further from the non-
reducing end of hexasaccharide sequences I to V. 
Closer inspection of interaction at the atomic level reveals that the high scoring 
residues – Arg464, Arg184 and Arg192 – form multi-valent hydrogen bonds (Figure 37). 
Specifically, Arg464 forms 3 strong hydrogen bonds, two with the B2S group and one with 
the C2S group, Arg184 forms 2 hydrogen bonds with the D2S and E2S groups, while Arg192 
forms 1 – 2 hydrogen bonds with E2S group. Together these four sulfate groups on the 
GAG are responsible for over 85% of the calculated hydrogen bonding score (not shown). 
This analysis suggests that a core, conserved tetrasaccharide BCDE with the minimal 
sequence GlcNp2S—GlcAp2S—GlcNp2S—UAp2S appears to be critical for ‗high-
affinity, high-specificity‘ binding to activated HCII. Likewise, sulfations at 3- and 6-
positions in residues F and D, respectively, introduce additional interactions with Arg193 
and Arg189, respectively, and are therefore desirable. 
6.3. Significance 
The interaction of H/HS with HCII has been commonly assumed to be non-
specific
32,217,225
 primarily because natural GAG preparation could not be separated into 
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high and low affinity fractions. This also poses major difficulties in structure elucidation 
because crystallization of a co-complex using heterogeneous, polydisperse GAG is nearly 
impossible. Our work suggests that there exist at least five hexasaccharide sequences that 
are predicted to recognize activated HCII with ‗high-affinity and high specificity‘. All five 
‗needles in the haystack‘ contain at least two GAG monosaccharides of the GlcNp2S3S or 
GlcAp2S type that are rare in natural preparations of H/HS. The fact that each sequence 
has at least two such rare monosaccharides (sequences II and III have three, while 
sequence V has four) suggest a rapidly diminishing probability of finding these structures 
naturally. H/HS sequences I – V are expected to be accessible through chemical 
synthesis,
157
 which may rejuvenate interest in understanding structure – function 
relationships in this system as well as advance the concept of designing potent HCII 
agonists as specific inhibitors of thrombin. Finally, considering that the structure of H/HS 
– heparin co-factor II complex is not available, our combinatorial virtual library screening 
results have far reaching implications. 
6.4. Computational Methods 
6.4.1. Protein Co-ordinates 
SYBYL 7.2 (Tripos Associates, St. Louis, MO), working on MIPS R16K or R14K 
IRIX 6.5-based SGI Tezro and Fuel graphical workstations, was used to model protein 
structures. The coordinates for the activated form of HCII were extracted from the crystal 
structure of the S195A thrombin-HCII Michaelis complex (protein data bank (PDB) entry 
1JMO), while the coordinates for native HCII were obtained from PDB entry 1JMJ.
34
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Following addition of hydrogen atoms, the protein structures were minimized with fixed 
heavy-atom co-ordinates using the Tripos Force Field for 1,000 iterations subject to a 
termination gradient of 0.05 kcal/(mol-Ǻ). For comparison of protein structures (HCII 
complexed with S195A thrombin (1JMO) and activated form of AT (chain I of 1AZX )
118
), 
the N-terminal end residues 61 through 100 in HCII and 2 through 25 in AT, as well as 
reactive center loop residues 428 to 446 in HCII and 378 to 399 in AT, were deleted. The 
main bodies of the two serpins (the core residues) were then aligned using homologous 
residues in an automated manner and RMSD between alpha carbons of corresponding 
residues calculated. 
6.4.2. Co-ordinates for H/HS Virtual Library 
The co-ordinates for H/HS hexasaccharide sequences present in the combinatorial 
virtual library were generated using a series of in-house SYBYL programming language 
scripts. See section 5.4.7 for further details 
6.4.3. Docking of the H/HS Virtual Library onto HCII 
Docking of saccharide ligands onto the native and activated form of HCII was 
performed with GOLD v.2.2 (Cambridge Crystallographic Data Center, Cambridge, 
UK).
207
 The substituents on the pyranose rings of H/HS sequences were allowed full 
conformational mobility in docking experiments. The binding site of H/HS sequences in 
native and activated HCII comprised of all atoms within 18 Ǻ from the C  atom of Lys185 
in the D helix, which covers Lys101, Arg103, Lys173, Arg184, Lys185, Arg189, Arg192, 
Arg193, Lys220, and Arg464 residues that are likely to form the putative HBS in HCII 
117 
 
(helices A and D). Unless otherwise specified, default parameters were employed during 
the GOLD docking run.
5
 
The docking protocol was essentially similar to that used for antithrombin (section 
5.4.8). Evaluation of the H/HS combinatorial hexasaccharide library was performed using 
the dual filter docking protocol (Figure 33) previously used in our study of the AT – 
heparin pentasaccharide system.
5
 The first stage (the ‗affinity‘ test) involved docking of 
46,656 H/HS sequences to HCII using 10,000 iterations per GA run. The high affinity 
H/HS sequences so identified (47 sequences or ~0.1% of the total) were then selected for 
the geometry convergence (‗specificity‘) test, which consisted of slower and more rigorous 
experimentation with 100,000 GA iterations performed in triplicate. The top two solutions 
of each docking experiment, i.e., 6 solutions, were retrieved and analyzed for RMSD 
among the backbone heavy atoms (pyranose ring atoms and interglycodic oxygens). An 
RMSD of less than 2.5 Ǻ between the 6 solutions suggested a high degree of convergence 
to a ‗unique‘ binding geometry.
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DESIGN, SYNTHESIS AND EVALUATION OF POTENTIAL NEXT 
GENERATION ANTITHROMBIN ACTIVATORS 
 
7.1. Introduction 
Previously synthesized non-saccharide antithrombin (AT) activators in our 
laboratory namely sulfated flavonoids and sulfated tetrahydroisoquinoline derivatives, 
were found to bind the extended heparin-binding site (EHBS) or elsewhere although they 
were designed to target the pentasaccharide-binding site (PBS). The X-ray crystal 
structures of antithrombin alone
188,232
 and in complex with heparins
118,119
 show that the 
PBS is exposed to solvent implying that the binding domain should be freely available. 
Yet, biochemical studies in solution show that the N-terminus of the polypeptide overlays 
on the PBS.
233
 This implies that the three key residues, Lys114, Lys125 and Arg129, are 
not readily accessible to ligands in solution. Thus, it is likely that sub-optimal activators 
that cannot engage all three key residues find it difficult to form a productive PBS-based 
antithrombin – ligand initial recognition complex,192 which can initiate the induced-fit 
conformational change in the serpin. Rather, the sub-optimal activators are ensnared by an 
adjacent electropositive domain, the EHBS, resulting in lower activation. Thus, a plausible 
non- saccharide design strategy would be to devise larger anionic molecules, which upon 
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binding in the EHBS will retain the capability to interact with Lys114, Lys125 and 
Arg129, and thus, turn the ‗key‘ to open the ‗lock‘.  
The design of sulfated flavonoids and sulfated tetrahydroisoquinoline derivatives 
was based on the structure of trisaccharide DEF and was time-consuming because it 
involved manual pre-positioning of the ligand in the pentasaccharide-binding site in AT. 
This reduces the structural variations that could be tested. In addition, the method involved 
a considerable degree of user-bias because binding modes are pre-defined. In order to 
increase our chances of targeting the PBS, we decided to use an approach that is solely 
based on the structure of the heparin-binding site (PBS + EHBS) in AT and allow for the 
selection of structures that favorably interact with the PBS. In addition, to explore a large 
number of possibilities, such a method would have to be rapid and automated. Given the 
success of our virtual library screening method with heparin/HS-protein interactions,
5
 
virtual screening seemed to be the most appropriate method to achieve the aforementioned 
goals. 
7.2. Results and discussion 
7.2.1. Virtual screening of non-saccharide sulfated small molecule libraries 
Our studies on the docking of the H5 sequence and its variants to the activated 
crystal structure of AT revealed that the GOLD score of the H5 sequence is 148 and its 
geometry was repeatedly predicted to within 2.5 Å in multiple docking experiments 
(section 5.2.4). Thus, our search for small organic activators used these benchmarks as 
targets. We began with the bicyclic-unicyclic system present in IAS5, and ‗synthesized‘ a 
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virtual library of 24,576 chemical structures with 17 different linkers (L) containing 1-6 
atoms and variations in the substitution pattern of sulfate groups (S1 → S8, Figure 38). In 
addition, we decided to include both configurations of the carboxylate group at position 3 
as well as molecules that are devoid of this group 
The small molecule non-saccharide library was built using LEGION
TM
, a powerful 
combinatorial library design software. LEGION
TM
 rapidly generates 2D structures in Sybyl 
Line Notation in a combinatorial manner. A plausible 3D geometry of the 2D structures 
generated by LEGION was obtained using CONCORD
TM
 and these structures were subject 
S1 → S9 = H/OSO3
X = H/COO
L = –CH2CH2CH2CH2–
L  = –CH2CH2CH2CH2CH2–
L  = –CH2CH2CH2CH2CH2CH2–
L  = –CH=CHCH2CH2–
L  = –CH2CH=CHCH2–
L  = –CH2CH2CH=CH–
L  = –CH=CHCH2CH2CH2–
L  = –CH2CH2CH2CH=CH–
L = – CO –
L  = – COO –
L  = – CONH –
L  = – CH2 –
L  = – CH2CH2 –
L  = – CH2CH2CH2 –
L  = – CH=CH –
L  = –CH2CH=CH–
L  = –CH=CHCH2–
N
X
S4
S3
S2
S1
L
S9
S8
S7
S6
S5
_
_
1
35
6
2‘
4‘
Bicyclic ring A
Unicyclic
ring B
 
Figure 38. Combinatorial virtual library of bicyclic-unicyclic structures based on 
IAS5 with linkers containing 1-6 atoms. The library was created by variation of 
substituents S1 → S9 and X, and the linker L. 
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to energy minimizations (see section 5.4.2) in an automated manner using in-house SPL 
scripts. The SPL scripts were written to simultaneously modify the atom and bond types of 
the sulfate groups so that they were identical to the types used for GAGs (section 5.4.4). 
The protocol used for virtual screening of non-saccharide molecules was essentially 
identical to that used for saccharides (Figure 33). 
The dual filter (GOLD score + geometry convergence) selected 93 ‗hits‘ from the 
24,576 structures in the virtual library. The GOLD scores of these hits ranged from 101 to 
132 as compared to 148 and 122 for the H5 sequence and a hexasaccharide that contains 
the H5 sequence and an additional IdoAp2S residue at its non-reducing end.   
 
Of the 93 ‗hits‘, 33 had an all carbon 4-atom linker, while 24 had an all carbon 5-atom 
linker (Figure 39). Of the 57 ‗hits‘ that had a 4-5 carbon linker, 38 had a trans 
                                                 
 When compared to H5, the hexasaccharide (H6) was found to consistently dock in a similar geometry 
although laterally displaced by a few Å. This resulted in a GOLD score of ~ 25 units less (section 5.2.6). 
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Figure 39. Histogram plot of the number of atoms in the linker for the 93 ‗hits‘ 
obtained from virtual screening of a non -saccharide sulfated library 
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N
OSO3
O3SO COO
_
_
_
3,5,6-trisubstituted 
tetrahydroisoquinoline
fragment
5
6 3
double bond with a strong preference to be alpha to either the nitrogen atom or the phenyl 
ring (Figure 38). Most of the remaining 19 of 57 ‗hits‘ contained a fully saturated 
methylene linker while a few contained a cis double bond.  
With respect to number and distribution of negative charges, majority of ‗hits‘ 
contained 4-6 negative charges. It is interesting that molecules possessing sulfation levels 
in excess of 6 were not selected to be ‗hits‘. Sixty nine of the 93 ‗hits‘ contained a 
carboxylate group at the 3-position of the tetrahydroisoquinoline 
ring. Of these, 43 were the R isomer and 26 were the S isomer. 
Most interestingly, 48 of the 93 ‗hits‘ contained a 3,5,6-
trisubstituted tetrahydroisoquinoline fragment (see figure) 
suggesting that sulfate groups at the 5 and 6-position of the tetrahydroisoquinoline ring 
favorably contribute towards affinity. 
The number and position of sulfate groups on the unicyclic ring of the ‗hits‘ are variable 
and do not show clearly discernible patterns. In fact, the position of sulfate groups on the 
unicyclic ring appears to correlate with the length of the linker. For ‗hits‘ with 4-5 carbon 
linkers, a sulfate group is located at the 2‘ position for majority of the compounds, while 
for ‗hits‘ with shorter linkers, sulfate groups tend to be at the 3‘, 4‘ and/or 5‘ positions. 
Since the ‗hits‘ with 4-5 carbon linkers are highest scoring, these results suggest that the 
sulfate group at the 2‘position interacts with a basic amino acid in AT (see Table 5, 
below). 
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Table 5. Summary of structural features of most favorable 'hits' 
 Number of ‗hits‘ GOLD Scores Percentage with 4 
or 5 carbon linkers 
N
OSO3
O3SO
COO
L
OSO3
_
_
_
_
R
R
2’
3
5
6
 
37 104-132 76% 
 
Figure 40 shows an overlay between pentasaccharide H5CRYS (see Figure 24 for 
structure) and R-ACT6955, a representative ‗hit‘ from the virtual screening study that 
contains the 3,5,6-trisubstituted tetrahydroisoquinoline fragment shown above and a 
2‘sulfate group in the unicyclic ring. The indicated pose of R-ACT6955 was repeatedly 
predicted in triplicate docking experiments to within 2.5 Å as a consequence of our dual-
filter protocol. The figure shows striking similarities in the location of 4 negative charges. 
While the 3 carboxylate, 5-sulfate and 6-sulfate groups of R-ACT6955 overlap with the E-
ring carboxylate, F-ring N-sulfate and G-ring carboxylate groups of H5CRYS, the 2‘ sulfate 
group of R-ACT6955 overlaps with the D-ring 6-sulfate group of H5CRYS. These charges 
interact with the critically important positive triad (Lys114, Lys125 and Arg129) which is 
located in the pentasaccharide-binding site (PBS) in antithrombin (AT). Additionally, the 
5‘ sulfate group of R-ACT6955 interacts with the extended heparin-binding site residue 
Arg132. Thus, while the bicyclic ring binds right in the center of the PBS, the unicyclic 
ring binds at the interface of the PBS and EHBS. It is important to note that the 6-sulfate 
group in R-ACT6955 overlaps with a carboxylate group of H5CRYS. Since sulfate groups 
contain three potential interaction points, the 6-sulfate group is predicted to simultaneously  
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Arg132
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Lys114, Arg46/47
N
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OSO3
O3SO OSO3
OSO3
OSO3
_
_
_
_
_
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F G
H
 
Figure 40. Overlay of heparin pentasaccharide H5 (green, obtained from the crystal 
structure 1TB6.pdb) and the repeatedly predicted docking pose of R-ACT6955 
(magenta, structure shown in in-lay), a hit from the virtual screening study of sulfated 
non-saccharide molecules. Overlying negative charges (sulfate + carboxylate groups) 
are encircled (black). The critical PBS residues Lys114, Lys125 and Arg129 interact 
with the 6-sulfate, 5-sulfate and 2‘-sulfate groups of R-ACT6955, respectively, which in 
turn overlay with the G-ring carboxylate, F-ring N-sulfate and D-ring 6-sulfate groups 
of the H5 sequence. In addition, the 3-carboxylate of R-ACT6955 and the E-ring 
carboxylate of H5 overlap and interact with Lys125. Note that R-ACT6955 is the R 
isomer. 
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interact with Lys114 (ionic) and the N-terminal residue Arg47 (hydrogen bond) whereas 
the G ring carboxylate of H5CRYS appears to interact only with N-terminal residue Arg46 
(hydrogen bond). It is also important to note that the overlap of the E ring carboxylate 
and3-carboxylate of R-ACT6955 will be dependent on the configuration at the 3 position 
of the tetrahydroisoquinoline ring. For optimal overlap, the ‗R‘ configuration is necessary. 
The most appealing result of our virtual screening study is the dependency of the 
overlap shown in Figure 40 with linker length for the series of ‗hits‘ that contain fragment 
I and the 2‘ sulfate group of the unicyclic ring. Figure 42 reveals that irrespective of the 
exact nature of the linker, the docking pose orients the interacting negative charges in an 
identical manner. For example, R-ACT6748 with a 5-carbon linker containing a cis-double 
bond has a binding mode similar to R-ACT6687 which contains a fully saturated linker. In 
fact, the unicyclic ring varies to position the 2‘ sulfate group identically. This binding 
mode does not depend on the configuration of the carboxylate group (R and S isomers 
dock similarly) or even the presence of this group (not shown). Thus, according to our 
results, the interaction between the 3-carboxylate group and Lys125 is a redundant 
interaction since S isomers cannot engage in a productive interaction. Nevertheless, 
structure-activity studies of pentasaccharide H5 using masked carboxylates (methyl esters) 
revealed that the E ring carboxylate plays an important role in activity.  
Based on the above results, it was decided to select R-ACT6955 as a synthetic target. R-
ACT6955 possesses structural features that are representative of the highest scoring 
                                                 
 The authors measured activity using a factor Xa inhibition assay. Hence it is not known if the E ring 
carboxylate is important for antithrombin affinity or activation or both. 
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‗hits‘  a) A four carbon linker possessing a trans double bond, b) a 3,5,6-trisubstituted 
tetrahydroisoquinoline fragment, c) a unicyclic ring bearing sulfate groups at  
the 2‘ and 5‘ positions that could interact with Arg129 and Arg132, respectively, and d) R 
configuration at position 3 which allows for optimal overlap with the E-ring carboxyate 
group of the H5 sequence. Due to the structural complexity of R-ACT6955, S-ACT3227 
was selected as a model compound because of the commercial availability of its 
tetrahydroisoquinoline fragment. In addition, the ‗right wing‘ of S-ACT3227 is structurally 
identical to that of R-ACT6955. Thus, the series of reactions that are used to construct S-
ACT3227 may also be used to synthesize R-ACT6955. Finally, S-ACT3227 is not a ‗hit‘ 
and will serve as a negative control to our design strategy. 
 
7.2.2. Synthesis of model compound S-ACT3227 
7.2.2.1. Synthetic plan 
We envisioned that S-ACT3227 can be synthesized from the key intermediate 1 in 
three steps namely demethylation using boron tribromide, microwave-assisted sulfation 
and selective ester cleavage (Figure 43). The conditions for these three steps have already  
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Figure 41. Structure of S-ACT3227 
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Figure 42. Overlay of different docked poses of 'hits' cotaining core fragment I and 2'-substituted unicyclic ring. Note the 
striking similarity of ortientation of the bicyclic ring and encircled negative charges. 
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been worked out in our laboratory (chapters 2 and 3). Disconnection of the olefin-phenyl 
ring linkage will result in amine 2 and substituted bromobenzene 3. In the forward sense, a 
palladium catalyzed Heck reaction of intermediates 2 and 3 will deliver 1. Intermediate 2 
may be rapidly assembled from the commercially available substituted 
tetrahydroisoquinoline 4. 
7.2.2.2. Synthesis of S-ACT3227 
Starting with commercially available 4, acid-catalyzed esterification in ethanol 
solvent yielded 5 in 74 % yield (Figure 44A). Alkylation of the amine 5 using 4-bromo-1-
butene and diisopropylethylamine (DIEA) base resulted in the tertiary amine 2 in 83 % 
yield. However, the Heck coupling of 2 and 3 proved to be problematic. Only traces of 
product were detected when palladium (II) acetate (5 mol%) and either tris-4-
methoxyphenylphosphine, tri-o-tolylphosphine or triphenylphosphine (10-20 mol%) was 
used as ligand in acetonitrile solvent. The yield of the reaction could not be improved in 
DMF or dioxane. Since significant quantities of 3 could be isolated from the reaction 
N
COOO3SO OSO3
OSO3
O3SO
__
_
_
_
N
COOEtMeO
OMe
OMe
MeO N
COOEtMeO
MeO
3 steps
+
OMe
OMe
Br
NH.HCl
COOHMeO
MeO
2 steps
S-ACT3227
1 2
3
4  
Figure 43. Retrosyntheic analysis of S-ACT3227 
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mixture, it was hypothesized that oxidative insertion of the Pd(II) catalyst was not taking 
place at significant rates. Thus, the electronic nature of the benzene ring was changed by 
replacing methyl groups with acetate groups (3 →7 →8) using standard protecting group 
manipulations (Figure 44B). While the coupling of 2 and 8 proved to be unproductive 
initially, the trans product (J = 15.9 Hz) was eventually isolated in 10 % yield when the 
reaction was carried using the Pd(0) catalyst tetrakistriphenylphosphine in acetonitrile 
solvent and potassium carbonate as base in the presence of 4 Å molecular sieves. 
Unfortunately, the yields were variable and were dependent on the scale of the reaction. 
Attempts to increase the yield of the reaction by adding stoichiometric amount of catalyst 
in 4 portions over a time interval of 24 hours only resulted in a decrease in yield. 
Gratifyingly, when the reaction was carried out under microwave conditions (140 ºC, 45 
min) on a 50 mg scale (0.16 mmol), the yield improved to 37 %. However, microwave 
synthesis at larger scales (e.g. 500 mg) delivered only trace amount of product. 
Settling for 5-20 % yields under non-microwave conditions, intermediate 9 was 
carried forward in multi-gram quantities. Thus, deprotection of the acetate groups using 
sodium bicarbonate in aqueous methanol at 50 ºC resulted in 10. Demethylation of 10 
using boron tribromide yielded a yellow solid, which was subjected to microwave-based 
sulfation to yield the pentasulfated product 11. The structure of 11, which showed a single 
peak on capillary electrophoresis, was deduced from 
1
H-NMR and 2D-HSQC experiments. 
Thus, under microwave conditions, the double bond gets sulfonated probably via an 
addition-elimination mechanism. For the purpose of screening, 11 (0.01 mmol, 11 mg) was 
treated with potassium tert-butoxide and water in dimethylsulfoxide solvent at room  
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Figure 44. Synthetic efforts towards S-ACT3227 resulted in 11 containing an additional sulfonate group
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Figure 45. Capillary electrophoretic monitoring of the deprotection of ethyl ester in 11. 
The analysis was carried out under reverse polarity conditions (-10 kV) so that the more 
negatively charged compounds elute earlier. At zero minutes, before the addition of 
potassium tert-butoxide, the black electropherogram was obtianed which corresponds to 
starting material 11. The analysis revealed that the reaction was completer after 5.5 
hours (red electropherogram). 
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temperature. The reaction was monitored by capillary electrophoresis (Figure 45) and the 
product (12) was isolated in essentially quantitative yield. 
Biochemical evaluation of 11 and 12 revealed that both these compounds could not 
activate antithrombin up to a concentration of 250 M (not shown). This suggests that 
these molecules do not bind either the PBS or the EHBS in antithrombin. While non-
specific binding to the EHBS has been eliminated, it is hoped that appropriate virtual-
screening-guided structural modifications may induce specific binding to the desired PBS. 
At this stage, it was decided to shift focus and devise a strategy to efficiently 
synthesize the ‗right wing‘ of R-ACT6955/S-ACT3227. The Heck reaction under 
optimized conditions (Pd(Ph3)4, K2CO3, MS (4 Å)) delivered low isolated yields of product 
because of a significant amount of mixed fraction obtained from silica gel column 
chromatography containing 9 and the exo-methylene regioisomer (Figure 44B). In fact 
only ~ 5% of bromobenzene 8 could be recovered from the reaction mixture. This led us to 
explore an alternative coupling strategy that would exclusively deliver the trans product. 
TBSO
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OMe
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+
HO
OMe
OMe
1) Pd(PPh3)4, K2CO3,
Tol/MeOH/H2O, 60 
ºC,  24 h
1) TBAF, THF, 2.5 h
46%, 2 steps
13 3 14
 
Figure 46. Efficient synthesis of the ‗right wing‘ of activators R-ACT6955 and S-
ACT3227. 
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Figure 47. Retrosynthetic analysis of substituted tetrahydroisoquinoline 15 
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Our efforts led to the synthesis of the trans product 14 in moderate yields by a Suzuki 
coupling of the pinacolboronate 13 and bromobenzene 3 without the need of using acetate 
protecting groups (Figure 46). 14 may then be used to generate suitable coupling partners 
for the synthesis of the carbon skeleton of potential activators, thus making the overall 
synthesis highly convergent. Given that the double bond gets functionalized under 
microwave-assisted sulfation conditions, it was decided that 14 needs to be hydrogenated 
before coupling in the course of future studies. 
7.2.3. Synthetic efforts towards the substituted tetrahydroisoquinoline 
fragment in R-ACT6955 
7.2.3.1. Synthetic plan 
The presence of a chiral center in substituted tetrahydroisoquinoline 15 was a major 
factor in deciding the synthetic route (Figure 47). Recognizing that 15 contains an -amino 
carboxylic acid moiety, we decided to use disconnections that would lead us to the 
aminoacid serine which is commercially available in optically pure form. Disconnections 
in such a manner would obviate the need for asymmetric synthesis. Given that a host of 
differentially methoxy-substituted benzaldehydes are commercially available, we decided 
to use reductive aminations to construct the indicated C-N bond in 16. Keeping these 
factors in mind, two different plans were conceived for the synthesis of substituted 
tetrahydroisoquinoline 15. In plan A, 15 could be made by an intramolecular Friedel-Crafts 
alkylation reaction of 16, which may be readily assembled from the D-serine derivative 17 
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and aldehyde 18. In plan B, a functional group transformation of the carboxylate ester in 
15 to a primary alcohol followed by oxidative state adjustment would lead to key 
intermediate 20. In the forward sense, 20 may be synthesized using the Friedel-Crafts 
acylation reaction from L-serine (22) and aldehyde 18. Note that 17 and 22 are 
enantiomers. 
7.2.3.2. Synthesis of substituted tetrahydroisoquinoline fragment in R-
ACT6955 
The execution of plan A was performed as outlined in Figure 48A. Aldehyde 23 
and aminoacid 17 were treated with sodium triacetoxy borohydride in the presence of 
triethylamine in 1,2-dichloroethane to obtain 24 in 65 % yield. However, attempts to 
cyclize 24 using trifluorormethane sulfonic acid to generate the superelectrophile 
intermediate were unsuccessful.
234
 Additionally, cyclization in acetic acid solvent or by 
using BF3.Et2O following literature precedent failed.
235
 To proceed further, it was decided 
to reduce the polarity of 24 by alkylation. Thus, treatment of 24 with 4-bromo-1-butene 
under basic conditions resulted in 25. Based on literature precedent, it was hoped that 
oxidation of 25 under acidic oxidation conditions will generate the aldehyde which may 
spontaneously cyclize to generate the hydroxyl ester 27.
236
 Thus, 25 was subjected to 
Swern oxidation conditions to obtain a product whose structure could not be 
unambiguously assigned through NMR spectroscopy. When the product from the Swern  
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Figure 48. Synthetic efforts towards the substituted tetrahydroisoquinoline ring system present in R-ACT6955 
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oxidation of 25 was treated with mesyl chloride under basic conditions, the mesyl 
derivative 26 was formed. Thus, the product obtained from the oxidation of 25 was an 
equilibrium mixture of the aldehyde and the enol tautomer which was intractable to NMR 
analysis. Although the , -unsaturated compound 26 may be cyclized by treatment with a 
Lewis acid,
237,238
 further work with this intermediate was not pursued because the 
configuration at C-3 would not be retained. 
So far as plan B was concerned, reductive amination of aldehyde 23 using L-
glycine ethyl ester 22 resulted in 28 (Figure 48B). Using standard protecting group 
chemistry, 28 was transformed to 29 in three high yielding steps. However, attempts to 
cyclize 29 via an aminoacid intermediate failed. Attempts to cyclize a simplified tert-butyl 
analog of 29 in which the CH2OTBS group was absent (prepared via a different synthetic 
route from glycine as starting material, not shown) using trifluoroacetic acid and 
trifluoroacetic anhydride
239,240
 were also unproductive. The reaction resulted in an 
unprecedented product whose structure could not be elucidated from 
1
H and 
13
C-NMR 
spectra. 
7.3. Summary and future directions 
Several promising ‗hits‘ emerged from our virtual screening study of 27,576 sulfated, non-
saccharide compounds with GOLD scores ranging from 101 to 132. A significant number 
of high scoring ‗hits‘ contained a common 3,5,6-trisubstituted tetrahydroisoquinoline 
fragment. The optimal linkers contained 4-5 carbon atoms. Comparison of the binding 
modes of the top scoring ‗hits‘ with that of the heparin pentasaccharide (H5CRYS) revealed 
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key points of overlap between negative charges in the non-saccharide molecules with those 
in H5CRYS. Additionally, the binding modes of these ‗hits‘ are similar irrespective of the 
exact nature of the linker. These results are summarized in Table 5. 
Two targets – R-ACT6955 and S-ACT3227 were selected for synthesis. Initial 
synthetic efforts led to the realization that the double bond in S-ACT3227 is incompatible 
with the microwave-assisted sulfation reaction. In addition, construction of an optically 
pure tetrahydroisoquinoline ring by incorporation of chirality inherent in L or D-serine 
proved to be problematic. A highly convergent synthetic approach was devised based on a 
Suzuki coupling reaction to afford the synthon containing a 4-carbon linker and the 
unicyclic ring. Coupling of this synthon or a derivative with the tetrahydroisoquinoline 
moiety will result in the carbon skeleton of the series of activators that contain a 4-carbon 
linker. 
For future work, we will target racemates as this will permit cyclization to be 
conducted under the well-established Pictet-Spengler conditions.
241
 Our plan is outlined in 
Figure 49. Starting from aldehyde 31, condensation with nitromethane followed by lithium 
aluminium hydride (LAH) reduction will yield 33, which has been reported in the 
literature.
242
 Pictet-Spengler cyclization of 33 using formaldehyde will result in 
tetrahydroisoquinoline 34. While 34 has not been reported to date, Pictet-Spengler 
cyclization had been reported on an analog of 33 containing a different methoxy 
substitution pattern on the phenyl ring.
243
 
Aldehyde 31 will also be used to synthesize the 3-substituted 
tetrahydroisoquinoline 37. Briefly, condensation with 2-nitroethanol will yield 35, which 
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has been reported.
244
 Silyl protection of the primary alcohol followed by LAH reduction 
and Pictet-Spengler condensation will result in 37. Oxidation state adjustment of 37 
followed by coupling with a hydrogenated derivative of 34 (Figure 46) will result in the 
carbon skeleton of potential activators. 
 
7.4. Experimental Section 
2-But-3-enyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid 
ethyl ester (2). To a stirred solution of 6,7-Dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-
carboxylic acid ethyl ester 5 (2.15 g, 8.1 mmol) in acetonitrile (27.0 mL) was added 
diisopropylethylamine (2.8 mL, 16.2 mmol) and 4-bromo-1-butene (1.6 mL, 16.2 mmol). 
The reaction was brought to reflux for 24 hours. After concentration, the residue was 
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Figure 49. Re-visiting the synthesis of the substituted tetrahydroisoquinoline moiety 
present in majority of virtual screening ‗hits‘. The scheme is based on Pictet-Spengler 
cyclization of primary amines and will result in a racemate. 
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purified by silica gel chromatography (4:1 → 3:1, hexanes:EtOAc) to afford 2 (2.14 g, 83 
%) as a pale yellow oil. 
1
H-NMR (CDCl3, 400 MHz): δ 6.53 (s, 1H), 6.48 (s, 1H), 5.74-
5.84 (m, 1H), 5.07-4.95 (m, 2H), 4.14-4.06 (2H, m), 3.95 (d, J = 15.2 Hz, 1H), 3.39 (s, 
3H), 3.78 (s, 3H), 3.79-3.75 (d, J = 15.2 Hz, 1H), 3.70 (app t, J = 4.8 Hz, 1 H), 3.00 (dd, J 
= 16.0, 4.4 Hz, 2H), 2.82-2.68 (m, 2H), 2.33-2.28 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H); 
13
C-
NMR (CDCl3, 75 MHz): δ 172.8, 147.6, 136.7, 126.0, 124.2, 116.0, 111.3, 109.3, 60.6, 
60.1, 56.07, 56.05, 54.4, 51.3, 32.5, 31.0, 14.6; ESI MS Calcd for C18H25NO4 [M+H]
+
 
320.19, Found 320.36 
2-Bromo-benzene-1,4-diol (7). To a stirred solution of 2-Bromo-1,4-dimethoxy-
benzene (2.50 g, 11.5 mmol) in dichloromethane (58.0 mL) was added a solution of boron 
tribromide (28.0 mL of a 1M solution in dichloromethane, 28.0 mmol) at -78 ºC. The 
resulting mixture was allowed to warm to room temperature. After 6 hours, the reaction 
mixture was cooled to 0 ºC and water (5 mL) was added dropwise. Ethyl acetate (200 mL) 
was added to the resulting suspension and vigorously stirred. After 30 minutes the 
suspension was filtered through a pad of Celite. A saturated solution of NH4Cl (50 mL) 
was added to the filtrate and the organic layer was separated. The aqueous layer was 
extracted with ethyl acetate (4  50 mL) and the combined layers were dried over Na2SO4 
and concentrated in vacuo. The residue was purified by silica gel chromatography (4:1, 
hexanes, EtOAc) to afford diol 7 (2.08 g, 96 %). 
1
H-NMR (CD3SOCD3, 300 MHz): δ 9.35 
(s, 1H), 9.04 (s, 1H), 6.84 (d, J = 3.0 Hz, 1H), 6.75 (d, J = 8.7 Hz, 1H), 6.58 (dd, J = 8.7, 
2.4 Hz, 1H); 
13
C-NMR (CD3SOCD3, 75 MHz): 151.1, 147.3, 119.5, 117.5, 116.1, 109.6 
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Acetic acid 4-acetoxy-2-bromo-phenyl ester (8). To a stirred solution of 2,2-
Bromo-benzene-1,4-diol 3 (2.08 g, 11.1 mmol) in N.N-Dimethylformamide (13 mL) was 
added acetic anhydride (21 mL, 222 mmol), triethylamine (31 mL, 222 mmol) and DMAP 
(271 mg, 2.22 mmol). The reaction flask was rinsed with N.N-Dimethylformamide (2 mL) 
and stirred for 5 hours. Water (75 mL) was added to the reaction mixture at 0 ºC and 
stirred for 0.5 hours after which diethylether (150 mL) was added. The organic layer was 
separated and the aqueous layer was extracted with diethylether (4 100 mL). The 
combined layers were dried (Na2SO4) and concentrated to obtain a residue that was 
purified using silica gel chromatography (17:3, hexanes, EtOAc) to afford the diacetate 8 
(2.35 g, 78 %). 
1
H-NMR (CDCl3, 300 MHz): δ 7.39 (d, J = 2.4 Hz, 1H). 7.15-7.06 (m, 
2H), 2.35 (s, 3H), 2.29 (s, 3H); 
13
C-NMR (CDCl3, 75 MHz): 169.1, 168.7, 148.7, 146.1, 
126.7, 124.2, 121.9, 21.2, 21.0; ESI MS Calcd for C10H9BrO4 [M+H]
+
 272.98, Found 
273.01 
2-[4-(2,5-Diacetoxy-phenyl)-but-3-enyl]-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylic acid ethyl ester (9). To a stirred solution of diacetate 8 (1.75 g, 
6.4 mmol) and amine 2 (2.25 g, 7.0 mmol) in acetonitrile (128 mL) was added K2CO3 
(2.65 g, 19.2 mmol), molecular sieves (4 Å, 500 mg) and 
tetrakispalladiumtriphenylphosphine (740 mg, 0.64 mmol). The reaction mixture was 
refluxed for 24 hours and filtered through a short pad of Celite. The filtrate was 
concentrated and purified by silica gel chromatography (3:2 →11:9, hexanes:EtOAc) to 
afford 9 (180 mg, 6 %). 
1
H-NMR (CDCl3, 300 MHz): δ 7.21 (d, J = 2.7 Hz, 1H), 7.00 (d, J 
= 9 Hz, 1H), 6.93 (dd, J = 9, 2.7 Hz, 1H), 6.57 (s, 1H), 6.53 (s, 1H), 6.42 (d, J = 15.9 Hz, 
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1H), 6.23 (dt, J = 15.9, 6.6 Hz, 1H), 4.12 (m, 2H), 3.99 (d, J = 15.0 Hz, 1H), 3.84 (d, J = 
15.0 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.74 (dd, J = 6,4.8 Hz, 1H), 3.07 (dd, J = 12.0, 4.7 
Hz, 1H), 2.96 (dd, J = 12, 3.3 Hz, 1H), 2.85 (m, 2H), 2.49 (m, 2H), 2.28 (s, 3H), 2.16 (s, 
3H), 1.21 (t, J = 6.0 Hz, 3H); 
13
C-NMR (CDCl3, 75 MHz): δ 172.8, 169.6, 169.5, 148.6, 
147.7, 145.2, 132.3, 131.6, 126.0, 124.2, 123.9, 123.6, 121.1, 119.5, 111.3, 109.3; ESI MS 
Calcd for C28H33NO8 [M+H]
+
 512.23, Found 512.32 
2-[4-(2,5-Dihydroxy-phenyl)-but-3-enyl]-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylic acid ethyl ester (10). To a stirred solution of 9 (180 mg, 0.35 
mmol) in methanol (5 mL) and water (2.5 mL) was added a saturated solution of NaHCO3 
(2.5 mL) and gently heated to 50 ºC. After 4 hours, the reaction mixture was partitioned 
between brine and ethyl acetate. The organic layer was separated and the aqueous layer 
was extracted with ethyl acetate. The combined layers were concentrated in vacuo and 
purified by silica gel chromatography (1:1, hexanes, EtOAc) to afford 10 (136 mg, 91 %). 
1
H-NMR (CDCl3, 300 MHz): δ 6.74 (d, J = 3.0 Hz, 1H), 6.63 – 6.52 (m, 5H), 6.10 (dt, J = 
16.2, 6.6 Hz, 1H), 4.11 – 4.18 (m, 2H), 4.02 (d, J = 15.3 Hz, 1H), 3.82 (d, J = 15.3 Hz, 
1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.60 (app t, J = 6.0 Hz, 1H), 3.10 (dd, J = 18, 5.6 Hz, 1H), 
3.02 (dd, J = 15.0, 4.8 Hz, 1H), 2.93 – 2.79 (m, 2H), 2.53 – 2.46 (m, 2H), 1.22 (t, J = 7.2 
Hz, 3H); ESI MS Calcd for C24H29NO6 [M+H]
+
 428.21, Found 428.40 
2-[4-(2,5-Dihydroxy-phenyl)-3-hydroxy-but-3-enyl]-6,7-dihydroxy-1,2,3,4-
tetrahydro-isoquinoline-3-carboxylic acid ethyl ester pentasulfate sodium salt (11). To 
a stirred solution of 10 (136 mg, 0.32 mmol) in dichloromethane (6.4 mL) was added a 
solution of boron tribromide (1.9 mL of a 1M solution in dichloromethane, 1.9 mmol) at -
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78 ºC. The resulting mixture was allowed to warm to room temperature. After 6 hours, the 
reaction mixture was cooled to 0 ºC and water (1 mL) was added dropwise. Ethyl acetate 
(50 mL) was added to the resulting suspension and vigorously stirred. After 30 minutes the 
suspension was filtered through a pad of Celite. A saturated solution of NH4Cl (10 mL) 
was added to the filtrate and the organic layer was separated. The aqueous layer was 
extracted with ethyl acetate (4  30 mL) and the combined layers were dried over Na2SO4 
and concentrated in vacuo. The residue was purified by passing through a short plug of 
silica gel (1:4, hexanes:EtOAc) to afford a yellow solid (22 mg). To a stirred solution of 
the resulting yellow solid in acetonitrile (500 L) and pyridine (194 L) was added 
pyridine-sulfur trioxide complex (350 mg). The resulting mixture was heated in a CEM-
Discover microwave synthesizer at 100 ºC for 30 minutes under sealed conditions. On 
cooling, the reaction was quenched with methanol (2 mL), concentrated and 
chromatographed on a Sephadex G10 column (75  1.5 cm) with water as eluant. 
Appropriate fractions (capillary electrophoretic analysis) were pooled, concentrated in 
vacuo. The sodium salt of the title compound (11) was obtained by chromatography using 
SP-Sephadex C25 sodium exchanger followed by lyophilization (11 mg, 4 %, 2 steps).
1
H-
NMR (D2O, 400 MHz): δ 7.24 (br s, 1H), 7.22 (s, 1H), 7.19 (s, 1H), 7.13 (d, J = 2.8 Hz, 
1H), 7.10 (dd, J = 8.8, 2.8 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 4.22 (d, J = 14.8 Hz, 1H), 
4.14 (t, J = 4.5 Hz, 1H), 4.08 – 4.01 (m, 3H), 3.15 – 3.11 (m, 2H), 3.03 (app t, J = 6.8 Hz, 
2H), 2.61 (app t, J = 6.4 Hz), 1.03 (t, J = 7.2 Hz, 3H); 2D-HSQC (D2O, 400 MHz, 
1
H; 100 
MHz , 
13
C): δ (1H, 13C) 7.22, 143.5; 7.22, 122.8; 7.10, 122.1; 7.19, 121.5; 7.13, 120.8; 
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7.03, 118.8; 4.04, 63.2; 4.14, 60.0; 3.03, 53.6; 4.07, 50.8; 4.20, 50.8; 2.61, 29.5; 3.16, 27.9; 
1.03, 13.4  
2-[4-(2,5-Dihydroxy-phenyl)-3-hydroxy-but-3-enyl]-6,7-dihydroxy-1,2,3,4-
tetrahydro-isoquinoline-3-carboxylic acid pentasulfate sodium salt (12). To a stirred 
solution of 11 (10 mg, 0.012 mmol) in dimethylsulfoxide (120 L) was added sodium tert-
butoxide (3.5 mg, 0.036 mmol) and water (0.3 L). After 5.5 hours, a solution of Na2HPO4 
(3.4 mg) in water (1 mL) was added. After 30 minutes, the reaction mixture was directly 
loaded onto a Sephadex G10 column and eluted with water. Appropriate fractions were 
pooled (capillary electrophoresis) and lyophilized to obtain the title compound 12 (10 mg, 
quant.). 
1
H-NMR (D2O, 300 MHz): δ 7.42 (s, 1H), 7.29 – 7.10 (m, 5H), 4.55 (d, J = 15.8 
Hz, 1H), 4.34 - 4.20 (m, 3H), 3.37 - 3.21 (m, 2H), 3.05 – 2.96 (m, 2H), 2.78 – 2.71 (m, 
2H). 
3-Hydroxy-2-(2,4,5-trimethoxy-benzylamino)-propionic acid methyl ester (24). 
To a stirred solution of 2,4,5-Trimethoxy-benzaldehyde 23 (3.4 g, 17.4 mmol) and D-
Serine hydrochloride methyl ester 17 (2.7 g, 17.4 mmol) in 1,2-Dichloro-ethane (62 mL) 
was added trithethylamine (4.9 mL). After 10 minutes, Sodium triacetoxyborohydride (5.2 
g, 24.4 mmol) was added portion-wise. The reaction mixture was heated to 60 ºC for 6 
hours. Ethyl acetate (150 mL) and saturated sodium bicarbonate (75 mL) was added to the 
reaction mixture and the organic layer was separated. The aqueous layer was extracted 
with ethyl acetate (3  100 mL) and the combined layers were concentrated in vacuo. The 
residue was purified by silica gel chromatography (99:1, EtOAc:MeOH) to afford the title 
compound 24 (3.36 g, 65 %). 
1
H-NMR (CDCl3, 300 MHz): δ 6.76 (s, 1H), 6.47 (s, 1H), 
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3.83 (s, 3H), 3.79 (s, 3H), 3.75 – 3.69 (m, 3H), 3.64 (s, 3H), 3.58 (dd, J = 10.8, 6.3 Hz, 
1H), 3.35 (app dd, J = 6.3, 4.5 Hz, 1H). 
13
C-NMR (CDCl3, 75 MHz): δ 173.7, 152.2, 
149.1, 142.9, 119.0, 97.6, 62.4, 62.0, 56.8, 56.39, 56.37, 52.2, 47.1, ESI MS Calcd for 
C14H21NO6 [M+H]
+
 300.14, Found 300.18 
2-[But-3-enyl-(2,4,5-trimethoxy-benzyl)-amino]-3-hydroxy-propionic acid 
methyl ester (25). To a stirred solution of 24 (300 mg, 1.0 mmol) in acetonitrile (2 mL) 
and diisopropylethylamine (0.9 mL) was added 4-Bromo-1-butene (500 L, 5.0 mmol). 
The reaction mixture was microwaved at 150 ºC for 20 minutes under sealed conditions. 
The reaction mixture was concentrated in vacuo and purified by flash chromatography on 
SiO2 (3:2, hexanes:EtOAc) to afford the title compound 25. 
1
H-NMR (CDCl3, 300 MHz): 
6.78 (s, 1H), 6.50 (s, 1H), 5.70 – 5.56 (m ,1H), 5.00 – 4.92 (m, 2H), 3.91 (d, J = 12.9 Hz, 
1H), 3.87 (s, 3H), 3,81 (s, 3H), 3.79 (s, 3H), 3.72 (s, 3H), 3.70 – 3.65 (m, 2H), 3.62 – 3.53 
(m, 2H), 3.28 (br s, 1H), 2.79 – 2.61 (m, 2H), 2.17 – 2.09 (m, 2H), 1.78 (br s, 1H); 13C-
NMR (CDCl3, 75 MHz): 172.0, 152.5, 149.2, 142.8, 137.0, 118.1, 116.3, 115.6, 97.6, 63.7, 
58.9, 56.9, 56.3, 56.2, 51.5, 50.4, 50.3, 33.1, ESI MS Calcd for C18H27NO6 [M+H] 
+
 
354.19, Found 354.30 
2-[But-3-enyl-(2,4,5-trimethoxy-benzyl)-amino]-3-methanesulfonyloxy-acrylic 
acid methyl ester (26). To a stirred solution of oxalyl chloride (37.5 L, 0.44 mmol) in 
dichloromethane (1.0 mL) was carefully added dimethylsulfoxide (62.5 L, 0.88 mmol) at 
-78 ºC. After 10 minutes, a solution of 25 (76 mg, 0.22 mmol) in dichloromethane (0.7 
mL) was added. After 15 minutes, Et3N (123 L, 0.88 mmol) was carefully added. After 
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15 minutes, the reaction was slowly allowed to warm to room temperature. After 30 
minutes, the reaction mixture was placed on a silica gel column and the product was 
isolated by flash chromatography using hexanes and EtOAc (1:4) to afford the aldehyde 
(74 mg, 95 %). To a stirred solution of the resulting residue (35 mg, 0.12 mmol) in 
dichloromethane (400 L) and Et3N (25 L) was added methanesulfonyl chloride (10.3 
L) at 0 ºC. After 1 hour, the reaction mixture was diluted with dichloromethane (2 mL) 
and loaded onto a short column of silica gel. The title compound (26) was isolated by flash 
chromatography using hexanes and ethyl acetate (13:7) (43 mg, 84 %). 
1
H-NMR (CDCl3, 
300 MHz): 7.19 (s, 1H), 6.98 (s, 1H), 6.48 (s, 1H), 5.85 – 5.72 (m, 1H), 5.07 – 4.96 (m, 
2H), 4.14 (br s, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H), 3.07 (m, 2H), 
2.88 (s, 3H), 2.22 (m, 2H); 
13
C-NMR (CDCl3, 75 MHz): 165.8, 151.9, 148.8, 143.1, 136.3, 
135.0, 128.4, 118.5, 116.3, 113.9, 97.6, 56.8, 56.5, 56.4, 52.3, 51.9, 50.3, 37.9, 33.0; ESI 
MS Calcd for C19H27NO8S [M+H] 
+
 430.15, Found 430.24  
3-Hydroxy-2-(2,4,5-trimethoxy-benzylamino)-propionic acid ethyl ester (28). 
To a stirred solution of 2,4,5-Trimethoxy-benzaldehyde 23 (2.00 g, 10.2 mmol) and L-
Serine ethyl ester 22 (1.73 g, 10.2 mmol) in 1,2-Dichloro-ethane (37 mL) was added Et3N 
(2.9 mL, 20.4 mmol). After 10 minutes, Sodium triacetoxyborohydride (3.03 g, 14.3 
mmol) was added and the reaction mixture was heated to 60 ºC. After 6 hours, ethyl 
acetate (100 mL) and saturated sodium bicarbonate (50 mL) was added to the reaction 
mixture and the organic layer was separated. The aqueous layer was extracted with ethyl 
acetate (3  75 mL) and the combined layers were concentrated in vacuo. The residue was 
purified by silica gel chromatography to afford the title compound (2.2 g, 69 %). 
1
H-NMR 
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(CDCl3, 300 MHz): δ 6.78 (s, 1H), 6.50 (s, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.86 (s, 3H), 3.82 
(s, 3H), 3.80 (s, 3H), 3.78 – 3.73 (m, 3H), 3.59 (dd, J = 9, 6.2 Hz, 1H), 3.36 (dd, J = 6.0, 
4.5 Hz, 1H), 1.13 (t, J = 7.1 Hz, 3H)); 
13
C-NMR (CDCl3, 75 MHz): 173.3, 152.2, 149.1, 
142.9, 119.1, 114.3, 97.6, 62.4, 62.0, 61.3, 56.8, 56.41, 56.39, 47.2, 14.4 
3-(tert-Butyl-dimethyl-silanyloxy)-2-(2,4,5-trimethoxy-benzylamino)-propionic 
acid ethyl ester (29). To a stirred solution of 28 (2.44 g, 7.8 mmol) in 1,4-Dioxane (31 
mL) was added K2CO3 (2.20 g, 15.6 mmol) and Fmoc-Cl (2.12 g, 8.2 mmol). After 1.5 
hours, the reaction mixture was partitioned between ethyl acetate (150 mL) and water (50 
mL). The organic layer was separated and the aqueous layer was extracted with ethyl 
acetate (3  100 mL). The combined layers were concentrated and the Fmoc derivative was 
isolated by flash chromatography on SiO2 (1:1, hexanes:EtOAc) (3.52 g,84 %). The 
resulting residue was dissolved in dichloromethane (66 mL) and treated with imidazole 
(899 mg, 13.2 mmol) and TBS-Cl (995 mg, 6.6 mmol). After 24 hours, saturated NH4Cl 
(50 mL) and dichloromethane (50 mL) were added. The organic layer was separated and 
the aqueous layer was extracted with dichloromethane (3  75 mL). The combined layers 
were concentrated in vacuo. The crude residue obtained (3.4 g) was dissolved in N,N-
dimethyl formamide (10 mL) and piperidine (0.5 mL) was added. After 1 hour, the 
reaction mixture was diluted with toluene (50 mL) and concentrated in vacuo. This 
procedure was repeated three times to obtain a solid which was purified by flash 
chromatography (7:3, hexanes:EtOAc) to obtain the title compound (29) (1.7 g, 76 %). 
1
H-
NMR (CDCl3, 300 MHz): 6.84 (s, 1H), 6.48 (s, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.86 (s, 3H), 
3.82 (s, 3H), 3.78 (s, 3H), 3.84 – 3.73 (m, 3H), 3.67 (m, 1H), 3.35 (t, J = 5.1 Hz, 1H), 2.30 
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(br s, 1H), 1.25 (t, J = 6.9 Hz, 3H), 0.84 (s, 9H), 0.00 (s, 6H); 
13
C-NMR (CDCl3, 75 MHz): 
173.6, 152.1, 148.8, 143.0, 119.8, 114.2, 97.6, 64.8, 62.8, 60.8, 56.7, 56.4, 46.9, 26.0 18.4, 
14.5, -5.29, -5.35; ESI MS Calcd for C21H37NO6Si [M+H] 
+
 428.25, Found 428.46 
4-(2,5-Dimethoxy-phenyl)-but-3-en-1-ol (14). To a stirred solution of 2-Bromo-
1,4-dimethoxy-benzene (50.0 mg, 0.23 mmol) and pinacol boronate 13 (78 mg, 0.25 
mmol) in toluene (2.9 mL) and methanol (625 L) was added a solution of K2CO3 (70.0 
mg) in water (250 L). To the resulting suspension, Pd(PPh3)4 (27 mg, 0.023 mmol) was 
added and the reaction mixture was heated to 60 ºC for 24 hours. The reaction mixture was 
diluted with ether (5 mL) and filtered through a short pad of Celite. The pad was washed 
with ether (3  5 mL) and the combined layers was concentrated in vacuo. The residue was 
purified by flash chromatography (24:1, hexane:EtOAc) to afford the title compound (14) ( 
41 mg, 55 %). 
1
H-NMR (CDCl3, 300 MHz): δ 6.99 (d, J = 2.7 Hz, 1H), 6.83 – 6.73 (m, 
3H), 6.19 (dt, J = 16.2, 6.9 Hz, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.78 – 3.74 (m, 2H), 2.54 – 
2.47 (m, 2H); 
13
C-NMR (CDCl3, 75 MHz): δ 153.9, 151.1, 127.6, 127.5, 127.3, 113.5, 
112.3, 112.1, 62.3, 56.4, 56.0, 37.0; ESI MS Calcd for C12H16O3 [M+H] 
+
 209.12, Found 
209.10 
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APPENDIX A 
 
A1. Experimental procedures and spectral data for synthetic schemes leading to IES5 
and IAS5  
 
Synthesis of amide 15: To a stirred suspension of amine 13 (2.25 g, 8.5 mmol), 
triethylamine (5.9 mL, 42.5 mmol) in dichloromethane (43 mL) at 0 ºC, was added acid  
                                                 
 Spectral data for  IES4 and intermediates leading to it may be found in Chapter 3 
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Figure 50. Synthesis of IES5, an analog of designed antithrombin activator IAS5 
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chloride 10c (2.05 g, 8.9 mmol) in portions. The reaction mixture was allowed to warm to 
room temperature and refluxed. After 3-4 hrs, the reaction mixture diluted with 
dichloromethane (50 mL), washed with 0.5 N HCl (3 × 50 mL) and 5 % potassium 
carbonate (3 × 50 mL), dried over anhydrous Na2SO4, and concentrated in vacuo to obtain 
a colorless oil (3.2 g, 82 %). 15:
 1
H NMR (400 MHz, CDCl3): δ 6.26-6.49 (m, 4H), 5.21 
(br s, 1H, isomer I), 4.83 (d, J = 17.2 Hz, 1H, isomer 1), 4.60 (br s, 1 H, isomer II), 4.30-
4.42 (m, 2H, isomer II), 4.23 (d, J = 17.2 Hz, 1H, isomer 1), 3.78-3.91 (m, 2H, isomers I-
II), 3.49-3.60 (m, 15H), 2.88-2.96 (m, 2H), 0.85-0.98 (m, 3H, isomers I-II) 
Polyphenols 16: To a stirred solution of the amide (3.2 g, 7.0 mmol) in 
dichloromethane (80 mL) at -78 ºC, was added BBr3 (42 mL of 1M solution in CH2Cl2, 1.2 
equiv per OMe group) under N2 over 15 minutes. After stirring for 12 hrs at rt, the reaction 
was quenched at 0 C with MeOH (10 mL) and water (10 mL). The reaction mixture was 
partitioned between EtOAc (220 mL) and 2N HCl (50 mL). The aqueous layer was diluted 
with brine (50 mL) and washed with EtOAc (6 х 50 mL). The combined organic layer was 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel 
chromatography (Hexanes/EtOAc = 1:1, 1:4, 1:4.5, 0:1) to give a yellow solid (1.9 g, 
68%). 16: 
1
H NMR (400 MHz, DMSO-d6): δ 9.18 (s, -OH), 9.16 (s -OH), 8.82 (m, -OH), 
8.52 (m, -OH), 6.29-6.53 (m, 4H), 5.01 (m, 1H, isomer I), 4.84 (m, 1H, isomer I), 4.70 (m, 
1H, isomer II), 4.36 (m, 2H, isomer II), 4.19 (m, 1H, isomer I), 3.55 (m, 2H, isomers I-II), 
2.95, (m, 2H, isomers I-II), 1.15 (m, 3H, isomers I-II); 
Per-sulfate IES5: To a stirred solution of the poly-alcohol (20 mg, 0.05 mmol) in  
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MeCN (1 mL) at rt, Et3N (0.35 mL, 2.5 mmol) and Me3N.SO3 (313 mg, 2.3 mmol) was 
added. The reaction vessel was sealed and micro-waved for 20 minutes at 100 ºC. The 
reaction was repeated for 4 times and the reaction mixture was pooled together. The MeCN 
layer was decanted and pooled, while the residue from each tube was washed with MeCN 
(5 mL) and centrifuged. The combined MeCN layers were concentrated in vacuo. Water (5 
mL) was added to the residue and stirred for 10 min. The water layer was concentrated to 
approximately 2 mL, loaded onto a Sephadex G10 column (~ 160 cm) and 
chromatographed using water as eluent. Fractions were combined based on RP-HPLC 
profiles, concentrated and re-loaded onto a SP Sephadex C25 column for sodium 
exchange. Appropriate fractions were pooled, concentrated in vacuo and lyophilized to 
obtain a white powder (140 mg, 60 %). IES5: 
1
H NMR (DMSO, 400 MHz) δ:  7.30-7.40 
(m, 4H, isomers I-II), 5.22 (s, 1H, isomer I), 4.89 (d, J = 17.2 Hz, 1H, isomer I), 4.84 (m, 
1H, isomer II), 4.38 (m, 2H, isomer II), 4.20 (d, J = 17.2 Hz, 1H, isomer I), 3.56-3.61 (m, 
2H, isomers I-II), 3.00-3.14 (m, 2H, isomers I-II). 
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A2. Capillary electropherograms for IAS5 and its analogs 
The following electropherograms were recorded to assess the purity of synthesized 
poly-sulfated compounds 1s-8s. Experimental conditions may be found in section 3.4.1). 
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